<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Maintenance therapy for chronic lymphocytic leukaemia - Lee, C-H - 2024 | Cochrane Library</title> <meta content="Maintenance therapy for chronic lymphocytic leukaemia - Lee, C-H - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013474.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Maintenance therapy for chronic lymphocytic leukaemia - Lee, C-H - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013474.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013474.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Maintenance therapy for chronic lymphocytic leukaemia" name="citation_title"/> <meta content="Cho-Hao Lee" name="citation_author"/> <meta content="Tri-Service General Hospital, National Defense Medical Center" name="citation_author_institution"/> <meta content="drleechohao@gmail.com" name="citation_author_email"/> <meta content="Yi-Ying Wu" name="citation_author"/> <meta content="Tri-Service General Hospital, National Defense Medical Center" name="citation_author_institution"/> <meta content="Tzu-Chuan Huang" name="citation_author"/> <meta content="Tri-Service General Hospital, National Defense Medical Center" name="citation_author_institution"/> <meta content="Chin Lin" name="citation_author"/> <meta content="National Defense Medical Center" name="citation_author_institution"/> <meta content="Yi-Fen Zou" name="citation_author"/> <meta content="Tri-Service General Hospital, National Defense Medical Center" name="citation_author_institution"/> <meta content="Ju-Chun Cheng" name="citation_author"/> <meta content="Tri-Service General Hospital, National Defense Medical Center" name="citation_author_institution"/> <meta content="Po-Huang Chen" name="citation_author"/> <meta content="Tri-Service General Hospital, National Defense Medical Center" name="citation_author_institution"/> <meta content="Hong-Jie Jhou" name="citation_author"/> <meta content="Changhua Christian Hospital" name="citation_author_institution"/> <meta content="Ching-Liang Ho" name="citation_author"/> <meta content="Tri-Service General Hospital, National Defense Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD013474.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/01/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013474.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013474.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013474.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alemtuzumab; Antibodies, Monoclonal [therapeutic use]; *Antineoplastic Agents [adverse effects]; Lenalidomide [therapeutic use]; *Leukemia, Lymphocytic, Chronic, B-Cell [drug therapy]; Rituximab [adverse effects]; Tyrosine Kinase Inhibitors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013474.pub2&amp;doi=10.1002/14651858.CD013474.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013474\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013474\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ko","th","ms","hr","fa","id","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013474.pub2",title:"Maintenance therapy for chronic lymphocytic leukaemia",firstPublishedDate:"Jan 4, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013474.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013474.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013474.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013474.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013474.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013474.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013474.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013474.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013474.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013474.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1126 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013474.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-sec-0146"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-sec-0024"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-sec-0025"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-sec-0131"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/appendices#CD013474-sec-0151"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/supinfo/CD013474-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/supinfo/CD013474-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Maintenance therapy for chronic lymphocytic leukaemia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Cho-Hao Lee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0005">Yi-Ying Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0006">Tzu-Chuan Huang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0007">Chin Lin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0008">Yi-Fen Zou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0009">Ju-Chun Cheng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0010">Po-Huang Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0011">Hong-Jie Jhou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information#CD013474-cr-0012">Ching-Liang Ho</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information/en#CD013474-sec-0160">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 January 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013474.pub2">https://doi.org/10.1002/14651858.CD013474.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013474-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013474-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013474-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013474-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013474-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013474-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013474-abs-0007">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013474-abs-0001" lang="en"> <section id="CD013474-sec-0001"> <h3 class="title" id="CD013474-sec-0001">Background</h3> <p>Chronic lymphocytic leukaemia (CLL) is the most common lymphoproliferative disease in adults and currently remains incurable. As the progression‐free period shortens after each successive treatment, strategies such as maintenance therapy are needed to improve the degree and duration of response to previous therapies. Monoclonal antibodies, immunomodulatory agents, and targeted therapies are among the available options for maintenance therapy. People with CLL who achieve remission after previous therapy may choose to undergo medical observation or maintenance therapy to deepen the response. Even though there is widespread use of therapeutic maintenance agents, the benefits and harms of these treatments are still uncertain. </p> </section> <section id="CD013474-sec-0002"> <h3 class="title" id="CD013474-sec-0002">Objectives</h3> <p>To assess the effects and safety of maintenance therapy, including anti‐CD20 monoclonal antibody, immunomodulatory drug therapy, anti‐CD52 monoclonal antibody, Bruton tyrosine kinase inhibitor, and B‐cell lymphoma‐2 tyrosine kinase inhibitor, for individuals with CLL. </p> </section> <section id="CD013474-sec-0003"> <h3 class="title" id="CD013474-sec-0003">Search methods</h3> <p>We conducted a comprehensive literature search for randomised controlled trials (RCTs) with no language or publication status restrictions. We searched CENTRAL, MEDLINE, Embase, and three trials registers in January 2022 together with reference checking, citation searching, and contact with study authors to identify additional studies. </p> </section> <section id="CD013474-sec-0004"> <h3 class="title" id="CD013474-sec-0004">Selection criteria</h3> <p>We included RCTs with prospective identification of participants. We excluded cluster‐randomised trials, cross‐over trial designs, and non‐randomised studies. We included studies comparing maintenance therapies with placebo/observation or head‐to‐head comparisons. </p> </section> <section id="CD013474-sec-0005"> <h3 class="title" id="CD013474-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures. We assessed risk of bias in the included studies using Cochrane's RoB 1 tool for RCTs. We rated the certainty of evidence for the following outcomes using the GRADE approach: overall survival (OS), health‐related quality of life (HRQoL), grade 3 and 4 adverse events (AEs), progression‐free survival (PFS), treatment‐related mortality (TRM), treatment discontinuation (TD), and all adverse events (AEs). </p> </section> <section id="CD013474-sec-0006"> <h3 class="title" id="CD013474-sec-0006">Main results</h3> <p>We identified 11 RCTs (2393 participants) that met the inclusion criteria, including seven trials comparing anti‐CD20 monoclonal antibodies (mAbs) (rituximab or ofatumumab) with observation in 1679 participants; three trials comparing immunomodulatory drug (lenalidomide) with placebo/observation in 693 participants; and one trial comparing anti‐CD 52 mAbs (alemtuzumab) with observation in 21 participants. No comparisons of novel small molecular inhibitors were found. </p> <p>The median age of participants was 54.1 to 71.7 years; 59.5% were males. The type of previous induction treatment, severity of disease, and baseline stage varied among the studies. Five trials included early‐stage symptomatic patients, and three trials included advanced‐stage patients (Rai stage III/IV or Binet stage B/C). Six trials reported a frequent occurrence of cytogenic aberrations at baseline (69.7% to 80.1%). The median follow‐up duration was 12.4 to 73 months. The risk of selection bias in the included studies was unclear. We assessed overall risk of performance bias and detection bias as low risk for objective outcomes and high risk for subjective outcomes. Overall risk of attrition bias, reporting bias, and other bias was low. </p> <p><b>Anti‐CD20 monoclonal antibodies (mAbs): rituximab or ofatumumab maintenance versus observation</b> </p> <p>Anti‐CD20 mAbs maintenance likely results in little to no difference in OS (hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.73 to 1.20; 1152 participants; 3 studies; moderate‐certainty evidence) and likely increases PFS significantly (HR 0.61, 95% CI 0.50 to 0.73; 1255 participants; 5 studies; moderate‐certainty evidence) compared to observation alone. </p> <p>Anti‐CD20 mAbs may result in: an increase in grade 3/4 AEs (rate ratio 1.34, 95% CI 1.06 to 1.71; 1284 participants; 5 studies; low‐certainty evidence); little to no difference in TRM (risk ratio 0.82, 95% CI 0.39 to 1.71; 1189 participants; 4 studies; low‐certainty evidence); a slight reduction to no difference in TD (risk ratio 0.93, 95% CI 0.72 to 1.20; 1321 participants; 6 studies; low‐certainty evidence); and an increase in all AEs (rate ratio 1.23, 95% CI 1.03 to 1.47; 1321 participants; 6 studies; low‐certainty evidence) compared to the observation group. </p> <p>One RCT reported that there may be no difference in HRQoL between the anti‐CD20 mAbs (ofatumumab) maintenance and the observation group (mean difference −1.70, 95% CI −8.59 to 5.19; 480 participants; 1 study; low‐certainty evidence). </p> <p><b>Immunomodulatory drug (IMiD): lenalidomide maintenance versus placebo/observation</b> </p> <p>IMiD maintenance therapy likely results in little to no difference in OS (HR 0.91, 95% CI 0.61 to 1.35; 461 participants; 3 studies; moderate‐certainty evidence) and likely results in a large increase in PFS (HR 0.37, 95% CI 0.19 to 0.73; 461 participants; 3 studies; moderate‐certainty evidence) compared to placebo/observation. </p> <p>Regarding harms, IMiD maintenance therapy may result in an increase in grade 3/4 AEs (rate ratio 1.82, 95% CI 1.38 to 2.38; 400 participants; 2 studies; low‐certainty evidence) and may result in a slight increase in TRM (risk ratio 1.22, 95% CI 0.35 to 4.29; 458 participants; 3 studies; low‐certainty evidence) compared to placebo/observation. The evidence for the effect on TD compared to placebo is very uncertain (risk ratio 0.71, 95% CI 0.47 to 1.05; 400 participants; 2 studies; very low‐certainty evidence). IMiD maintenance therapy probably increases all AEs slightly (rate ratio 1.41, 95% CI 1.28 to 1.54; 458 participants; 3 studies; moderate‐certainty evidence) compared to placebo/observation. </p> <p>No studies assessed HRQoL.</p> <p><b>Anti‐CD52 monoclonal antibodies (mAbs): alemtuzumab maintenance versus observation</b> </p> <p>Maintenance with alemtuzumab may have little to no effect on PFS, but the evidence is very uncertain (HR 0.55, 95% CI 0.32 to 0.95; 21 participants; 1 study; very low‐certainty evidence). We did not identify any study reporting the outcomes OS, HRQoL, grade 3/4 AEs, TRM, TD, or all AEs. </p> </section> <section id="CD013474-sec-0007"> <h3 class="title" id="CD013474-sec-0007">Authors' conclusions</h3> <p>There is currently moderate‐ to very low‐certainty evidence available regarding the benefits and harms of maintenance therapy in people with CLL. Anti‐CD20 mAbs maintenance improved PFS, but also increased grade 3/4 AEs and all AEs. IMiD maintenance had a large effect on PFS, but also increased grade 3/4 AEs. However, none of the above‐mentioned maintenance interventions show differences in OS between the maintenance and control groups. The effects of alemtuzumab maintenance are uncertain, coupled with a warning for drug‐related infectious toxicity. We found no studies evaluating other novel maintenance interventions, such as B‐cell receptor inhibitors, B‐cell leukaemia‐2/lymphoma‐2 inhibitors, or obinutuzumab. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013474-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013474-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013474-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013474-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013474-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013474-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD013474-abs-0013">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013474-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013474-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013474-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013474-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013474-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013474-abs-0002" lang="en"> <h3>Is maintenance therapy following previous treatment better than observation or placebo for treating chronic lymphocytic leukaemia in adults? </h3> <p><b>What is the aim of this review?</b> </p> <p>We aimed to determine whether the currently available maintenance treatments for disease control in adults with chronic lymphocytic leukaemia (CLL) have an acceptable balance between benefits and harms following previous treatment. </p> <p><b>Key messages</b> </p> <p>We found that maintenance therapy in adults with CLL after previous therapy probably has little to no effect on long‐term survival. We also found that maintenance therapy probably increases the disease control period, but is associated with an increase in drug‐related serious adverse events and all adverse events. </p> <p><b>What was studied in this review?</b> </p> <p>CLL is a blood cancer that affects the lymphocytes, a group of white blood cells that help the body fight infection and disease. In the past 20 years, the control rate and survival of patients have significantly improved due to the use of chemotherapy plus immunotherapy, followed by the introduction of novel oral targeted therapy as the mainstream treatment for CLL. Despite these advancements, CLL patients may still develop disease that is resistant to treatment. Maintenance treatments aim to improve treatment response and extend survival, but may also increase the risk of adverse events. Available drugs for maintenance intervention include anti‐CD20 monoclonal antibodies (mAbs), immunomodulatory drugs, and anti‐CD52 mAbs. These drugs carry risks of serious side effects due to prolonged administration. It remains unclear whether the benefits of maintenance treatments outweigh the risks, as they may not achieve a satisfactory balance between disease control and prolonged survival without increasing treatment‐related death or adverse events. CLL patients who achieve remission after the first phase of treatment must therefore weigh the benefits and risks of medical observation or maintenance therapy carefully. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know if maintenance therapy following previous treatment is effective in controlling disease for adults with CLL and if it causes any adverse effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared maintenance therapy with placebo (dummy treatment) or observation, or head‐to‐head comparisons of maintenance therapies. We compared and summarised the results and rated our confidence in the evidence based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We identified 11 studies (2393 participants) for inclusion in the review. All studies were randomised controlled trials (RCTs), which are the most reliable clinical studies as they randomly allocate people to receive treatment (intervention group) or no treatment (control group). We synthesised the evidence from 10 studies (2341 participants) to assess the benefits and harms of maintenance therapy for CLL when compared with control groups receiving observation or placebo (dummy treatment). </p> <p>Compared to observation, anti‐CD20 mAbs probably have little to no effect on overall survival (evidence from 3 studies with 1152 participants), but probably increase the time in which the disease is controlled (progression‐free survival) (evidence from 5 studies with 1255 participants). </p> <p>Compared to placebo/observation, IMiD probably has little to no effect on overall survival (evidence from 3 studies with 461 participants), but probably results in a large increase in progression‐free survival (evidence from 3 studies with 461 participants). </p> <p>Compared to observation, anti‐CD20 mAbs may result in increased serious side effects (evidence from 5 studies with 1284 participants), but may not affect the chance of dying from treatment (evidence from 4 studies with 1189 participants). Anti‐CD20 mAbs may slightly reduce the number of people who stopped treatment (evidence from 6 studies with 1321 participants), but may slightly increase the overall number of side effects (evidence from 6 studies with 1321 participants). </p> <p>Compared to placebo/observation, IMiD may result in increased serious side effects (evidence from 2 studies with 400 participants), and may slightly increase the number of people who died due to maintenance treatment (evidence from 3 studies with 458 participants). The evidence for the effect of IMiD on number of people who stopped treatment is very uncertain (evidence from 2 studies with 400 participants), but IMiD probably increases the overall number of side effects (evidence from 3 studies with 458 participants). </p> <p>There was insufficient evidence to determine whether anti‐CD20 mAbs maintenance therapy affected health‐related quality of life, and our confidence in the evidence is low (evidence from 1 study with 480 participants). </p> <p>No studies evaluated other new maintenance interventions, such as B‐cell receptor inhibitors, B‐cell leukaemia‐2/lymphoma‐2 inhibitors, or obinutuzumab. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The overall certainty (confidence) of the evidence was mostly moderate to low due to issues within the trials such as the potential for bias, differences in baseline characteristics, and imprecise estimates of intervention effects. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The evidence is current as of January 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013474-sec-0146" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013474-sec-0146"></div> <h3 class="title" id="CD013474-sec-0147">Implications for practice</h3> <section id="CD013474-sec-0147"> <p>There is currently moderate‐ to very low‐certainty evidence available on the benefits and harms of maintenance therapy for people with chronic lymphocytic leukaemia (CLL). Anti‐CD20 monoclonal antibodies (rituximab, ofatumumab) or immunomodulatory drug (lenalidomide) maintenance therapy, when compared to observation or placebo, probably improves progression‐free survival, but possibly at the cost of increasing grade 3 and 4 and all adverse events. However, none of the above maintenance interventions currently show a difference between maintenance and control group in overall survival. </p> </section> <h3 class="title" id="CD013474-sec-0148">Implications for research</h3> <section id="CD013474-sec-0148"> <p>Further trials using tyrosine kinase inhibitors for induction therapy, rather than chemo‐immunotherapy, are needed to determine the potential effectiveness of maintenance therapy in people with CLL. Head‐to‐head comparisons of different maintenance therapies are also needed. In addition, we did not include patients who received continuous therapy with small molecular inhibitor and responded, but continued or discontinued treatment beyond response, due to inconsistency with the conventional definition of maintenance therapy. We may consider including this category of trials in future updated reviews, as it becomes a major treatment modality for CLL patients. Finally, because minimal residual disease‐guided treatment strategies have only recently become mainstream in haematological care, trials with minimal residual disease‐guided maintenance therapy designs should also be included and studied in future research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013474-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013474-sec-0008"></div> <div class="table" id="CD013474-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐CD20 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐CD20 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic lymphocytic leukaemia<br/><b>Setting:</b> inpatient and outpatient care<br/><b>Intervention:</b> anti‐CD20 mAb maintenance therapy<br/><b>Comparison:</b> observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with anti‐CD20 mAb maintenance therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>Follow‐up: range 33.7 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.73 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1152<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy probably results in little to no difference in overall survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000<br/>(180 to 353) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life<br/>Follow‐up: median 40.9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 1.9.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.7 lower<br/>(8.59 lower to 5.19 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may not reduce health‐related quality of life. <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 3/4 adverse events<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.34<br/>(1.06 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1284<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in an increase in grade 3/4 adverse events. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1000<br/>(466 to 752) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.61<br/>(0.50 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1255<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy probably increases progression‐free survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>639 per 1000<br/>(585 to 693) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment‐related mortality<br/>Follow‐up: range 33.7 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 0.82<br/>(0.39 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1189<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in little to no difference in treatment‐related mortality. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/>(26 to 116) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment discontinuation<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 0.93<br/>(0.72 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1321<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in a slight reduction in treatment discontinuation. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>409 per 1000<br/>(320 to 533) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All adverse events<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.23<br/>(1.03 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1321<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>4 9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in a slight increase in all adverse events. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>984 per 1000<br/>(824 to 1176) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to serious imprecision (wide confidence intervals, which cross the line of no difference).<br/><sup>2</sup>Assumed risk was calculated based on large cohort study (Mato et al 2020, DOI: 10.1182/bloodadvances.2019001145).<br/><sup>3</sup>We could not address publication bias through funnel plots, as fewer than 10 studies were included in comparison. Given our comprehensive search for unpublished studies, including contacting the experts and researchers in the field, we believe suspicion about publication bias is reduced.<br/><sup>4</sup>Downgraded one level due to serious risk of bias (high risk of bias due to lack of blinding).<br/><sup>5</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 56%).<br/><sup>6</sup>Assumed risk was calculated based on control group.<br/><sup>7</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 47%, two studies suggest benefit and two suggest harm).<br/><sup>8</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 64%).<br/><sup>9</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 56%; inconsistency in the reporting criteria for adverse events (AEs): two studies reported all AEs occurring in more than 2% of participants, while another two studies reported all AEs occurring in more than 10% of participants. Additionally, one study reported all AEs, while another study reported AEs of grade 3, 4, and 5 occurring in more than 5% of participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013474-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Immunomodulatory drug maintenance therapy compared to placebo/observation for people with chronic lymphocytic leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Immunomodulatory drug maintenance therapy compared to placebo/observation for people with chronic lymphocytic leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic lymphocytic leukaemia<br/><b>Setting:</b> inpatient and outpatient care<br/><b>Intervention:</b> immunomodulatory drug maintenance therapy<br/><b>Comparison:</b> placebo/observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with immunomodulatory drug maintenance therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/>(0.61 to 1.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>461<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy probably results in little to no difference in overall survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000<br/>(179 to 460) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting the outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 3/4 adverse events<br/>Follow‐up: range 17.9 months to 31.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.82<br/>(1.38 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>400<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy may result in an increase in grade 3/4 adverse events. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>748 per 1000<br/>(571 to 983) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.37<br/>(0.19 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>461<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy probably results in a large increase in progression‐free survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000<br/>(585 to 870) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment‐related mortality<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 1.22<br/>(0.35 to 4.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>458<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy may result in a slight increase in treatment‐related mortality. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/>(7 to 82) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment discontinuation<br/>Follow‐up: range 17.9 months to 31.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 0.71<br/>(0.47 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>400<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>8 9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of immunomodulatory drug maintenance therapy on treatment discontinuation. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>776 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>551 per 1000<br/>(365 to 815) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All adverse events<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.41<br/>(1.28 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>458<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy probably increases all adverse events slightly. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1242 per 1000<br/>(1134 to 1368) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to serious imprecision (wide confidence intervals, which cross the line of relative risk reduction threshold).<br/><sup>2</sup>Assumed risk was calculated based on large cohort study (Mato et al 2020, DOI: 10.1182/bloodadvances.2019001145).<br/><sup>3</sup>We could not address publication bias through funnel plots, as fewer than 10 studies were included in comparison. Given our comprehensive search for unpublished studies, including contacting the experts and researchers in the field, we believe suspicion about publication bias is reduced.<br/><br/><sup>4</sup>Downgraded two levels due to very serious imprecision (wide confidence intervals, small number of participants)<br/><sup>5</sup>Assumed risk was calculated based on control group.<br/><sup>6</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 68%).<br/><sup>7</sup>Downgraded two levels due to very serious imprecision (very wide confidence intervals, which cross the line of relative risk reduction threshold, and low event rates).<br/><sup>8</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 75%).<br/><sup>9</sup>Downgraded two levels due to very serious imprecision (wide confidence intervals, which cross the line of relative risk reduction threshold, and small number of participants).<br/><sup>10</sup>Downgraded one level for serious inconsistency (inconsistencies in the reporting criteria for adverse events (AEs): one study reported all AEs occurring in more than 10% of participants, while another study reported AEs of grade 1 and 2 occurring in &gt; 10% of participants, but only reported treatment‐related AEs of grade 3, 4, and 5. Additionally, one study only reported grade 3, 4, and 5 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013474-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐CD52 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐CD52 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic lymphocytic leukaemia<br/><b>Setting:</b> inpatient and outpatient care<br/><b>Intervention:</b> anti‐CD52 mAb maintenance therapy<br/><b>Comparison:</b> observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Anti‐CD52 mAb maintenance therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade 3/4 adverse events – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>Follow‐up: median 12.4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.55<br/>(0.32 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD52 mAb maintenance therapy may lead to an increase in progression‐free survival, but the evidence is very uncertain. <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>604 per 1000<br/>(419 to 746) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment‐related mortality – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment discontinuation – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All adverse events – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious risk of bias (single study that does not report methods of random sequence generation or allocation, high risk of bias due to lack of blinding).<br/><sup>2</sup>Downgraded two levels for very serious imprecision (single study, 21 participants, terminated early, likely underpowered to demonstrate an effect).<br/><sup>3</sup>Assumed risk was calculated based on large cohort study (Mato et al 2020, DOI: 10.1182/bloodadvances.2019001145). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013474-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013474-sec-0009"></div> <section id="CD013474-sec-0010"> <h3 class="title" id="CD013474-sec-0010">Description of the condition</h3> <p>Chronic lymphocytic leukaemia (CLL) is the most common lymphoproliferative disease in adults (<a href="./references#CD013474-bbs2-0198" title="SiegelRL , MillerKD , JemalA . Cancer statistics, 2015. CA: a Cancer Journal for Clinicians2015;65(1):5-29.">Siegel 2015</a>). The median age of diagnosis is 72 years (<a href="./references#CD013474-bbs2-0124" title="EichhorstB , RobakT , MontserratE , GhiaP , HillmenP , HallekM , et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2015;26(Suppl 5):v78-84. [DOI: 10.1093/annonc/mdv303.]">Eichhorst 2015</a>), and the age‐adjusted incidence is five per 100,000 person‐years (<a href="./references#CD013474-bbs2-0152" title="HowladerN , NooneAM , KrapchoM , MillerD , BishopK , AltekruseSF , et al. SEER cancer statistics review, 1975–2013. seer.cancer.gov/archive/csr/1975_2013/.">Howlader 2016</a>; <a href="./references#CD013474-bbs2-0199" title="Number of new cases and age-standardized rates of primary cancer, by cancer type and sex. www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310074701 (accessed 9 February 2020).">Statistics Canada 2016</a>). CLL has a highly variable clinical course and prognosis (<a href="./references#CD013474-bbs2-0145" title="HallekM . Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology2013;88(9):803-16. [DOI: 10.1002/ajh.23491]">Hallek 2013a</a>). Median overall survival (OS) varies from 18 months to over 20 years (<a href="./references#CD013474-bbs2-0124" title="EichhorstB , RobakT , MontserratE , GhiaP , HillmenP , HallekM , et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2015;26(Suppl 5):v78-84. [DOI: 10.1093/annonc/mdv303.]">Eichhorst 2015</a>; <a href="./references#CD013474-bbs2-0197" title="SiddonAJ , RinderHM . Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. American Journal of Clinical Patholology2013;139(6):708-12. [DOI: 10.1309/AJCPLIR4GZWX3XKA]">Siddon 2013</a>), and some individuals may lead a normal life with few or no symptoms for many years without requiring treatment. CLL is generally considered to be an indolent disease that progresses slowly, with most individuals needing treatment only after years of clinical medical observation (<a href="./references#CD013474-bbs2-0147" title="HallekM . Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. American Journal of Hematology2015;90(5):446-60.">Hallek 2015</a>). The severity of disease is reflected by the enlargement of the lymph nodes, liver, and spleen; present of B symptoms; an increased blood lymphocyte count; dysplastic haematopoiesis‐induced cytopenias; and autoimmune complications (<a href="./references#CD013474-bbs2-0149" title="HallekM , ChesonBD , CatovskyD , Caligaris-CappioF , DighieroG , DöhnerH , et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood2017;09:806398. [DOI: 10.1182/blood-2017-09-806398]">Hallek 2018</a>). The two most widely used staging systems, proposed by Rai and colleagues, <a href="./references#CD013474-bbs2-0182" title="RaiKR , SawitskyA , CronkiteEP , ChananaAD , LevyRN , PasternackBS . Clinical staging of chronic lymphocytic leukemia. Blood1975;46(2):219-34. [PMID: 1139039]">Rai 1975</a> and Binet and colleagues, <a href="./references#CD013474-bbs2-0094" title="BinetJL , AuquierA , DighieroG , ChastangC , PiguetH , GoasguenJ , et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48(1):198-206. [PMID: 7237385]">Binet 1981</a>, distinguish early (Rai 0; Binet A), intermediate (Rai I, II; Binet B), and advanced (Rai III/IV; Binet C) stages of disease, which are characterised by substantial differences in clinical course and long‐term survival. The current clinical staging systems are often of limited prognostic value at diagnosis, which usually occurs at the early stage of the disease (<a href="./references#CD013474-bbs2-0094" title="BinetJL , AuquierA , DighieroG , ChastangC , PiguetH , GoasguenJ , et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48(1):198-206. [PMID: 7237385]">Binet 1981</a>; <a href="./references#CD013474-bbs2-0143" title="HallekM , ChesonBD , CatovskyD , Caligaris-CappioF , DighieroG , DohnerH , et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111(12):5446-56. [DOI: 10.1182/blood-2007-06-093906]">Hallek 2008</a>; <a href="./references#CD013474-bbs2-0182" title="RaiKR , SawitskyA , CronkiteEP , ChananaAD , LevyRN , PasternackBS . Clinical staging of chronic lymphocytic leukemia. Blood1975;46(2):219-34. [PMID: 1139039]">Rai 1975</a>). Later, cytogenetic anomalies, including del(17p) deletions, somatic tumor protein p53 (<i>TP53</i>) gene, and immunoglobulin variable heavy‐chain mutations (IGHV), have been found to be more effective in distinguishing more and less aggressive forms of CLL (<a href="./references#CD013474-bbs2-0169" title="MertensD , StilgenbauerS . Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?Journal of Clinical Oncology2014;32(9):869-72.">Mertens 2014</a>). </p> <p>Most people with CLL do not require immediate treatment at the time of diagnosis. Treatment is usually initiated when the disease progresses, such as with progressive B symptoms, persistent cytopenias, hepatosplenomegaly, or autoimmune phenomena. However, most people with CLL will ultimately need treatment during their lifetime. Most individuals with CLL are treated when they are in an advanced stage of the disease and are experiencing symptoms or have haematopoietic insufficiency (<a href="./references#CD013474-bbs2-0143" title="HallekM , ChesonBD , CatovskyD , Caligaris-CappioF , DighieroG , DohnerH , et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111(12):5446-56. [DOI: 10.1182/blood-2007-06-093906]">Hallek 2008</a>). Prognostic markers such as IGHV mutation status, fluorescence in situ hybridisation, zeta chain of T cell receptor associated protein kinase 70 (<i>ZAP70</i> ), CD38 molecule (<i>CD38</i>), and β2‐microglobulin can be used to predict the time to first CLL treatment. The standard of care for CLL has rapidly evolved from monotherapy with chlorambucil or purine analogues (fludarabine, pentostatine) to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP); cyclophosphamide and vincristine with prednisolone (COP); or fludarabine with cyclophosphamide, to chemo‐immunotherapy with fludarabine‐based chemotherapy plus anti‐CD20 monoclonal antibodies (mAbs) (rituximab) (<a href="./references#CD013474-bbs2-0112" title="CramerP , LangerbeinsP , EichhorstB , HallekM . Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). European Journal of Haematology2016;96(1):9-18.">Cramer 2016</a>; <a href="./references#CD013474-bbs2-0129" title="FischerK , CramerP , BuschR , BöttcherS , BahloJ , SchubertJ , et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology2012;30(26):3209-16.">Fischer 2012</a>; <a href="./references#CD013474-bbs2-0144" title="HallekM , FischerK , Fingerle-RowsonG , FinkAM , BuschR , MayerJ , et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376(9747):1164-74. [DOI: 10.1016/S0140-6736(10)61381-5]">Hallek 2010</a>; <a href="./references#CD013474-bbs2-0209" title="ThompsonPA , WierdaWG . Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood2016;127(3):279-86. [DOI: 10.1182/blood-2015-08-634816]">Thompson 2016a</a>). Recently, a number of novel drugs have been developed that target key pathogenic pathways in CLL, such as Bruton tyrosine kinase (<i>BTK</i>) and phosphoinositide 3‐kinase (PI3K) inhibitors that disrupt B‐cell receptor (BCR) signalling, and venetoclax, an antagonist of the anti‐apoptotic protein B‐cell leukaemia/lymphoma 2 (BCL‐2). B‐cell receptor kinase inhibitors (BCRi) like ibrutinib and idelalisib are initially beneficial for older individuals, and later show benefits for the entire population (<a href="./references#CD013474-bbs2-0098" title="BurgerJA , KeatingMJ , WierdaWG , HartmannE , HoellenriegelJ , RosinNY , et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncology2014;15(10):1090-9.">Burger 2014</a>; <a href="./references#CD013474-bbs2-0101" title="ByrdJC , FurmanRR , CoutreSE , FlinnIW , BurgerJA , BlumKA , et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine2013;369(1):32-42. [DOI: 10.1056/NEJMoa1215637]">Byrd 2013</a>; <a href="./references#CD013474-bbs2-0102" title="ByrdJC , BrownJR , O'BrienS , BarrientosJC , KayNE , ReddyNM , et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine2014;371(3):213-23. [DOI: 10.1056/NEJMoa1400376]">Byrd 2014</a>; <a href="./references#CD013474-bbs2-0132" title="FurmanRR , SharmanJP , CoutreSE , ChesonBD , PagelJM , HillmenP , et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England Journal of Medicine2014;370(11):997-1007. [DOI: 10.1056/NEJMoa1315226]">Furman 2014</a>; <a href="./references#CD013474-bbs2-0157" title="JonesJA , RobakT , BrownJR , AwanFT , BadouxX , CoutreS , et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematology2017;4(3):e114-26.">Jones 2017</a>; <a href="./references#CD013474-bbs2-0178" title="O'BrienS , JonesJA , CoutreSE , MatoAR , HillmenP , TamC , et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology2016;17(10):1409-18.">O’Brien 2016</a>; <a href="./references#CD013474-bbs2-0222" title="ZelenetzAD , BarrientosJC , BrownJR , CoiffierB , DelgadoJ , EgyedM , et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology2017;18(3):297-311. [DOI: 10.1016/S1470-2045(16)30671-4]">Zelenetz 2017</a>). Most people with CLL respond to first‐line therapy. Although durable and sustained remissions can be achieved, the majority of people with CLL relapse within five years of initial treatment (<a href="./references#CD013474-bbs2-0196" title="ShindiapinaP , FarrukTA . Management of patients with relapsed chronic lymphocytic leukemia. American Journal of Hematology and Oncology2016;12:25-30.">Shindiapina 2016</a>; <a href="./references#CD013474-bbs2-0217" title="WierdaW , O'BrienS , WenS , FaderlS , Garcia-ManeroG , ThomasD , et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology2005;23(18):4070-8. [DOI: 10.1200/JCO.2005.12.516]">Wierda 2005</a>). Patients who relapse often become resistant to chemotherapy, develop fludarabine resistance, and experience poor outcomes due to limited treatment options and acquired genetic characteristics (unmutated immunoglobulin heavy chain gene, 17p13 deletion, and <i>TP53</i> mutations) in relapsed leukaemia clones (i.e. clonal evolution), with a poor prognosis (<a href="./references#CD013474-bbs2-0121" title="DohnerH , StilgenbauerS , BennerA , LeupoltE , KroberA , BullingerL , et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine2000;343(26):1910-6. [DOI: 10.1056/NEJM200012283432602]">Dohner 2000</a>; <a href="./references#CD013474-bbs2-0139" title="GreverMR , LucasDM , DewaldGW , NeubergDS , ReedJC , KitadaS , et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology2007;25(7):799-804. [DOI: 10.1200/JCO.2006.08.3089]">Grever 2007</a>; <a href="./references#CD013474-bbs2-0219" title="WierdaWG , ZelenetzAD , GordonLI , AbramsonJS , AdvaniRH , AndreadisCB , et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network2017;15(3):293-311. [DOI: 10.6004/jnccn.2017.0030]">Wierda 2017</a>). The novel <i>BTK</i>‐targeting agent ibrutinib has shown promising clinical responses for both naive and refractory CLL patients, but primary or acquired resistance is still common and often leads to poor clinical outcomes (<a href="./references#CD013474-bbs2-0134" title="GeorgeB , ChowdhurySM , HartA , SircarA , SinghSK , NathUK , et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers (Basel)2020;12(5):1328. [DOI: 10.3390/cancers12051328]">George 2020</a>). Such individuals usually have significantly reduced overall survival due to early progression and poor response to salvage therapy (<a href="./references#CD013474-bbs2-0111" title="CramerP , FinkAM , BuschR , EichhorstB , WendtnerCM , PflugN , et al. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leukemia &amp; Lymphoma2013;54(8):1821-2. [DOI: 10.3109/10428194.2013.796050]">Cramer 2013</a>). </p> <p>Previous National Comprehensive Cancer Network guidelines recommended retreatment with the chemo‐immunotherapy used as first‐line therapy for individuals who require second‐line treatment if they achieved a duration of response of more than two years (<a href="./references#CD013474-bbs2-0219" title="WierdaWG , ZelenetzAD , GordonLI , AbramsonJS , AdvaniRH , AndreadisCB , et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network2017;15(3):293-311. [DOI: 10.6004/jnccn.2017.0030]">Wierda 2017</a>). However, fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and bendamustine (RB) yield short remission times, and few previously treated individuals will have a complete response to treatment (<a href="./references#CD013474-bbs2-0090" title="BadouxXC , KeatingMJ , WenS , LeeBN , SivinaM , ReubenJ , et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood2011;118(13):3489-98. [DOI: 10.1182/blood-2011-03-339077]">Badoux 2011a</a>; <a href="./references#CD013474-bbs2-0186" title="RobakT . Improving FCR immunochemotherapy in CLL. Blood2010;115(3):437-8. [DOI: 10.1182/blood-2009-10-251249]">Robak 2010a</a>; <a href="./references#CD013474-bbs2-0217" title="WierdaW , O'BrienS , WenS , FaderlS , Garcia-ManeroG , ThomasD , et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology2005;23(18):4070-8. [DOI: 10.1200/JCO.2005.12.516]">Wierda 2005</a>); these types of retreatment modalities have become alternative treatment options due to the increasing number of treatment options. Second‐line treatment with BCRi such as ibrutinib or idelalisib, or B‐cell lymphoma 2 inhibitors (BCL‐2i) such as venetoclax leads to partial and sustained responses in most individuals with refractory or relapsed disease, but complete responses with no minimal residual disease (MRD) are rare (<a href="./references#CD013474-bbs2-0102" title="ByrdJC , BrownJR , O'BrienS , BarrientosJC , KayNE , ReddyNM , et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine2014;371(3):213-23. [DOI: 10.1056/NEJMoa1400376]">Byrd 2014</a>; <a href="./references#CD013474-bbs2-0132" title="FurmanRR , SharmanJP , CoutreSE , ChesonBD , PagelJM , HillmenP , et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England Journal of Medicine2014;370(11):997-1007. [DOI: 10.1056/NEJMoa1315226]">Furman 2014</a>; <a href="./references#CD013474-bbs2-0210" title="ThompsonPA , TamCS , O'BrienSM , WierdaWG , StingoF , PlunkettW , et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood2016;127(3):303-9. [DOI: 10.1182/blood-2015-09-667675]">Thompson 2016b</a>). As the progression‐free period generally becomes shorter after each successive treatment period, strategies such as maintenance are needed to improve the depth and duration of the response to previous therapies. It has been proposed that maintenance therapy after chemo‐immunotherapy might prolong the duration of remission by preventing the re‐emergence of malignant CLL clones (<a href="./references#CD013474-bbs2-0088" title="AbrisquetaP , VillamorN , TerolMJ , Gonzalez-BarcaE , GonzalezM , FerraC , et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood2013;122(24):3951-9. [DOI: 10.1182/blood-2013-05-502773]">Abrisqueta 2013</a>; <a href="./references#CD013474-bbs2-0216" title="WendtnerCM , RitgenM , SchweighoferCD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. [DOI: 10.1038/sj.leu.2403354]">Wendtner 2004</a>), and that maintenance regimens should be considered for individuals with high‐risk CLL (<a href="./references#CD013474-bbs2-0201" title="StilgenbauerS , ZenzT . Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology. American Society of Hematology. Education Program2010;1:481-8. [DOI: 10.1182/asheducation-2010.1.481]">Stilgenbauer 2010</a>). In 2015, a study by van Oers and colleagues reported a significant improvement in progression‐free survival (PFS) following ofatumumab maintenance in people with CLL in remission after retreatment compared to observation (<a href="./references#CD013474-bbs2-0214" title="Van OersMH , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncology2015;16(13):1370-9. [DOI: 10.1016/S1470-2045(15)00143-6]">Van Oers 2015</a>). This pilot trial was followed by other trials of maintenance therapy, including the CLLM1 (<a href="./references#CD013474-bbs2-0128" title="FinkAM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. [DOI: 10.1016/S2352-3026(17)30171-0]">Fink 2017</a>), CONTINUUM (<a href="./references#CD013474-bbs2-0106" title="Chanan-KhanAA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. [DOI: 10.1016/S2352-3026(17)30168-0]">Chanan‐Khan 2017</a>), CLL‐2007‐SA (<a href="./references#CD013474-bbs2-0117" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , DilhuydyMS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. [DOI: 10.1016/S2352-3026(17)30235-1]">Dartigeas 2018</a>), and CLL‐8a (<a href="./references#CD013474-bbs2-0138" title="GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. [DOI: 10.1016/S2352-3026(16)30045-X]">Greil 2016</a>) trials, which reported good outcomes with lenalidomide and rituximab maintenance. The ongoing GALACTIC trial is evaluating the maintenance effect of the novel anti‐CD20 mAb obinutuzumab since 2017 (<a href="./references#CD013474-bbs2-0176" title="OughtonJB , CollettL , HowardDR , HockadayA , MunirT , McMahonK , et al. GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials2017;18(1):353. [DOI: 10.1186/s13063-017-2107-0]">Oughton 2017</a>). </p> <p>Despite the demonstrated ability of maintenance therapy to increase duration of response and deepen response in chemo‐immunotherapy, there is ongoing debate about the long‐term benefits and harms of this treatment modality. In the modern era of targeted therapy, the common treatment strategy is continuous treatment until progression, which combines induction and maintenance therapy to prevent refractory and resistant disease. The choice of maintenance therapy currently depends on the front‐line therapy used, the presence of high‐risk patient characteristics, and individual fitness (<a href="./references#CD013474-bbs2-0139" title="GreverMR , LucasDM , DewaldGW , NeubergDS , ReedJC , KitadaS , et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology2007;25(7):799-804. [DOI: 10.1200/JCO.2006.08.3089]">Grever 2007</a>; <a href="./references#CD013474-bbs2-0148" title="HallekM . Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. American Journal of Hematology2017;92(9):946-65. [DOI: 10.1002/ajh.24826]">Hallek 2017</a>). There is a need for methods to determine the optimal maintenance treatment to maximise clinically relevant outcomes in people with CLL after previous therapy. To summarise the available data and discuss the role of maintenance in current treatment algorithms, we conducted a systematic review and pairwise meta‐analysis of all phase‐3 randomised clinical trials comparing maintenance therapy regimens in people with CLL. </p> </section> <section id="CD013474-sec-0011"> <h3 class="title" id="CD013474-sec-0011">Description of the intervention</h3> <p>Many available treatment methods can effectively induce disease remission and improve duration of response compared to observation. Allogeneic stem‐cell transplantation is the only potentially curative treatment for CLL (<a href="./references#CD013474-bbs2-0122" title="DregerP , ScheteligJ , AndersenN , CorradiniP , vanGelderM , GribbenJ , et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Blood2014;124(26):3841-9. [DOI: 10.1182/blood-2014-07-586826]">Dreger 2014</a>), but as it is feasible in only a small minority of individuals, prolonged PFS and OS are the realistic treatment goals for the majority of individuals. Before 2022, the standard of care for younger individuals with CLL without del 17p/TP53 mutation was front‐line chemo‐immunotherapy with regimens such as FCR (<a href="./references#CD013474-bbs2-0144" title="HallekM , FischerK , Fingerle-RowsonG , FinkAM , BuschR , MayerJ , et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376(9747):1164-74. [DOI: 10.1016/S0140-6736(10)61381-5]">Hallek 2010</a>; <a href="./references#CD013474-bbs2-0210" title="ThompsonPA , TamCS , O'BrienSM , WierdaWG , StingoF , PlunkettW , et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood2016;127(3):303-9. [DOI: 10.1182/blood-2015-09-667675]">Thompson 2016b</a>). BCRi such as ibrutinib are frequently used in older individuals and in those with relapsed disease (<a href="./references#CD013474-bbs2-0101" title="ByrdJC , FurmanRR , CoutreSE , FlinnIW , BurgerJA , BlumKA , et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine2013;369(1):32-42. [DOI: 10.1056/NEJMoa1215637]">Byrd 2013</a>). Intensifying FCR by adding drugs such as mitoxantrone results in additional toxicity without improving therapeutic efficacy (<a href="./references#CD013474-bbs2-0126" title="FaderlS , WierdaW , O'BrienS , FerrajoliA , LernerS , KeatingMJ . Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL &lt;70 years. Leukemia Research2010;34(3):284-8. [DOI: 10.1016/j.leukres.2009.07.008]">Faderl 2010</a>). Chemo‐immunotherapy approaches still do not result in a cure for the majority of individuals. Steady incidences of relapses are observed, and novel drugs have not demonstrated a complete reduction in relapse rates, particularly in refractory or relapsed CLL. This is evident from the need for treatment options after the exhaustion of BCR inhibitors, posing a persistent challenge (<a href="./references#CD013474-bbs2-0158" title="JonesJA , MatoAR , WierdaWG , DavidsMS , ChoiM , ChesonBD , et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology2018;19(1):65-75.">Jones 2018</a>; <a href="./references#CD013474-bbs2-0168" title="MatoAR , HillBT , LamannaN , BarrPM , UjjaniCS , BranderDM , et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Annals of Oncology2017;28(5):1050-6.">Mato 2017</a>; <a href="./references#CD013474-bbs2-0208" title="ThompsonPA , O'BrienSM , WierdaWG , FerrajoliA , StingoF , SmithSC , et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer2015;121(20):3612-21.">Thompson 2015</a>). In the follow‐up of front‐line therapy trials using novel drugs, it remains unclear whether a cure may be attainable in such settings. The current standard of first‐line treatment for CLL patients is small molecular inhibitors, which have shown better response rates compared to traditional chemo‐immunotherapy. While targeting agents such as ibrutinib, acalabrutinib, zanubrutinib, and venetoclax have shown promising clinical responses in CLL patients, the presence of refractory or resistant disease after induction therapy remains an unsolved issue. In conclusion, with the exception of CLL with better cytogenetic prognosis (mutated IgVH and functional p53) treated with FCR, for which there may be a fraction that could be cured (<a href="./references#CD013474-bbs2-0210" title="ThompsonPA , TamCS , O'BrienSM , WierdaWG , StingoF , PlunkettW , et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood2016;127(3):303-9. [DOI: 10.1182/blood-2015-09-667675]">Thompson 2016b</a>), CLL remains an incurable disease. </p> <p>The objective of maintenance therapy, which follows induction or salvage therapy, is to prevent recurrence and to strengthen the effect of previous treatment. It is not an integral part of the standard treatment for CLL. Early on, chlorambucil was used as a treatment‐until‐progression strategy with trials using up to 12 months of chlorambucil treatment (<a href="./references#CD013474-bbs2-0161" title="KellerJW , KnospeWH , RaneyM , Huguley CM Jr, JohnsonL , BartolucciAA , et al. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial. Cancer1986;58(6):1185-92.">Keller 1986</a>; <a href="./references#CD013474-bbs2-0172" title="MontserratE , AlcaláA , ParodyR , DomingoA , García-CondeJ , BuenoJ , et al. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer1985;56(10):2369-75.">Montserrat 1985</a>; <a href="./references#CD013474-bbs2-0215" title="VidalL , GurionR , RamR , RaananiP , BaireyO , RobakT , et al. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) – a systematic review and meta-analysis of randomized trials. Leukemia &amp; Lymphoma2016;57(9):2047-57.">Vidal 2016</a>). However, the benefit was very limited to achieve complete remissions even with prolonged treatment, and close to 50% of individuals were progressive within one year (i.e. during projected treatment), suggesting a relatively rapid development of resistance (<a href="./references#CD013474-bbs2-0215" title="VidalL , GurionR , RamR , RaananiP , BaireyO , RobakT , et al. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) – a systematic review and meta-analysis of randomized trials. Leukemia &amp; Lymphoma2016;57(9):2047-57.">Vidal 2016</a>). Anti‐CD52 antibody (alemtuzumab) maintenance was subsequently attempted, and long‐term analysis of a phase 3 trial showed significant improvement of survival endpoints (<a href="./references#CD013474-bbs2-0191" title="SchweighoferCD , RitgenM , EichhorstBF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. [DOI: 10.1111/j.1365-2141.2008.07394.x]">Schweighofer 2009</a>). However, severe drug‐related toxicities (especially increased opportunistic infections) rendered these advantages moot (<a href="./references#CD013474-bbs2-0100" title="ByrdJC , PetersonBL , RaiKR , HurdD , HohlR , PerryMC , et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia &amp; Lymphoma2009;50(10):1589-96.">Byrd 2009</a>; <a href="./references#CD013474-bbs2-0156" title="JonesJA , RuppertAS , ZhaoW , LinTS , RaiK , PetersonB , et al. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leukemia &amp; Lymphoma2013;54(12):2654-9.">Jones 2013</a>; <a href="./references#CD013474-bbs2-0160" title="KaufmanMS , CaramanicaA , JansonD , DriscollN , JohnsonC , KohnN , et al. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Medical Oncology2011;28(2):532-8. [DOI: 10.1007/s12032-010-9478-3]">Kaufman 2011</a>; <a href="./references#CD013474-bbs2-0167" title="LinTS , DonohueKA , ByrdJC , LucasMS , HokeEE , BengtsonEM , et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. Journal of Clinical Oncology2010;28(29):4500-6.">Lin 2010</a>; <a href="./references#CD013474-bbs2-0216" title="WendtnerCM , RitgenM , SchweighoferCD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. [DOI: 10.1038/sj.leu.2403354]">Wendtner 2004</a>). </p> <p>As antibody and immunomodulatory drug (IMiD) strategies became available, their potential to counteract these problems was explored. Some small phase 2 trials showed that consolidation/maintenance treatment with lenalidomide, <a href="./references#CD013474-bbs2-0107" title="ChangJE , HavighurstT , KimK , EickhoffJ , TraynorAM , Kirby-SlimpR , et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. British Journal of Haematology2016;173(2):283-91. [DOI: 10.1111/bjh.13957]">Chang 2016</a>; <a href="./references#CD013474-bbs2-0194" title="ShanafeltTD , RamsayAG , ZentCS , LeisJF , TunHW , CallTG , et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood2013;121(20):4137-41. [DOI: 10.1182/blood-2012-12-470005]">Shanafelt 2013</a>; <a href="./references#CD013474-bbs2-0202" title="StratiP , KeatingMJ , BurgerJA , O'BrienSM , WierdaWG , EstrovZ , et al. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica2017;102(12):e494-6. [DOI: 10.3324/haematol.2017.171561]">Strati 2017</a>, or rituximab, <a href="./references#CD013474-bbs2-0088" title="AbrisquetaP , VillamorN , TerolMJ , Gonzalez-BarcaE , GonzalezM , FerraC , et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood2013;122(24):3951-9. [DOI: 10.1182/blood-2013-05-502773]">Abrisqueta 2013</a>; <a href="./references#CD013474-bbs2-0095" title="BoMD , Del PrincipeMI , PozzoF , RagusaD , BulianP , RossiD , et al. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of Hematology2014;93(10):1765-74. [DOI: 10.1007/s00277-014-2117-x]">Bo 2014</a>; <a href="./references#CD013474-bbs2-0119" title="Del PoetaG , Del PrincipeMI , BuccisanoF , MaurilloL , CapelliG , LucianoF , et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer2008;112(1):119-28. [DOI: 10.1002/cncr.23144]">Del Poeta 2008</a>; <a href="./references#CD013474-bbs2-0131" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. [DOI: 10.1002/ajh.23668]">Foa 2014</a>, is feasible. Following the development of a maintenance paradigm in other indolent lymphoma entities (<a href="./references#CD013474-bbs2-0141" title="HainsworthJD , LitchyS , BurrisHA , Scullin DC Jr, CorsoSW , YardleyDA , et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology2002;20(20):4261-7.">Hainsworth 2002</a>), a phase 2 trial which observed prolonged use of rituximab in CLL was launched by Hainsworth and colleagues (<a href="./references#CD013474-bbs2-0142" title="HainsworthJD , LitchyS , BartonJH , HoustonGA , HermannRC , BradofJE , et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology2003;21(9):1746-51.">Hainsworth 2003</a>). Rituximab induction follow‐up of four weekly courses of rituximab in six‐monthly intervals as maintenance for two years achieved a median PFS of 18.6 months. There are currently five significant completed randomised trials investigating the maintenance role of anti‐CD20 antibodies in CLL (<a href="./references#CD013474-bbs2-0117" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , DilhuydyMS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. [DOI: 10.1016/S2352-3026(17)30235-1]">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0138" title="GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. [DOI: 10.1016/S2352-3026(16)30045-X]">Greil 2016</a>; <a href="./references#CD013474-bbs2-0189" title="RobakT , BłońskiJ , SkotnickiAB , PiotrowskaM , WróbelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG – CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74.">Robak 2018</a>; <a href="./references#CD013474-bbs2-0214" title="Van OersMH , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncology2015;16(13):1370-9. [DOI: 10.1016/S1470-2045(15)00143-6]">Van Oers 2015</a>). Clinical trials of IMiD (lenalidomide) have reported prolongation of PFS (<a href="./references#CD013474-bbs2-0106" title="Chanan-KhanAA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. [DOI: 10.1016/S2352-3026(17)30168-0]">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0128" title="FinkAM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. [DOI: 10.1016/S2352-3026(17)30171-0]">Fink 2017</a>). Fink and colleagues recruited individuals with a high risk of cytogenetic aberrations after four cycles of front‐line FCR induction by screening 468 individuals to randomise 89 individuals to either lenalidomide with ramp‐up dosing design or placebo. After a median follow‐up of 17.9 months, lenalidomide showed a significant benefit for prolongation of PFS (hazard ratio 0.168) (<a href="./references#CD013474-bbs2-0128" title="FinkAM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. [DOI: 10.1016/S2352-3026(17)30171-0]">Fink 2017</a>). </p> <p>In recent years, significant progress has been made in understanding the biology of CLL, leading to the development of novel therapeutic strategies that have greatly enhanced patient outcomes (<a href="./references#CD013474-bbs2-0221" title="YosifovDY , WolfC , StilgenbauerS , MertensD . From Biology to Therapy: The CLL Success Story. Hemasphere2019;3(2):e175. [DOI: 10.1097/HS9.0000000000000175]">Yosifov 2019</a>). Specifically, the identification of specific therapeutic targets within intracellular signalling pathways, such as the B‐cell receptor (BCR) or BCL‐2 (B‐cell lymphoma), has transformed CLL treatment. While chemo‐immunotherapy‐based regimens were the mainstay of treatment for many years, they have been surpassed by target therapy‐based regimens and their combinations, which have shown remarkable efficacy. Moreover, the introduction of second‐generation anti‐CD20 molecules in conjunction with targeted agents has further altered the treatment landscape. Although these advancements have provided benefits to the majority of CLL patients, the elderly and/or high‐risk patients have likely benefited the most, experiencing significant improvements in their quality of life and life expectancy (<a href="./references#CD013474-bbs2-0099" title="BurgerJA . Treatment of chronic lymphocytic leukemia. New England Journal Medicine2020;383(5):460-73. [DOI: 10.1056/NEJMra1908213]">Burger 2020</a>). Nevertheless, the adoption of these new treatment approaches has posed challenges, such as the emergence of drug resistance, adverse side effects, and disease refractory and relapse. </p> <p>The concepts of maintenance therapy are not only applied to conventional chemo‐immunotherapy, but also to current targeted agent‐based regimens. The CLL2‐BXX phase 2 trials consist of four relevant trials that aimed to explore the effects of subsequent induction and maintenance treatment with an anti‐CD20 antibody (obinutuzumab or ofatumumab) and a targeted oral agent (ibrutinib, idelalisib, or venetoclax) (<a href="./references#CD013474-bbs2-0113" title="CramerP , vonTresckowJ , BahloJ , EngelkeA , LangerbeinsP , FinkAM , et al. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology2018;14(6):499-513. [DOI: 10.2217/fon-2017-0442]">Cramer 2018</a>). The CLL2‐BIG trial evaluated obinutuzumab plus ibrutinib as maintenance therapy, reporting a response rate of 27.1%, with six participants (10.2%) achieving a complete remission, or complete response (CR) with incomplete recovery of the bone marrow as their best response (<a href="./references#CD013474-bbs2-0212" title="TresckowUV , CramerP , RobrechtS , LangerbeinsP , FinkAM , Al-SawafO , et al. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia2022;36(8):2125–8. [DOI: 10.1038/s41375-022-01629-7]">Tresckow 2022</a>). In addition, 42 of 59 (71.1%) participants had undetectable minimal residual disease in peripheral blood at the last staging during maintenance therapy. The CLL2‐BIO trial evaluated ofatumumab plus ibrutinib as maintenance therapy for 24 months, showing good efficacy with an overall response rate of 92% and an improved CR/complete response with incomplete haematologic recovery (CRi) rate from 24.6% (end of induction) to 40.2% (post‐maintenance therapy) (<a href="./references#CD013474-bbs2-0114" title="CramerP , TresckowJV , RobrechtS , BahloJ , FürstenauM , LangerbeinsP , et al. Bendamustine followed by ofatumumab andibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO). Haematologica2021;106(2):543–54. [DOI: 10.3324/haematol.2019.223693]">Cramer 2021</a>). </p> <p>Novel targeted agents such as ibrutinib, acabrutinib, and idelalisib are also treating CLL with a treatment‐until‐progression strategy. This treatment design is similar to the concept of maintenance therapy, which aims to deepen the response and prolong the duration of response, as well as prevent refractory and resistance. </p> <p>Because maintenance therapy might preserve clinical or even molecular remission, omitting maintenance therapy could result in disease relapse, necessitating salvage therapy with high‐dose chemotherapy, with or without autologous or allogeneic haematopoietic cell transplantation. Omitting maintenance therapy might ultimately result in a negative effect on the OS of individuals with CLL. </p> </section> <section id="CD013474-sec-0012"> <h3 class="title" id="CD013474-sec-0012">How the intervention might work</h3> <p>Maintenance therapy to improve the quality and duration of treatment response is practised in indolent lymphoma entities (<a href="./references#CD013474-bbs2-0141" title="HainsworthJD , LitchyS , BurrisHA , Scullin DC Jr, CorsoSW , YardleyDA , et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology2002;20(20):4261-7.">Hainsworth 2002</a>). CLL shares similar characteristics, and recent randomised phase 3 trials described below have reported significant benefits in PFS, but more evidence is needed regarding OS (<a href="./references#CD013474-bbs2-0093" title="BeaucheminC , JohnstonJB , Lapierre MÈ, AissaF , LachaineJ . Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Current Oncology2015;22(3):e148-56.">Beauchemin 2015</a>). Maintenance and consolidation both prolong treatment with the intent of strengthening the response after postremission treatment. Consolidation therapy is combined with induction treatment. Maintenance is a follow‐up treatment to induction therapy intended to stabilise and deepen the response. In clinical practice, these two therapeutic interventions are difficult to distinguish in individuals where neither approach has a curative effect regardless of intent. In this review, all postremission interventions are considered 'maintenance therapy'. </p> <section id="CD013474-sec-0013"> <h4 class="title">Anti‐CD52 monoclonal antibodies (anti‐CD52 mAbs): alemtuzumab</h4> <p>Alemtuzumab (Campath, MabCampath) is a humanised antibody specific for CD52, a surface protein expressed on B cells in both CLL and normal B and T cells (<a href="./references#CD013474-bbs2-0217" title="WierdaW , O'BrienS , WenS , FaderlS , Garcia-ManeroG , ThomasD , et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology2005;23(18):4070-8. [DOI: 10.1200/JCO.2005.12.516]">Wierda 2005</a>). In an early phase 3 study, individuals with CLL in at least partial remission after front‐line chemotherapy with either fludarabine or fludarabine plus cyclophosphamide were randomised to either maintenance treatment with alemtuzumab 30 mg three times per week for a maximum of 12 weeks or observation (<a href="./references#CD013474-bbs2-0216" title="WendtnerCM , RitgenM , SchweighoferCD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. [DOI: 10.1038/sj.leu.2403354]">Wendtner 2004</a>). At median follow‐up of 21.4 months, individuals receiving alemtuzumab had significantly longer PFS (24.7 months) than controls, but the study was stopped because of unacceptable infectious toxicity. Follow‐up surveillance reported that five individuals given alemtuzumab achieved molecular remission, but all individuals in the control group had evidence of MRD. At median follow‐up of 48 months, individuals given alemtuzumab had significantly prolonged PFS compared with the observation group (<a href="./references#CD013474-bbs2-0191" title="SchweighoferCD , RitgenM , EichhorstBF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. [DOI: 10.1111/j.1365-2141.2008.07394.x]">Schweighofer 2009</a>). Despite its toxicity, maintenance treatment with alemtuzumab induced molecular remission and reduced MRD, resulting in significantly improved long‐term clinical outcome. </p> </section> <section id="CD013474-sec-0014"> <h4 class="title">Immunomodulatory drug (IMiD): lenalidomide</h4> <p>Lenalidomide is a 4‐amino‐glutamyl analogue of thalidomide that has clinical activity in CLL (<a href="./references#CD013474-bbs2-0185" title="RichesJC , GribbenJG . Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia. Current Cancer Drug Targets2016;16(8):689-700. [PMID: 27055579]">Riches 2016</a>). Lenalidomide has a unique mechanism of action, not only targeting cancer cells, but also modulating or interrupting multiple interactions of CLL cells and elements in their microenvironment, <a href="./references#CD013474-bbs2-0089" title="Acebes-HuertaA , Huergo-ZapicoL , Gonzalez-RodriguezAP , Fernandez-GuizanA , PayerAR , Lopez-SotoA , et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Research International2014;1:265840. [DOI: 10.1155/2014/265840]">Acebes‐Huerta 2014</a>; <a href="./references#CD013474-bbs2-0183" title="RamsayAG , JohnsonAJ , LeeAM , GorgunG , Le DieuR , BlumW , et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation2008;118(7):2427-37. [DOI: 10.1172/JCI35017]">Ramsay 2008</a>; <a href="./references#CD013474-bbs2-0220" title="WuL , AdamsM , CarterT , ChenR , MullerG , StirlingD , et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clinical Cancer Research2008;14(14):4650-7. [DOI: 10.1158/1078-0432.CCR-07-4405]">Wu 2008</a>, that promote leukaemia or influence survival (<a href="./references#CD013474-bbs2-0091" title="BadouxXC , KeatingMJ , WangX , O'BrienSM , FerrajoliA , FaderlS , et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood2011;117(11):3016-24. [DOI: 10.1182/blood-2010-08-304683]">Badoux 2011b</a>; <a href="./references#CD013474-bbs2-0104" title="Chanan-KhanA , MillerKC , MusialL , LawrenceD , PadmanabhanS , TakeshitaK , et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology2006;24(34):5343-9. [DOI: 10.1200/JCO.2005.05.0401]">Chanan‐Khan 2006</a>; <a href="./references#CD013474-bbs2-0108" title="ChenCI , BergsagelPL , PaulH , XuW , LauA , DaveN , et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. Journal of Clinical Oncology2011;29(9):1175-81. [DOI: 10.1200/JCO.2010.29.8133]">Chen 2011</a>; <a href="./references#CD013474-bbs2-0127" title="FerrajoliA , LeeBN , SchletteEJ , O'BrienSM , GaoH , WenS , et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood2008;111(11):5291-7. [DOI: 10.1182/blood-2007-12-130120]">Ferrajoli 2008</a>). Its multifaceted mechanism of action and diverse effects on CLL cells have been reflected in improved immuno‐surveillance outcomes (<a href="./references#CD013474-bbs2-0155" title="ItchakiG , BrownJR . Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs2017;26(5):633-50. [DOI: 10.1080/13543784.2017.1313230]">Itchaki 2017</a>; <a href="./references#CD013474-bbs2-0159" title="KaterAP , ToninoSH , EgleA , RamsayAG . How does lenalidomide target the chronic lymphocytic leukemia microenvironment?Blood2014;124(14):2184-9. [DOI: 10.1182/blood-2014-05-578286]">Kater 2014</a>). Two large randomised controlled trials reported significant prolongation of PFS in individuals with CLL who were given lenalidomide maintenance (<a href="./references#CD013474-bbs2-0106" title="Chanan-KhanAA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. [DOI: 10.1016/S2352-3026(17)30168-0]">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0128" title="FinkAM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. [DOI: 10.1016/S2352-3026(17)30171-0]">Fink 2017</a>). The CLLM1 study (NCT01556776) randomly assigned 89 individuals with CCL 2:1 to receive lenalidomide 5 mg maintenance or placebo. The hazard ratio (HR) for PFS was 0.16 (95% confidence interval (CI) 0.07 to 0.37) with a median follow‐up of 17.9 months. Median PFS was not reached (95% CI 32.3 to not evaluable) in the lenalidomide group, and was 13.3 months (95% CI 9.9 to 19.7) in the placebo group. However, study recruitment was stopped early because of poor accrual (<a href="./references#CD013474-bbs2-0128" title="FinkAM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. [DOI: 10.1016/S2352-3026(17)30171-0]">Fink 2017</a>). The global CONTINUUM study (NCT00774345) found that maintenance therapy with lenalidomide prolonged PFS without affecting potential subsequent lines of therapy (<a href="./references#CD013474-bbs2-0106" title="Chanan-KhanAA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. [DOI: 10.1016/S2352-3026(17)30168-0]">Chanan‐Khan 2017</a>). In the CONTINUUM trial, eligible individuals had achieved complete or partial responses to second‐line therapy and were randomly assigned to maintenance therapy with lenalidomide (160 individuals) starting at 2.5 mg/day with escalation to 5 mg or 10 mg as tolerated or to a placebo group (154 individuals). Lenalidomide reduced the risk of progression by more than half compared with placebo (HR 0.40, 95% CI 0.29 to 0.55), but no difference was found in OS during follow‐up (<a href="./references#CD013474-bbs2-0106" title="Chanan-KhanAA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. [DOI: 10.1016/S2352-3026(17)30168-0]">Chanan‐Khan 2017</a>). </p> </section> <section id="CD013474-sec-0015"> <h4 class="title">Anti‐CD20 monoclonal antibodies (anti‐CD20 mAbs): rituximab, ofatumumab, obinutuzumab</h4> <p>The CD20 antigen is present in more than 90% of B‐cell lymphoma cells and is neither shed nor internalised after antibody binding (<a href="./references#CD013474-bbs2-0206" title="TedderTF , EngelP . CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today1994;15(9):450-4. [DOI: 10.1016/0167-5699(94)90276-3]">Tedder 1994</a>), which makes it a target for immunotherapy with monoclonal anti‐CD20 antibody. Preclinical studies have shown that anti‐CD20 activity includes complement‐dependent cytotoxicity, antibody‐dependent cellular cytotoxicity, and the induction of cell growth arrest and apoptosis (<a href="./references#CD013474-bbs2-0165" title="LiB , ShiS , QianW , ZhaoL , ZhangD , HouS , et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Research2008;68(7):2400-8. [DOI: 10.1158/0008-5472.CAN-07-6663]">Li 2008</a>; <a href="./references#CD013474-bbs2-0166" title="LiB , ZhaoL , GuoH , WangC , ZhangX , WuL , et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood2009;114(24):5007-15. [DOI: 10.1182/blood-2009-06-225474]">Li 2009</a>; <a href="./references#CD013474-bbs2-0207" title="TeelingJL , FrenchRR , CraggMS , vanden BrakelJ , PluyterM , HuangH , et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood2004;104(6):1793-800. [DOI: 10.1182/blood-2004-01-0039]">Teeling 2004</a>). However, the increased occurrence of neutropenia and infections in individuals who received anti‐CD20 has generated concern (<a href="./references#CD013474-bbs2-0138" title="GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. [DOI: 10.1016/S2352-3026(16)30045-X]">Greil 2016</a>; <a href="./references#CD013474-bbs2-0144" title="HallekM , FischerK , Fingerle-RowsonG , FinkAM , BuschR , MayerJ , et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376(9747):1164-74. [DOI: 10.1016/S0140-6736(10)61381-5]">Hallek 2010</a>; <a href="./references#CD013474-bbs2-0187" title="RobakT , DmoszynskaA , Solal-CelignyP , WarzochaK , LoscertalesJ , CatalanoJ , et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology2010;28(10):1756-65. [DOI: 10.1200/JCO.2009.26.4556]">Robak 2010b</a>; <a href="./references#CD013474-bbs2-0214" title="Van OersMH , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncology2015;16(13):1370-9. [DOI: 10.1016/S1470-2045(15)00143-6]">Van Oers 2015</a>). </p> <section id="CD013474-sec-0016"> <h5 class="title">Rituximab</h5> <p>Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. It has a synergic effect when administered in combination with chemotherapeutic agents used in standard first‐line treatment regimens (<a href="./references#CD013474-bbs2-0173" title="NabhanC , RosenST . Chronic lymphocytic leukemia: a clinical review. JAMA2014;312(21):2265-76. [DOI: 10.1001/jama.2014.14553]">Nabhan 2014</a>). The immuno‐chemotherapeutic combination regimen increases treatment benefits compared with chemotherapy alone (<a href="./references#CD013474-bbs2-0148" title="HallekM . Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. American Journal of Hematology2017;92(9):946-65. [DOI: 10.1002/ajh.24826]">Hallek 2017</a>). Because of its benefit in induction therapy, the benefits of rituximab for maintenance therapy have been tested. Early data from small observational and uncontrolled, early‐phase consolidation and maintenance trials suggest that maintenance therapy consisting of prolonged rituximab antibody therapy after use in induction can prolong disease‐free survival (<a href="./references#CD013474-bbs2-0088" title="AbrisquetaP , VillamorN , TerolMJ , Gonzalez-BarcaE , GonzalezM , FerraC , et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood2013;122(24):3951-9. [DOI: 10.1182/blood-2013-05-502773]">Abrisqueta 2013</a>; <a href="./references#CD013474-bbs2-0095" title="BoMD , Del PrincipeMI , PozzoF , RagusaD , BulianP , RossiD , et al. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of Hematology2014;93(10):1765-74. [DOI: 10.1007/s00277-014-2117-x]">Bo 2014</a>; <a href="./references#CD013474-bbs2-0119" title="Del PoetaG , Del PrincipeMI , BuccisanoF , MaurilloL , CapelliG , LucianoF , et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer2008;112(1):119-28. [DOI: 10.1002/cncr.23144]">Del Poeta 2008</a>; <a href="./references#CD013474-bbs2-0131" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. [DOI: 10.1002/ajh.23668]">Foa 2014</a>). The French Innovative Leukemia Organization conducted a multicentre phase 3 study that compared rituximab maintenance therapy versus observation to prolong PFS in individuals with CLL who were homogeneously treated with front‐line FCR (<a href="./references#CD013474-bbs2-0117" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , DilhuydyMS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. [DOI: 10.1016/S2352-3026(17)30235-1]">Dartigeas 2018</a>). After a median follow‐up of 47.7 months, median PFS was longer in the rituximab group (59.3 months) than in the observation group (49.0 months; HR 0.55, 95% CI 0.40 to 0.75). Another phase 3 study randomly assigned 263 individuals in at least partial remission after first‐line (80%) or second‐line (20%) therapy to either two years of maintenance rituximab or to observation (<a href="./references#CD013474-bbs2-0138" title="GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. [DOI: 10.1016/S2352-3026(16)30045-X]">Greil 2016</a>). Rituximab maintenance significantly improved PFS (median 47.0 months versus 35.5 months; HR 0.50, 95% CI 0.33 to 0.75), with no significant difference in OS. The median PFS achieved by FCR is three to seven years (<a href="./references#CD013474-bbs2-0130" title="FischerK , BahloJ , FinkAM , GoedeV , HerlingCD , CramerP , et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood2016;127(2):208-15. [DOI: 10.1182/blood-2015-06-651125]">Fischer 2016</a>; <a href="./references#CD013474-bbs2-0210" title="ThompsonPA , TamCS , O'BrienSM , WierdaWG , StingoF , PlunkettW , et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood2016;127(3):303-9. [DOI: 10.1182/blood-2015-09-667675]">Thompson 2016b</a>), and evidence of MRD‐related relapse in the peripheral blood emerges very early at a median of 12.0 months after chemo‐immunotherapy. However, it was delayed to 31.3 months by rituximab maintenance (<a href="./references#CD013474-bbs2-0138" title="GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. [DOI: 10.1016/S2352-3026(16)30045-X]">Greil 2016</a>). </p> </section> <section id="CD013474-sec-0017"> <h5 class="title">Ofatumumab</h5> <p>Ofatumumab is a human type I CD20 (IgG1‐κ) monoclonal antibody, with potent in vitro complement‐dependent cytotoxicity even in rituximab‐refractory cells (<a href="./references#CD013474-bbs2-0092" title="BarthMJ , Hernandez-IlizaliturriFJ , MavisC , TsaiPC , GibbsJF , DeebG , et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology2012;156(4):490-8. [DOI: 10.1111/j.1365-2141.2011.08966.x]">Barth 2012</a>), a higher antibody‐dependent cytotoxicity than rituximab (<a href="./references#CD013474-bbs2-0181" title="RafiqS , ButcharJP , CheneyC , MoX , TrottaR , CaligiuriM , et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. Journal of Immunology2013;190(6):2702-11. [DOI: 10.4049/jimmunol.1202588]">Rafiq 2013</a>), and in vivo efficacy in rituximab‐refractory CCL (<a href="./references#CD013474-bbs2-0218" title="WierdaWG , KippsTJ , MayerJ , StilgenbauerS , WilliamsCD , HellmannA , et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology2010;28(10):1749-55. [DOI: 10.1200/JCO.2009.25.3187]">Wierda 2010</a>). The PROLONG trial was a phase 3 study of ofatumumab maintenance in individuals with CLL in complete or partial remission after second‐line or subsequent therapy (<a href="./references#CD013474-bbs2-0214" title="Van OersMH , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncology2015;16(13):1370-9. [DOI: 10.1016/S1470-2045(15)00143-6]">Van Oers 2015</a>). Participants were randomised to two years of either ofatumumab or observation. Ofatumumab maintenance resulted in an improvement in PFS (median 29.4 months versus 15.2 months; HR 0.50, 95% CI 0.38 to 0.66). There was no difference in OS. </p> </section> <section id="CD013474-sec-0018"> <h5 class="title">Obinutuzumab</h5> <p>Obinutuzumab (formerly GA101) is a new‐generation humanised anti‐CD20 mAbs with a type II glycoengineered Fc portion selected to increase its affinity for FcγRIIIa receptors on immune effector cells. The increased affinity for neutrophils and macrophages is intended to elicit enhanced antibody‐dependent cellular cytotoxicity (<a href="./references#CD013474-bbs2-0096" title="BolognaL , GottiE , ManganiniM , RambaldiA , IntermesoliT , IntronaM , et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. Journal of Immunology2011;186(6):3762-9. [DOI: 10.4049/jimmunol.1000303]">Bologna 2011</a>; <a href="./references#CD013474-bbs2-0116" title="DalleS , ReslanL , Besseyre de HortsT , HerveauS , HertingF , PlesaA , et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Molecular Cancer Therapeutics2011;10(1):178-85. [DOI: 10.1158/1535-7163.MCT-10-0385]">Dalle 2011</a>; <a href="./references#CD013474-bbs2-0175" title="NiederfellnerG , LammensA , MundiglO , GeorgesGJ , SchaeferW , SchwaigerM , et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood2011;118(2):358-67. [DOI: 10.1182/blood-2010-09-305847]">Niederfellner 2011</a>). As the cells targeted by obinutuzumab are B cells rather than other lymphocytes including T cells, obinutuzumab is likely to be significantly less immunosuppressive than alemtuzumab (<a href="./references#CD013474-bbs2-0103" title="CartronG , deGuibertS , DilhuydyMS , MorschhauserF , LeblondV , DupuisJ , et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood2014;124(14):2196-202. [DOI: 10.1182/blood-2014-07-586610]">Cartron 2014</a>). The GALACTIC study (ISRCTN64035629) is an ongoing phase 2/3, multicentre, randomised, open, parallel‐group trial in previously treated individuals with CLL (<a href="./references#CD013474-bbs2-0176" title="OughtonJB , CollettL , HowardDR , HockadayA , MunirT , McMahonK , et al. GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials2017;18(1):353. [DOI: 10.1186/s13063-017-2107-0]">Oughton 2017</a>). Participants were randomised to either obinutuzumab maintenance or observation. The phase 2 study will assess safety and short‐term efficacy to screen responses eligible for continuing to the phase 3 study. Planned enrolment was 188 participants at 40 study centres in the UK (<a href="./references#CD013474-bbs2-0176" title="OughtonJB , CollettL , HowardDR , HockadayA , MunirT , McMahonK , et al. GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials2017;18(1):353. [DOI: 10.1186/s13063-017-2107-0]">Oughton 2017</a>). </p> </section> </section> <section id="CD013474-sec-0019"> <h4 class="title">Small molecular inhibitors (ibrutinib, acalabrutinib, zanubrutinib, idelalisib, duvelisib, venetoclax) </h4> <section id="CD013474-sec-0020"> <h5 class="title">Bruton tyrosine kinase inhibitors (BTKi): ibrutinib, acalabrutinib, zanubrutinib</h5> <p>Ibrutinib (Imbruvica), a covalent oral inhibitor of <i>BTK</i>, was the first BTKi to be approved by the US Food and Drug Administration (FDA) for first‐line and refractory or relapsed treatment in individuals with CLL (<a href="./references#CD013474-bbs2-0097" title="BrownJR , HillmenP , O'BrienS , BarrientosJC , ReddyNM , CoutreSE , et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia2018;32(1):83-91.">Brown 2018</a>; <a href="./references#CD013474-bbs2-0102" title="ByrdJC , BrownJR , O'BrienS , BarrientosJC , KayNE , ReddyNM , et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine2014;371(3):213-23. [DOI: 10.1056/NEJMoa1400376]">Byrd 2014</a>; <a href="./references#CD013474-bbs2-0190" title="RobertsAW , DavidsMS , PagelJM , KahlBS , PuvvadaSD , GerecitanoJF , et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England Journal of Medicine2016;374(4):311-22.">Roberts 2016</a>). Second‐generation BTK inhibitors, including acalabrutinib and zanubrutinib, have been formulated to reduce toxicity and improve tolerability compared to ibrutinib. Acalabrutinib has less potent inhibition of tyrosine‐protein kinase compared to ibrutinib and does not inhibit epidermal growth factor receptor (<i>EGFR</i> ) or IL2 inducible T cell kinase (<i>ITK</i>). Zanubrutinib is an orally administered BTK inhibitor with less potent inhibition of ITK and EGFR. All three BTK inhibitors – ibrutinib (<a href="./references#CD013474-bbs2-0097" title="BrownJR , HillmenP , O'BrienS , BarrientosJC , ReddyNM , CoutreSE , et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia2018;32(1):83-91.">Brown 2018</a>; <a href="./references#CD013474-bbs2-0102" title="ByrdJC , BrownJR , O'BrienS , BarrientosJC , KayNE , ReddyNM , et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine2014;371(3):213-23. [DOI: 10.1056/NEJMoa1400376]">Byrd 2014</a>), acalabrutinib (<a href="./references#CD013474-bbs2-0136" title="GhiaP , PlutaA , WachM , LysakD , KozakD , SimkovicM , et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology2020;38(25):2849-61. [DOI: 10.1200/JCO.19.03355]">Ghia 2020</a>; <a href="./references#CD013474-bbs2-0195" title="SharmanJP , EgyedM , JurczakW , SkarbnikA , PagelJM , FlinnIW , et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet2020;395(10232):1278-91.">Sharman 2020</a>), and zanubrutinib (<a href="./references#CD013474-bbs2-0205" title="TamCS , GiannopoulosK , JurczakW , ŠimkovičM , ShadmanM , ÖsterborgA , et al. SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus Bendamustine + Rituximab (BR) in patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood2021;138:396. [DOI: 10.1182/blood-2021-148457]">Tam 2021</a>) – are currently FDA approved for the treatment of CLL. The common toxicities of BTK inhibitors are generally well tolerated and usually resolve on their own for most individuals with CLL, including those who are frail. The notable adverse events of BTK inhibitors are increased bruising, hypertension, and incidence of atrial fibrillation. </p> </section> <section id="CD013474-sec-0021"> <h5 class="title">Phosphatidylinositol 3‐kinase inhibitors (PI3Ki): idelalisib, duvelisib</h5> <p>Idelalisib (GS‐1101 or CAL‐101) is an orally bioavailable and selective tyrosine kinase inhibitor of the phosphatidylinositol 3‐kinase (PI3K). PI3K isoform is essential for antigen‐induced BCR signalling. Idelalisib combined with rituximab has shown benefit in individuals with refractory or relapse CLL as induction or salvage treatment (<a href="./references#CD013474-bbs2-0132" title="FurmanRR , SharmanJP , CoutreSE , ChesonBD , PagelJM , HillmenP , et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England Journal of Medicine2014;370(11):997-1007. [DOI: 10.1056/NEJMoa1315226]">Furman 2014</a>), and is FDA approved. The common adverse events are colitis, pneumonitis, and liver function impairment. Further to their role as induction or salvage treatment, BCR inhibitors were also tested in subsequent maintenance therapy. However, most ibrutinib and idelalisib trials have used a treat‐until‐progression approach that makes distinguishing induction and maintenance phases difficult. Two trials have combined ibrutinib or idelalisib with bendamustin rituximab chemo‐immunotherapy regimens in pretreated individuals (<a href="./references#CD013474-bbs2-0105" title="Chanan-KhanAA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology2016;17(2):200-11. [DOI: 10.1016/S1470-2045(15)00465-9]">Chanan‐Khan 2016</a>; <a href="./references#CD013474-bbs2-0222" title="ZelenetzAD , BarrientosJC , BrownJR , CoiffierB , DelgadoJ , EgyedM , et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology2017;18(3):297-311. [DOI: 10.1016/S1470-2045(16)30671-4]">Zelenetz 2017</a>), and recently the German CLL study group proposed a “sequential triple‐T concept” of targeted, tailored treatment aiming for total eradication of CLL (<a href="./references#CD013474-bbs2-0113" title="CramerP , vonTresckowJ , BahloJ , EngelkeA , LangerbeinsP , FinkAM , et al. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology2018;14(6):499-513. [DOI: 10.2217/fon-2017-0442]">Cramer 2018</a>; <a href="./references#CD013474-bbs2-0146" title="HallekM . Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood2013;122(23):3723-34.">Hallek 2013b</a>). In that approach, individuals with CLL would receive two cycles of bendamustine followed by induction and maintenance treatment with CD20‐antibody plus a BCR inhibitor. The CLL2‐BIG trial (NCT02345863), evaluating ibrutinib and GA101 obinutuzumab; the CLL2‐BCG trial (NCT02445131), evaluating idelalisib and obinutuzumab; and the CLL2‐BIO trial (NCT02689141), evaluating ibrutinib and ofatumumab, have completed recruitment, and analysis of the primary endpoint outcomes are under way (<a href="./references#CD013474-bbs2-0113" title="CramerP , vonTresckowJ , BahloJ , EngelkeA , LangerbeinsP , FinkAM , et al. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology2018;14(6):499-513. [DOI: 10.2217/fon-2017-0442]">Cramer 2018</a>; <a href="./references#CD013474-bbs2-0193" title="SeymourJF , KippsTJ , EichhorstB , HillmenP , D'RozarioJ , AssoulineS , et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. New England Journal of Medicine2018;378(12):1107-20.">Seymour 2018</a>). </p> </section> <section id="CD013474-sec-0022"> <h5 class="title">B‐cell lymphoma‐2 inhibitor (BCL‐2i): venetoclax</h5> <p>BCL‐2, encoded in humans by the BCL2 apoptosis regulator (<i>BCL2</i>) gene, is the founding member of the Bcl‐2 family of apoptosis regulator proteins, by either inducing (pro‐apoptotic) or inhibiting (anti‐apoptotic) cell death (<a href="./references#CD013474-bbs2-0213" title="TsujimotoY , FingerLR , YunisJ , NowellPC , CroceCM . Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science1984;226(4678):1097-9. [DOI: 10.1126/science.6093263]">Tsujimoto 1984</a>). Dysregulation of BCL‐2 is associated with the development of many haematological malignancies and with treatment resistance, and these regulatory pathways can now be therapeutically targeted. The BCL2 inhibitor venetoclax was approved by the FDA in 2016 for second‐line treatment of individuals with CLL associated with 17p deletion. The recent phase 3 MURANO trial reported the long‐term outcome of venetoclax effect in individuals with refractory or relapsed CLL. While venetoclax plus rituximab combination demonstrated superior PFS than conventional bendamustine plus rituximab (HR 0.16, 95% CI 0.12 to 0.23 of three‐year PFS), subsequent single maintenance venetoclax (400 mg once daily) also yielded efficacious free of disease progression (one‐year PFS: 87.4%) (<a href="./references#CD013474-bbs2-0193" title="SeymourJF , KippsTJ , EichhorstB , HillmenP , D'RozarioJ , AssoulineS , et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. New England Journal of Medicine2018;378(12):1107-20.">Seymour 2018</a>). </p> </section> </section> </section> <section id="CD013474-sec-0023"> <h3 class="title" id="CD013474-sec-0023">Why it is important to do this review</h3> <p>Although published trials have supported the use of anti‐CD20 monoclonal antibodies and IMiD (lenalidomide) as effective and well‐tolerated maintenance therapy options for individuals with CLL (<a href="./references#CD013474-bbs2-0110" title="CoiffierB , LepretreS , PedersenLM , GadebergO , FredriksenH , vanOersMH , et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood2008;111(3):1094-100. [DOI: 10.1182/blood-2007-09-111781]">Coiffier 2008</a>; <a href="./references#CD013474-bbs2-0144" title="HallekM , FischerK , Fingerle-RowsonG , FinkAM , BuschR , MayerJ , et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376(9747):1164-74. [DOI: 10.1016/S0140-6736(10)61381-5]">Hallek 2010</a>; <a href="./references#CD013474-bbs2-0187" title="RobakT , DmoszynskaA , Solal-CelignyP , WarzochaK , LoscertalesJ , CatalanoJ , et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology2010;28(10):1756-65. [DOI: 10.1200/JCO.2009.26.4556]">Robak 2010b</a>), over the last decade the evidence has fluctuated, and new data for existing maintenance and novel target agents from recent randomised controlled trials have become available. A Cochrane Review was therefore necessary to provide up‐to‐date information for daily practice. </p> <p>Our previous systematic review (<a href="./references#CD013474-bbs2-0163" title="LeeCH , ChenPH , LinC , WangCY , HoCL . A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia. PLOS ONE2020;3:123. [DOI: 10.1371/journal.pone.0226879]">Lee 2020</a>), searched on 2019, used a network‐meta analysis to compare the relative effectiveness of available maintenance therapies for CLL. The results showed that maintenance therapy has the potential to prolong the duration of response, but can also increase the risk of adverse events for people with CLL. It is important for physicians and patients to engage in shared decision‐making to weigh the benefits and harms of maintenance therapy. Cochrane Reviews are a type of systematic review that aims to provide a readable and unbiased summary of the evidence for both physicians and patients. They adhere to strict methodological and reporting standards and use the GRADE approach to systematically assess the certainty of the evidence. Updating this topic with a Cochrane Review can provide physicians, other key decision‐makers, and even patients with access to high‐quality information on the evidence‐based results of maintenance treatments for CLL such as anti‐CD52 antibodies, anti‐CD20 antibodies, IMiD, and novel small molecular inhibitors, and help them make informed clinical decisions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013474-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013474-sec-0024"></div> <p>To assess the effects and safety of maintenance therapy, including anti‐CD20 monoclonal antibody, immunomodulatory drug therapy, anti‐CD52 monoclonal antibody, Bruton tyrosine kinase inhibitor, and B‐cell lymphoma‐2 tyrosine kinase inhibitor, for individuals with chronic lymphocytic leukaemia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013474-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013474-sec-0025"></div> <section id="CD013474-sec-0026"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013474-sec-0027"> <h4 class="title">Types of studies</h4> <p>As prespecified in the protocol (<a href="./references#CD013474-bbs2-0162" title="Lee C-H, Wu Y-Y, Huang T-Z, LinC , Zou Y-F, Cheng J-C, et al. Maintenance therapy for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD013474. [DOI: 10.1002/14651858.CD013474]">Lee 2019</a>), we included randomised controlled trials (RCTs), specifically RCTs that detailed prospective identification of participants. If studies had sufficient information and details outlined in their design, including participant characteristics, interventions, and outcomes, both the abstract and full‐text publications were evaluated. We imposed no limitation on length of follow‐up conducted in the studies or on language of publication. Any variants of randomised trials (e.g. cluster‐randomised and cross‐over trials) and non‐randomised studies were ineligible. We excluded cluster‐randomised trials because of the potential for bias based on how individual participants were identified and recruited within clusters, and cross‐over trials because of the potential for bias from carry‐over effects from one trial period to subsequent trial periods. Lastly, we excluded non‐randomised studies based on the potential of confounders and the likelihood of increased heterogeneity resulting from residual confounding, as well as other biases that occur variedly across such studies. </p> </section> <section id="CD013474-sec-0028"> <h4 class="title">Types of participants</h4> <p>We included individuals with histologically confirmed B‐cell CLL. Included studies must have used the CLL diagnostic criteria specified by the 1989 and 2007 International Workshops on CCL or the World Health Organization (WHO) classification of lymphomas (<a href="./references#CD013474-bbs2-0094" title="BinetJL , AuquierA , DighieroG , ChastangC , PiguetH , GoasguenJ , et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48(1):198-206. [PMID: 7237385]">Binet 1981</a>; <a href="./references#CD013474-bbs2-0109" title="ChesonBD , BennettJM , GreverM , KayN , KeatingMJ , O'BrienS , et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood1996;87(12):4990-7. [PMID: 8652811]">Cheson 1996</a>; <a href="./references#CD013474-bbs2-0143" title="HallekM , ChesonBD , CatovskyD , Caligaris-CappioF , DighieroG , DohnerH , et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111(12):5446-56. [DOI: 10.1182/blood-2007-06-093906]">Hallek 2008</a>; <a href="./references#CD013474-bbs2-0203" title="SwerdlowSH , CampoE , PileriSA , HarrisNL , SteinH , SiebertR , et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood2016;127(20):2375-90. [DOI: 10.1182/blood-2016-01-643569]">Swerdlow 2016</a>). We included trials that enrolled individuals in at least partial haematological or molecular remission after previous treatment, with randomisation to maintenance performed either before induction or after the achievement of partial remission. Induction therapy, including chemotherapy alone, chemo‐immunotherapy, and targeted therapy, was permitted. We excluded people with CLL who had received maintenance therapy without prior induction therapy or those who had undergone stem cell transplantation with curative intent. Trials that included mixed populations of individuals with different haematological malignancies were eligible if data were available separately for the CLL cohort. Trials for which subgroup data for individuals with CLL were not provided in the publication and for which no response was obtained from the original investigators were excluded from quantitative analysis. </p> </section> <section id="CD013474-sec-0029"> <h4 class="title">Types of interventions</h4> <p>We included randomised trials of anti‐CD52 mAb, anti‐CD20 mAb, IMiD, BTKi, PI3Ki, or BCL‐2i given as maintenance/consolidation treatment to individuals in at least partial remission after previous treatment. We excluded non‐specific agents, such as interferon and cyclophosphamide, that were previously considered but are no longer eligible due to being of historical interest only. We also excluded treatment modalities that either could not clearly differentiate between induction and maintenance phases, or where treatment was continued until disease progression. We included studies comparing these interventions with placebo or observation controls, or head‐to‐head comparisons. </p> <section id="CD013474-sec-0030"> <h5 class="title">Experimental interventions</h5> <p>We included studies evaluating the following interventions.</p> <p> <ul id="CD013474-list-0001"> <li> <p>Anti‐CD20 monoclonal antibodies</p> </li> <li> <p>Immunomodulatory drugs</p> </li> <li> <p>Anti‐CD52 monoclonal antibodies</p> </li> <li> <p>BTK inhibitors</p> </li> <li> <p>PI3K inhibitors</p> </li> <li> <p>BCL‐2 inhibitors</p> </li> </ul> </p> </section> <section id="CD013474-sec-0031"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD013474-list-0002"> <li> <p>Placebo/observation</p> </li> </ul> </p> </section> <section id="CD013474-sec-0032"> <h5 class="title">Comparisons</h5> <p>We included studies using the following comparisons.</p> <p> <ul id="CD013474-list-0003"> <li> <p>Anti‐CD20 antibodies versus placebo/observation</p> </li> <li> <p>Immunomodulatory drugs versus placebo/observation</p> </li> <li> <p>Anti‐CD52 antibodies versus placebo/observation</p> </li> <li> <p>BTK inhibitors versus placebo/observation</p> </li> <li> <p>PI3K inhibitors versus placebo/observation</p> </li> <li> <p>BCL‐2 inhibitors versus placebo/observation</p> </li> <li> <p>Head‐to‐head comparisons of active interventions</p> </li> </ul> </p> </section> </section> <section id="CD013474-sec-0033"> <h4 class="title">Types of outcome measures</h4> <p>Regardless of the reported outcomes of specific studies, we included trials if they met the criteria described above. Additionally, we considered trials regardless of any estimated relative differences in outcomes. We assessed outcome measurements based on the consensus guidelines published by the International Workshop on CLL for the design and conduct of clinical trials for individuals with CLL (<a href="./references#CD013474-bbs2-0149" title="HallekM , ChesonBD , CatovskyD , Caligaris-CappioF , DighieroG , DöhnerH , et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood2017;09:806398. [DOI: 10.1182/blood-2017-09-806398]">Hallek 2018</a>). For binary outcomes, if a study reported outcomes at multiple time points, we used the latest reported time point in the meta‐analysis. For time‐to‐event outcomes, we used data with the longest follow‐up if duplicate publications existed. </p> <section id="CD013474-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013474-list-0004"> <li> <p>Overall survival (OS): the time from study enrolment until death from any cause.</p> </li> <li> <p>Health‐related quality of life (HRQoL): quality of life measures included the EORTC QLG Core Questionnaire (EORTC QLQ‐C30) and QLQ‐CLL17. We preferred to extract data from the EORTC QLQ‐C30 first; if these data were unavailable, we would alternatively extract QLQ‐CLL17 (<a href="./references#CD013474-bbs2-0180" title="Poll-FranseL , OerlemansS , BredartA , KyriakouC , SztankayM , PalluaS , et al. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Quality of Life Research2018;27(2):333-45. [DOI: 10.1007/s11136-017-1718-y]">Poll‐Franse 2018</a>). </p> </li> <li> <p>Grade 3 and 4 adverse events (AEs): defined using the common terminology criteria for adverse events (<a href="./references#CD013474-bbs2-0115" title="US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (assessed 27 November 2022).">CTCAE 5.0</a>), or as defined in the trial. Measured at any time after the initiation of treatment and up to 28 days after discontinuation of the study treatment. </p> </li> </ul> </p> </section> <section id="CD013474-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013474-list-0005"> <li> <p>Progression‐free survival (PFS): as described in each trial, namely as the time from study entry until objective disease progression or death. </p> </li> <li> <p>Treatment‐related mortality (TRM): measured at any time after the start of treatment and up to 28 days after discontinuation of the study treatment. </p> </li> <li> <p>Treatment discontinuation (TD): defined as treatment discontinuation from any cause at any time after participants were randomised into intervention/comparator groups. </p> </li> <li> <p>All adverse events (AEs): measured at any time after the start of treatment and up to 28 days after discontinuation of the study treatment. </p> </li> <li> <p>Complete response rate (CRR): measured at least two months after the last treatment.</p> </li> <li> <p>Overall response rate (ORR): measured at least two months after the last treatment.</p> </li> <li> <p>Minimal residual disease (MRD): the level of MRD negativity that is clinically important is 0.01%, which is lesser than 1 CLL cell per 10,000 leukocytes. Measured at least two months after the last treatment. </p> </li> </ul> </p> </section> </section> </section> <section id="CD013474-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>The Systematic Review Initiative's Information Specialist, working in collaboration with the Cochrane Haematology Group, developed the search strategy. All qualified studies were included in the analysis, as outlined above. </p> <section id="CD013474-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched databases and sources following the recommendations in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0164" title="LefebvreC , ManheimerE , Glanville J (editors). Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). We used the RCT filter strategy developed by <a href="./references#CD013474-bbs2-0120" title="DickersinC , SchererR , LefebvreC . Identifying relevant studies for systematic reviews. BMJ1994;309:1286-91.">Dickersin 1994</a>. These platforms are listed in the following subsection. Search strategies are provided in the listed Appendices. </p> <section id="CD013474-sec-0038"> <h5 class="title">Databases of medical literature</h5> <p> <ul id="CD013474-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 1) in the Cochrane Library (<a href="./appendices#CD013474-sec-0152">Appendix 1</a>) </p> </li> <li> <p>MEDLINE via Ovid (1946 to 30 January 2022) (<a href="./appendices#CD013474-sec-0153">Appendix 2</a>) </p> </li> <li> <p>Embase (1988 to 30 January 2022) (<a href="./appendices#CD013474-sec-0154">Appendix 3</a>) </p> </li> </ul> </p> </section> <section id="CD013474-sec-0039"> <h5 class="title">Clinical trial registries</h5> <p> <ul id="CD013474-list-0007"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov/</a>) (searched 30 January 2022) (<a href="./appendices#CD013474-sec-0155">Appendix 4</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (searched 30 January 2022) (<a href="./appendices#CD013474-sec-0156">Appendix 5</a>) </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>) \(searched 30 January 2022) (<a href="./appendices#CD013474-sec-0157">Appendix 6</a>) </p> </li> </ul> </p> </section> </section> <section id="CD013474-sec-0040"> <h4 class="title">Searching other resources</h4> <p>As prespecified in the protocol (<a href="./references#CD013474-bbs2-0162" title="Lee C-H, Wu Y-Y, Huang T-Z, LinC , Zou Y-F, Cheng J-C, et al. Maintenance therapy for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD013474. [DOI: 10.1002/14651858.CD013474]">Lee 2019</a>), we searched the following additional sources. </p> <p> <ul id="CD013474-list-0008"> <li> <p>Manual reference search: review author(s) manually searched the references of all identified trials, relevant review articles, and current treatment guidelines for further literature. </p> </li> <li> <p>Personal contacts: review authors contacted the lead investigators of relevant studies.</p> </li> <li> <p>Conference proceedings:</p> <ul id="CD013474-list-0009"> <li> <p>American Society of Hematology (ASH) (from 2020 to 2022);</p> </li> <li> <p>European Haematology Association (EHA) (from 2020 to 2022);</p> </li> <li> <p>American Society of Clinical Oncology (ASCO) (from 2020 to 2022); and</p> </li> <li> <p>European Society of Medical Oncology (ESMO) (from 2020 to 2022).</p> </li> </ul> </li> </ul> </p> <p>We included literature that matched our inclusion criteria whenever we were able to obtain adequate information from either the abstract or personal communication with the corresponding authors of the relevant studies. Additionally, we contacted the corresponding authors of relevant studies to identify any unpublished material, missing data, or information regarding ongoing studies. </p> <p>The most recent set of searches was conducted on 30 January 2022, from which all records were screened for relevance. Any and all studies meeting the eligibility criteria were fully incorporated into this research and review. </p> </section> </section> <section id="CD013474-sec-0041"> <h3 class="title" id="CD013474-sec-0041">Data collection and analysis</h3> <section id="CD013474-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CHL and YFZ) independently screened the abstracts of retrieved publications and decided whether to review the full text. In case of disagreement, the full text was obtained to aid in further discussion. Any studies that did not meet the inclusion criteria at this stage were considered ineligible and were excluded. We obtained the full‐text copies of all publications that potentially met the inclusion criteria. Two review authors (CHL and YFZ) independently read the obtained studies and selected studies for inclusion in the review. In case of disagreement, a third review author (CLH) reviewed the full publication of the disputed study. We included a PRISMA flow chart in the review to illustrate the study selection process (<a href="./references#CD013474-bbs2-0171" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006–12.">Moher 2009</a>). We used EndNote reference management software to identify and remove duplicate records (<a href="./references#CD013474-bbs2-0125" title="EndNote X8.1. Version accessed 30 January 2022. Philadelphia: Clarivate. Available at endnote.com.">EndNote X8.1</a>). We have documented the reasons for excluding studies that may have been reasonably expected to be included in the analysis in the <a href="./references#CD013474-sec-0167" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD013474-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CHL and YFZ) independently extracted data using a pre‐piloted form based on the standardised Cochrane data extraction form. If necessary, we contacted study authors for supplementary information (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). If the review authors were unable to reach a consensus, a third review author (CLH) made the final decision. After agreement on the extracted data, the data were entered into Review Manager Web (<a href="./references#CD013474-bbs2-0184" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). </p> <p>We extracted the information outlined below from the collated data.</p> <p> <ul id="CD013474-list-0010"> <li> <p>General information: author; title; source; publication date; country; language; and duplicate publications. </p> </li> <li> <p>Quality assessment: sequence generation; allocation concealment; blinding (participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other sources of bias. </p> </li> <li> <p>Study characteristics: trial design; study aims, setting, and dates; source of participants; inclusion/exclusion criteria; comparability of groups; subgroup analysis; statistical methods; power calculations; compliance with assigned treatment; length of follow‐up; time of randomisation. </p> </li> <li> <p>Participant characteristics: eligibility and recruitment method; baseline demographics including age; number of participants recruited/allocated/evaluated; disease status after first‐line or previous treatment; participants lost to follow‐up; Rai/Binet stage. </p> </li> <li> <p>Interventions: drugs and dosages; administration route, frequency, and duration of maintenance and follow‐up. </p> </li> <li> <p>Outcomes: definition and methods of measuring PFS; OS/mortality; complete/partial response rate; grades 3 to 4 adverse events requiring treatment discontinuation; withdrawal rates, including the number of individuals excluded from outcome assessment after randomisation and the reasons for their exclusion. If possible, we extracted data at the study‐arm level, rather than the summary effects. </p> </li> <li> <p>Others: study sponsorship/funding; stated conflicts of interest of the investigators.</p> </li> </ul> </p> <p>We extracted relevant outcome data on an intention‐to‐treat basis, as required, to calculate summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain the number of events and the population totals to create a 2 x 2 table. For continuous outcomes, means and standard deviations, or other data needed to calculate those estimates, were obtained. For count outcomes, we extracted the number of events, the number of the total population, and the median follow‐up. For time‐to‐event outcomes, we extracted hazard ratios (HRs) and 95% confidence intervals (CIs). </p> <section id="CD013474-sec-0044"> <h5 class="title">Potential effect modifiers</h5> <p>We extracted the following potential effect modifiers from each study.</p> <p> <ul id="CD013474-list-0011"> <li> <p>Population characteristics (age)</p> </li> <li> <p>Timing of maintenance therapy (front‐line or above second‐line)</p> </li> <li> <p>Intervention (type of drug)</p> </li> <li> <p>Comparison (placebo or observation)</p> </li> </ul> </p> </section> <section id="CD013474-sec-0045"> <h5 class="title">Duplicate and companion publications</h5> <p>All articles were mapped to unique trials, with all relevant data juxtaposed for identifying duplicate publications, companion records, or multiple published reports of an identical trial. </p> </section> </section> <section id="CD013474-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias in the included studies using the Cochrane RoB 1 tool, according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Based on this evaluation, we compiled a risk of bias table for each included study using Review Manager Web (<a href="./references#CD013474-bbs2-0184" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). Two review authors (CHL and YFZ) independently assessed risk of bias in each included study, with any disagreements addressed by group consensus or by consulting a third review author (CL) for the final decision. Risk of bias criteria are outlined below (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p> <ul id="CD013474-list-0012"> <li> <p>Random sequence generation (selection bias): was the random sequence appropriately generated? </p> </li> <li> <p>Allocation concealment (selection bias): was allocation adequately concealed?</p> </li> <li> <p>Blinding of participants and personnel (performance bias): where possible, were the study participants and personnel adequately blinded? </p> </li> <li> <p>Blinding of outcome assessment (detection bias): was blinding of the outcome assessors effective in preventing systematic differences such that the outcomes could be determined? </p> </li> <li> <p>Incomplete outcome data (attrition bias): did any missing data (drop‐out during the study or exclusions from the analysis) introduce bias? </p> </li> <li> <p>Selective reporting (reporting bias): were reports of the study free of selective outcome reporting? </p> </li> <li> <p>Other sources of bias: was the study apparently free of other problems that could put it at risk of bias? </p> </li> </ul> </p> <p>We judged the risk of bias domains for each included study as ‘low risk’, ‘high risk’, or ‘unclear risk’ (defined below), as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p> <ul id="CD013474-list-0013"> <li> <p>Low risk of bias: if the criterion is adequately fulfilled in the study, the study is at a low risk of bias for the given domain. </p> </li> <li> <p>High risk of bias: if the criterion is not fulfilled in the study, the study is at a high risk of bias for the given domain. </p> </li> <li> <p>Unclear risk of bias: if the study report provides insufficient information to permit a clear judgement of low risk or high risk, or if the risk of bias is unknown for the given domain. </p> </li> </ul> </p> <p>We evaluated the risk of performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessment) separately for each outcome. We grouped outcomes by subjective or objective measurement when reporting the findings in the risk of bias tables. </p> <section id="CD013474-sec-0047"> <h5 class="title">Objective measurements (endpoints are not considered to be influenced by blinding)</h5> <p> <ul id="CD013474-list-0014"> <li> <p>Overall survival</p> </li> <li> <p>Treatment‐related mortality</p> </li> <li> <p>Treatment discontinuation</p> </li> <li> <p>Minimal residual disease</p> </li> </ul> </p> </section> <section id="CD013474-sec-0048"> <h5 class="title">Subjective measurements (endpoints are considered to be potentially influenced by blinding) </h5> <p> <ul id="CD013474-list-0015"> <li> <p>Health‐related quality of life</p> </li> <li> <p>Grade 3/4 adverse events</p> </li> <li> <p>Progression‐free survival</p> </li> <li> <p>All adverse events</p> </li> <li> <p>Complete response rate</p> </li> <li> <p>Overall response rate</p> </li> </ul> </p> </section> </section> <section id="CD013474-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>We evaluated the intention‐to‐treat results, and calculated risk ratios with 95% confidence intervals (CIs) for dichotomous data. We used hazard ratios (HRs) with 95% CIs for the analysis of time‐to‐event outcomes. If HRs were not available, we made every effort to estimate the HR as accurately as possible using the available data and a purpose‐built method based on the Parmar and Tierney approach (<a href="./references#CD013474-bbs2-0179" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>; <a href="./references#CD013474-bbs2-0211" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>). If data were only available that could be extracted from figures, we used GetData Graph Digitizer software (<a href="./references#CD013474-bbs2-0135" title="GetData Graph Digitizer. Version 2.26. Fedorov, 2019. Available at getdata1.software.informer.com/2.2/.">GetData Graph Digitizer</a>). We calculated mean differences (MD) with 95% CIs for continuous outcomes. If different instruments were used to assess continuous treatment outcomes, we estimated standardised mean differences (SMD) with 95% CIs. For count data, we calculated rate ratios with 95% CIs. In the case of duplicate publications, we used data with the longest follow‐up. </p> </section> <section id="CD013474-sec-0050"> <h4 class="title">Unit of analysis issues</h4> <p>The individual participant was the unit of analysis. All cross‐over and cluster‐randomised trials were excluded. </p> </section> <section id="CD013474-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>We accounted for missing data as recommended in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We analysed data by the effect of assignment to intervention (the intention‐to‐treat effect). We contacted authors of the included trials to request relevant missing data and additional information not reported in the trial publications. </p> <p>If the number of trial participants assessed for a given outcome was not reported, we used the number of participants randomised per treatment arm as the denominator. We calculated numerators using percentages if only percentages but no absolute number of events were reported for binary outcomes. If estimates for mean and standard deviations were missing, we calculated these statistics from reported data, using the approaches described in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0151" title="HigginsJPT , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>), and imputed as previously described (<a href="./references#CD013474-bbs2-0133" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7-10. [DOI: 10.1016/j.jclinepi.2005.06.006]">Furukawa 2006</a>). If results were reported graphically but not numerically, we estimated the missing data from the figures. If not all participants (i.e. randomised participants) were included in the evaluated data, we assessed the missing information on a case‐by‐case basis to determine whether the loss was random or non‐random or could not be categorised. Apart from the data acquisition methods mentioned above, we did not input any missing data. </p> </section> <section id="CD013474-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We estimated heterogeneity using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic among the trials in each analysis. We used P = 0.10 for the Chi<sup>2</sup> test for statistical significance. We interpreted the I<sup>2</sup> statistic as described below, in accordance with Section 9.5.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0118" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>): </p> <p> <ul id="CD013474-list-0016"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: indicates moderate heterogeneity;</p> </li> <li> <p>50% to 90%: indicates substantial heterogeneity;</p> </li> <li> <p>75% to 100%: indicates considerable heterogeneity.</p> </li> </ul> </p> <p>If we observed substantial heterogeneity (I<sup>2</sup> &gt; 50%), we reported it and explored all possible causes through subgroup analyses (<a href="./references#CD013474-bbs2-0118" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>). The Tau<sup>2</sup> estimate of between‐study variance was calculated in a random‐effects meta‐analysis. If excessive heterogeneity was not explained by subgroup analysis, the outcome results were not pooled in the meta‐analysis, and a narrative description of the study results was presented instead. </p> </section> <section id="CD013474-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>Potential reporting biases were reported graphically through funnel plots, which were statistically tested by conducting a linear regression test for all outcomes if at least 10 trials were included. Funnel plots of treatment effect were compared with trial precision to illustrate asymmetry that indicated the potential for selection bias (e.g. the selective publication of trials with positive findings; <a href="./references#CD013474-bbs2-0123" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629–34. [DOI: 10.1136/bmj.315.7109.629]">Egger 1997</a>). Funnel plot asymmetry was tested using a linear regression analysis (<a href="./references#CD013474-bbs2-0123" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629–34. [DOI: 10.1136/bmj.315.7109.629]">Egger 1997</a>). We considered P &lt; 0.1 as significant for this test (<a href="./references#CD013474-bbs2-0200" title="SterneJA , EggerM , Moher D on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Sterne 2011</a>). </p> </section> <section id="CD013474-sec-0054"> <h4 class="title">Data synthesis</h4> <p>We conducted all data analysis as recommended in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0118" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>). Data were entered using the Cochrane Review Manager 5 statistical package (<a href="./references#CD013474-bbs2-0184" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>), and summarised using both fixed‐effect and random‐effects models. We used random‐effects models in the primary analyses and the fixed‐effect model for sensitivity analyses. We interpreted random‐effects meta‐analyses with due consideration of the complete distribution of effects. In addition, we performed statistical analyses based on the statistical guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p>We calculated dichotomous outcomes using the Mantel–Haenszel method. We used the inverse variance method to measure continuous outcomes. We used the generic inverse variance method to measure count and time‐to‐event outcomes. </p> <p>Multi‐arm studies were eligible for inclusion in the review. Our approach to performing data synthesis of such studies was either to omit groups irrelevant to the comparison or to combine multiple groups considered eligible as the experimental and/or comparator intervention. This was performed to create a single pair‐wise comparison. Only one multi‐arm trial was included in the review (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>). </p> </section> <section id="CD013474-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to explore potential causes of heterogeneity by performing subgroup analyses. This was done by stratifying the outcomes to assess heterogeneity for the following parameters. </p> <p> <ul id="CD013474-list-0017"> <li> <p>Type of drug</p> </li> <li> <p>Age of participants (adults &lt; 70 versus adults ≥ 70 years of age)</p> </li> <li> <p>When maintenance therapy was given (first‐line or treatment of previously treated individuals) </p> </li> </ul> </p> <p>We assessed differences between subgroups using the Chi<sup>2</sup> test (<a href="./references#CD013474-bbs2-0118" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>). </p> <p>If the number of studies was low, we did not perform subgroup analyses. Instead, we presented the results of stratified analyses for different anti‐CD20 drugs without testing for differences between subgroups. </p> </section> <section id="CD013474-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to test the robustness of the results by conducting a fixed‐effect pair‐wise meta‐analysis. Additionally, we planned a sensitivity analysis to compare studies at high risk of bias for random sequence generation, allocation concealment, and blinding with those at low risk of bias (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p>We did not perform a sensitivity analysis comparing anti‐CD20 mAbs at high risk of bias for random sequence generation, allocation concealment, and blinding to those at low risk of bias for two reasons: (i) there was no high risk of bias in the domains of random sequence generation and allocation concealment; and (ii) blinding for objective outcomes was all low risk of bias, while blinding for subjective outcomes was all high risk of bias. </p> <p>Regarding the IMiD comparison, we were also unable to conduct a sensitivity analysis as there was no high risk of bias in the domains of random sequence generation and allocation concealment. </p> <p>Regarding anti‐CD52 mAb, we did not perform sensitivity analysis as only one trial was included. </p> </section> <section id="CD013474-sec-0057"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD013474-sec-0058"> <h5 class="title">Certainty of the evidence</h5> <p>We used GRADEpro GDT software to assess the certainty of the body of evidence for each outcome (<a href="./references#CD013474-bbs2-0137" title="GRADEpro GDT. Version accessed 6 August 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>), as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013474-bbs2-0150" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>; <a href="./references#CD013474-bbs2-0192" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>). The GRADE approach considers problems associated with not only internal validity (risk of bias, inconsistency, imprecision, and publication bias) but also those associated with external validity (directness of results). Three review authors (CHL, YFZ, and CL) independently rated the certainty of the evidence for each outcome, with any disagreements resolved by discussion or by a senior review author (CLH). </p> <p>We downgraded evidence rated as high certainty by one level for serious, or by two levels for extremely serious concerns for each limitation. We explained our decisions to downgrade the certainty of the evidence in footnotes, and added comments to aid the reader’s understanding of the review when necessary. </p> <p>The levels of certainty of the evidence are as follows.</p> <p> <ul id="CD013474-list-0018"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> <section id="CD013474-sec-0059"> <h5 class="title">Tabulated summary of findings</h5> <p>We used the GRADE approach to tabulate research findings and judgement summaries, as described by the GRADE Working Group. For each comparison, a summary of the evidence was demonstrated for the main outcomes in a summary of findings table, as follows. </p> <p> <ul id="CD013474-list-0019"> <li> <p>Overall survival</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Grade 3 and 4 adverse events</p> </li> <li> <p>Progression‐free survival</p> </li> <li> <p>Treatment‐related mortality</p> </li> <li> <p>Treatment discontinuation</p> </li> <li> <p>All adverse events</p> </li> </ul> </p> <p>This table provides key information related to the best estimate of the magnitude of the effect in relative terms. It also includes the absolute differences for each relevant comparison of alternative management strategies, numbers of participants and studies addressing each important outcome, and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD013474-bbs2-0140" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [DOI: 10.1016/ j.jclinepi.2010.04.026]">Guyatt 2011</a>; <a href="./references#CD013474-bbs2-0192" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013474-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013474-sec-0060"></div> <section id="CD013474-sec-0061"> <h3 class="title">Description of studies</h3> <p>For details, see <a href="./references#CD013474-sec-0166" title="">Characteristics of included studies</a>, <a href="./references#CD013474-sec-0167" title="">Characteristics of excluded studies</a>, <a href="./references#CD013474-sec-0168" title="">Characteristics of studies awaiting classification</a>, and <a href="./references#CD013474-sec-0169" title="">Characteristics of ongoing studies</a>. </p> <section id="CD013474-sec-0062"> <h4 class="title">Results of the search</h4> <p>A study flow diagram is presented in <a href="#CD013474-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013474-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD013474-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> <p>As of 30 January 2022, we conducted a literature search of the electronic databases and trial registries and identified a total of 6396 references. After collating these references in a library (<a href="./references#CD013474-bbs2-0125" title="EndNote X8.1. Version accessed 30 January 2022. Philadelphia: Clarivate. Available at endnote.com.">EndNote X8.1</a>), and removing 2252 duplicates, we screened the remaining 5188 articles based on title and abstract and excluded 5090 articles that did not meet our inclusion criteria. We retrieved 63 published articles and 35 registered trials for full‐text screening, of which 11 records met our inclusion criteria for qualified synthesis. One report (conference abstracts) is currently awaiting classification (<a href="./references#CD013474-bbs2-0085" title="JaksicB , BrugiatelliM . High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL--IGCI CLL-01 trial. Nouvelle Revue Francaise d'Hematologie1988;30(5-6):437-42. ">Jaksic 1988</a>). We excluded 47 articles for the following reasons: </p> <p> <ul id="CD013474-list-0020"> <li> <p>single‐arm trials (27 articles);</p> </li> <li> <p>no eligible intervention regimen (7 articles);</p> </li> <li> <p>no eligible intervention strategy (5 articles);</p> </li> <li> <p>non‐randomised historical comparison group (4 articles);</p> </li> <li> <p>other types of studies (4 articles).</p> </li> </ul> </p> <p>We also excluded 26 registered trials, for the following reasons: 23 were single‐arm trials; one was a prospective case‐control study; one had no comparator group; and one was withdrawn prior to recruitment. Notably, of the registered trials, eight were included in our qualified review (all of which overlapped with published articles), and two prospectively registered trials are still ongoing (<a href="./references#CD013474-bbs2-0086" title="NCT03280160. Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab. clinicaltrials.gov/show/NCT03280160 (first received 9 September 2017). ">NCT03280160</a>; <a href="./references#CD013474-bbs2-0087" title="Oughton JB , CollettL , Howard DR , HockadayA , MunirT , McMahonK , et al. GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials2017;18(1):353. ">Oughton 2017</a>). </p> <p>We also identified 12 additional records through manual searches and our searches of conference proceedings (ASCO, ASA, ESMO, and EHA). Most of these records involved individuals with cancer or haematological malignancies, which were not identified by our search strategy due to the lack of CLL indexing. None of these records were included after full‐text screening. We contacted the corresponding or first authors, or both, of the record awaiting classification, as well as the two ongoing trials, because we were unsure if full publications existed for these studies (see <a href="./references#CD013474-sec-0168" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD013474-sec-0169" title="">Characteristics of ongoing studies</a>). We finally included 11 records in our qualified review. </p> </section> <section id="CD013474-sec-0063"> <h4 class="title">Included studies</h4> <p>For details of each study, see <a href="./references#CD013474-sec-0166" title="">Characteristics of included studies</a>. </p> <p>We included 11 RCTs involving a total of 2393 participants (range 21 to 480 per trial) in the review (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). Data from one included trial (52 participants) were not analysed in the meta‐analysis because they did not report the prespecified outcomes for the CLL group (E4402 trial <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a> did not report the results for the CLL subgroup). </p> <section id="CD013474-sec-0064"> <h5 class="title">Trial design and setting</h5> <p>The included trials were grouped by types of intervention. Seven trials compared anti‐CD20 mAb with observation. Among them, five trials compared rituximab maintenance therapy with observation (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>), and two trials compared ofatumumab maintenance therapy with observation (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). Three trials compared lenalidomide maintenance therapy with placebo/observation (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>), and one trial compared alemtuzumab maintenance therapy with observation (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). </p> <p>One study reported no periods for trial recruitment (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). Recruitment for the earliest trial began in November 2003, <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>, and lasted until March 2016, <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>. All included studies were published as full‐text publications. </p> <p>Ten of the included trials were two‐armed RCTs, while the remaining trial was a four‐armed RCT (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>). In order to include this last trial in the review, we divided it into two subgroups and analysed it correspondingly. One subgroup included participants with induction chemotherapy of fludarabine plus rituximab followed by with/without lenalidomide maintenance therapy. The other subgroup evaluated participants with induction chemotherapy of fludarabine, cyclophosphamide, and rituximab (FCR) followed by with or without lenalidomide maintenance therapy. </p> <p>Nine studies were phase 3 trials (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>), and two were phase 2 trials (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>). </p> <p>Six multicentre trials were conducted across different countries (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). Two trials were conducted in Italy with a multicentre design (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>). One multicentre trial was conducted in the USA (<a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>), and another multicentre trial was conducted in France (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>). </p> <p>The median duration of follow‐up in five trials that administered rituximab maintenance therapy ranged from 14.4 months, <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>, to 73 months, <a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>. The median duration of follow‐up in two trials that administered ofatumumab maintenance therapy was 40.9 months, <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>, and unavailable, <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>, respectively. In three trials of lenalidomide as maintenance therapy, the median duration of follow‐up ranged from 17.9 months, <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>, to 31.5 months, <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>. The median duration of follow‐up in one trial of alemtuzumab maintenance therapy was 12.4 months (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). </p> </section> <section id="CD013474-sec-0065"> <h5 class="title">Study participants</h5> <p>A total of 2393 adult patients with CLL post‐previous therapy were randomly allocated to a maintenance therapy group or an observation/placebo group. Participants of the male gender accounted for 60.5% and 58.5%, and median age ranged from 57.8 to 71.7 years old and from 54.1 to 71.1 years old in the maintenance group and control group, respectively. The type of previous induction and disease severity varied between studies. In rituximab maintenance trials, one trial used rituximab for induction (<a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>); one trial used rituximab plus cladribine plus cyclophosphamide (RCC) (<a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>); one trial used rituximab plus chlorambucil (RC) (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>); and two trials used fludarabine plus cyclophosphamide plus rituximab (FCR) (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>). </p> <p>In the ofatumumab maintenance trials, one trial used ofatumumab for induction (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>), and another used either FCR or rituximab and bendamustine (RB) (<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). All three lenalidomide maintenance trials used FCR or RB for induction therapy (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). The induction chemotherapy of alemtuzumab utilised either fludarabine or fludarabine/cyclophosphamide (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). </p> <p>There were variations in baseline disease severity. Eight trials reported baseline Binet or Rai stage status (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), whereas the remaining three trials did not (<a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a> included non‐Hodgkin’s lymphoma reported ISS (international staging system) stage; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a> and <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a> did not report baseline stage). Among the eight trials that reported baseline stage, five had a higher proportion of participants in the early stage with Rai stage I/II or Binet stage A with symptoms or high cytogenetic aberrations (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). The other three trials had a higher proportion of participants in Rai stage III/IV or Binet stage B/C (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). Regarding cytogenic evaluation, only three trials did not present these data (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>); six trials showed the presence of cytogenic aberrations more frequently, ranging from 69.7% to 80.1% (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>), whereas the remaining two trials were opposites (71.9% and 67.7% without cytogenic abnormalities in <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a> and <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>, respectively). Most trials performed the analysis for immunoglobulin heavy‐chain variable region gene (IGHV) mutation status, with unmutated IGHV rate of approximately 41.4% to 91% (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), with the exception of three trials for which baseline IGHV status was not reported (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> </section> <section id="CD013474-sec-0066"> <h5 class="title">Study interventions</h5> <p>In seven trials, participants received intravenous anti‐CD20 mAbs as maintenance therapy (n = 847) versus observation (n = 832). In five trials, participants received intravenous rituximab as maintenance therapy (n = 583) versus observation (n = 579): four trials administered 375 mg/m<sup>2</sup> every 12 weeks (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>), and one trial administered 500 mg/m<sup>2</sup> every eight weeks for up to two years or until disease progression (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>). In two trials, participants received intravenous ofatumumab as maintenance therapy (n = 264) for up to two years with a target dosage of 1000 mg, <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>, or 2000 mg versus observation (n = 253), <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>. </p> <p>In another three trials, participants received oral IMiD (lenalidomide) as maintenance therapy (n = 360) with a targeted dosage of 5 mg, <a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>, or 15 mg, <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>, daily until progression versus placebo/observation (n = 333). In another trial, participants received 30 mg intravenous anti‐CD52 mAb (alemtuzumab, n = 11) three times per week for up to 12 weeks versus observation (n = 10) (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). </p> <section id="CD013474-sec-0067"> <h6 class="title">Anti‐CD20 mAb – rituximab maintenance trials</h6> <p><a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>: participants with previously untreated CLL (Binet stage A or B with active disease or stage C) who received induction therapy of RC and achieved complete response, complete response with incomplete bone marrow recovery, and partial response were randomised to maintenance rituximab 375 mg/m<sup>2</sup> intravenously once every 8 weeks for 12 doses or to observation. </p> <p><a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a> and Egle 2019: participants who achieved complete response, complete response with incomplete bone marrow recovery, or partial response following previous first‐ or second‐line rituximab‐containing chemo‐immunotherapy were randomised to either rituximab or observation. Participants in the maintenance group were offered intravenous rituximab 375 mg/m<sup>2</sup> with a three‐month interval up to two years or until disease progression. </p> <p><a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>: participants who achieved a partial or complete response after induction therapy were randomised to maintenance rituximab 375 mg/m<sup>2</sup> intravenously once every three months until treatment failure or observation group rechallenged rituximab until disease progression. </p> <p><a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>: participants with CLL who achieved clinical response following previous first‐ or second‐line rituximab‐containing chemo‐immunotherapy were randomly assigned to maintenance rituximab 375 mg/m<sup>2</sup> intravenously with a three‐month interval and up to two years or until disease progression or to observation. </p> <p><a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>: participants with CLL with an immunologically confirmed diagnosis (CD5‐, CD19‐, CD23‐, and CD20‐positive clone), at stages I to IV according to the Rai classification, achieved a partial response or complete response after six cycles. RCC induction was randomly assigned to either rituximab 375 mg/m<sup>2</sup> intravenously, up to eight cycles every 12 weeks, or observation. </p> </section> <section id="CD013474-sec-0068"> <h6 class="title">Anti‐CD20 mAb – ofatumumab maintenance trials</h6> <p><a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>: participants with bulky fludarabine‐refractory CLL who achieved at least stable disease or better after ofatumumab induction therapy underwent randomisation (2:1) to either intravenous ofatumumab fixed 2000 mg once every 4 weeks for up to an additional 24 weeks or no further treatment. </p> <p><a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>: participants who achieved either partial response or complete response after second‐ or third‐line therapy were randomised to either intravenous ofatumumab 1000 mg once every eight weeks for up to two years or to observation. </p> </section> <section id="CD013474-sec-0069"> <h6 class="title">IMiD – lenalidomide maintenance trials</h6> <p><a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>: participants with CLL who responded to chemo‐immunotherapy two to five months after completion of first‐line therapy and who were assessed to be at high risk for early progression, defined by minimal residual disease (MRD) levels of 10<sup>−2</sup> or higher or MRD levels of 10<sup>−4</sup> to &lt; 10<sup>−2</sup> after completion of first‐line treatment combined with either an unmutated IGHV status of del(17p) or <i>TP53</i> mutation at baseline, were randomly assigned to either oral lenalidomide or placebo. Lenalidomide was initiated at 5 mg daily in the first 28 days’ cycle; if well‐tolerated, the dose was increased to 10 mg daily in each 28‐day cycle in cycles 2 to 6. A target dose of 15 mg daily was given starting with the seventh cycle up to progression of the disease. Further increase in dosage (to 20 mg starting with the 13th cycle and to 25 mg starting with the 19th cycle) was guided by MRD assessments and allowed in participants with MRD levels of 10<sup>−4</sup> or higher in peripheral blood who could tolerate previous dose levels. The maximal daily dose of lenalidomide was 25 mg. </p> <p><a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>: participants who received bendamustine, antiCD20 antibody, chlorambucil, or alemtuzumab as first‐ or second‐line treatment and achieved at least achieved a partial response were randomised to lenalidomide maintenance or placebo. Lenalidomide was started at 2 or 5 mg, once per day during days 1 to 28. If lenalidomide was well‐tolerated, an increase in dose to 5 mg/day was permitted cycle 2 onward. If the participant completed five continuous cycles of 5 mg/day lenalidomide, which was tolerated well and an MRD‐negative complete response was not achieved, the dose could be increased to 10 mg/day. Treatment continued until disease progression or unacceptable toxic effects. </p> <p><a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>: participants with naive CLL who had an asymptomatic intermediate (Rai I or II) or high‐risk (Rai III or IV) stage CLL and a performance status of 2 or more and achieved clinical response were blindly randomised to receive either oral lenalidomide or observation. Lenalidomide was started at 5 mg initially for days 1 to 21 and increased to 10 mg if tolerated for six months. </p> </section> <section id="CD013474-sec-0070"> <h6 class="title">Anti‐CD52 mAb – alemtuzumab maintenance trials</h6> <p><a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>: participants who responded to induction treatment with either fludarabine or fludarabine plus cyclophosphamide were randomised to either 30 mg intravenous alemtuzumab three times per week for up to 12 weeks or to observation. The starting dose of alemtuzumab was 3 mg on day 1; if well tolerated, it was increased to 10 mg on day 2 and the target dose of 30 mg on day 3. The 30 mg dose was subsequently given three times a week for a maximum of 12 weeks. </p> </section> </section> <section id="CD013474-sec-0071"> <h5 class="title">Study outcomes</h5> <section id="CD013474-sec-0072"> <h6 class="title">Primary outcome measure</h6> <p>Our primary outcomes were overall survival (OS), health‐related quality of life (HRQoL), and grade 3/4 adverse events (AEs). A total of 10 trials were included in the meta‐analyses for these outcomes. </p> <p>Six trials reported OS, which was presented as median hazard ratios (HRs) and 95% confidence intervals (CIs). Three trials compared anti‐CD20 mAbs maintenance with observation (two with rituximab (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>), and one with ofatumumab (<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>)), and three trials compared lenalidomide maintenance versus placebo/observation (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). OS data for <a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a> were extracted from survival curves. </p> <p>Only one trial reported HRQoL, which compared ofatumumab with observation presented as mean difference (MD) and standard deviation (SD) (<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). </p> <p>Seven trials reported grade 3 and 4 AEs, which were calculated from tables: five trials compared anti‐CD20 mAbs maintenance with observation (four with rituximab (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), and one with ofatumumab (<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>)), and two trials compared lenalidomide maintenance versus placebo (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). </p> </section> <section id="CD013474-sec-0073"> <h6 class="title">Secondary outcome measures</h6> <p>Nine trials reported progression‐free survival (PFS), with a total of five trials comparing anti‐CD20 mAbs maintenance with observation (three trials with rituximab (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), and two trials with ofatumumab (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>;<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>)); two trials comparing lenalidomide with placebo (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>), and one trial comparing lenalidomide with observation (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>); and one trial comparing alemtuzumab with observation (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a> only reported a three‐year PFS rate. We extracted PFS data for <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>, <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>, <a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>, and <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a> from survival curves due to the lack of actual values. </p> <p>Seven trials reported treatment‐related mortality (TRM) outcomes: four anti‐CD20 mAbs trials (two with rituximab (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>), and two with ofatumumab (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>;<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>)), and three lenalidomide maintenance trials (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). </p> <p>Eight trials reported treatment discontinuation (TD): six anti‐CD20 mAbs trials (four with rituximab maintenance (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), and two with ofatumumab maintenance (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>)), and two lenalidomide maintenance trials (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). </p> <p>Three trials reported complete response rate (CRR) and overall response rate (ORR): two rituximab maintenance trials (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), and one alemtuzumab maintenance trial (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). </p> <p>Nine trials reported all adverse events: six anti‐CD20 mAbs trials (four with rituximab maintenance (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), and two with ofatumumab maintenance (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>)), and three lenalidomide trials (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). </p> <p>No trials reported the outcome of MRD.</p> </section> </section> <section id="CD013474-sec-0074"> <h5 class="title">Study funding</h5> <p>All trials reported their sources of funding. Seven trials received commercial sponsorship from the pharmaceutical industry; one trial received funding from Sanofi Genzyme (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>); four trials from Roche (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>); three trials from Novartis AG, Inc (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>); and three trials from GlaxoSmithKline and Genmab A/S, Inc. (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). Seven trials were supported by the national government or academic research funding (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> </section> </section> <section id="CD013474-sec-0075"> <h4 class="title">Ongoing studies</h4> <p>We identified two ongoing trials (for details, see <a href="./references#CD013474-sec-0169" title="">Characteristics of ongoing studies</a>) (<a href="./references#CD013474-bbs2-0086" title="NCT03280160. Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab. clinicaltrials.gov/show/NCT03280160 (first received 9 September 2017). ">NCT03280160</a>; <a href="./references#CD013474-bbs2-0087" title="Oughton JB , CollettL , Howard DR , HockadayA , MunirT , McMahonK , et al. GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials2017;18(1):353. ">Oughton 2017</a>). </p> <p>The planned enrolment for these two trials included a total of 272 participants. We will be monitoring their progress, and when published, they will be included in future updates of this review if deemed eligible. </p> </section> <section id="CD013474-sec-0076"> <h4 class="title">Excluded studies</h4> <p>For details, see <a href="./references#CD013474-sec-0167" title="">Characteristics of excluded studies</a>. </p> <p>We excluded a total of 73 studies merged from 47 publications and 26 registered trials. We excluded publications for the following reasons: single‐arm trial (<a href="./references#CD013474-bbs2-0012" title="AbrisquetaP , VillamorN , Terol MJ , Gonzalez-BarcaE , GonzalezM , FerraC , et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood2013;122(24):3951-9. ">Abrisqueta 2013</a>; <a href="./references#CD013474-bbs2-0013" title="Chang JE , HavighurstT , KimK , EickhoffJ , Traynor AM , Kirby-SlimpR , et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. British Journal of Haematology2016;173(2):283-91. ">Chang 2016</a>; <a href="./references#CD013474-bbs2-0014" title="EgleA , SteurerM , MelchardtT , WeissL , Gassner FJ , ZaborskyN , et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Annual Hematology2018;97(10):1825-39. ">Egle 2018</a>; <a href="./references#CD013474-bbs2-0023" title="Flinn IW , Ruppert AS , HarwinW , WaterhouseD , PapishS , Jones JA , et al. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. American Journal of Hematology2016;91(10):1020-5. ">Flinn 2016</a>; <a href="./references#CD013474-bbs2-0024" title="Hainsworth JD , LitchyS , Barton JH , Houston GA , Hermann RC , Bradof JE , et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology2003;21(9):1746-51. ">Hainsworth 2003</a>; <a href="./references#CD013474-bbs2-0028" title="Kaufman MS , CaramanicaA , JansonD , DriscollN , JohnsonC , KohnN , et al. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Medical Oncology (Northwood, London, England)2011;28(2):532-8. ">Kaufman 2011</a>; <a href="./references#CD013474-bbs2-0029" title="Keller JW , Knospe WH , RaneyM , Huguley C M Jr, JohnsonL , Bartolucci AA , et al. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial. Cancer1986;58(6):1185-92. ">Keller 1986</a>; <a href="./references#CD013474-bbs2-0030" title="KempinS , SunZ , Kay NE , Paietta EM , Mazza JJ , Ketterling RP , et al. Pentostatin, cyclophosphamide, and rituximab followed by alemtuzumab for relapsed or refractory chronic lymphocytic leukemia: a phase 2 trial of the ECOG-Acrin Cancer Research Group (E2903). Acta Haematologica2019;142(4):224-32. ">Kempin 2019</a>; <a href="./references#CD013474-bbs2-0032" title="LamannaN , Jurcic JG , NoyA , MaslakP , Gencarelli AN , Panageas KS , et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. Journal of Clinical Oncology2009;27(4):491-7. ">Lamanna 2009</a>; <a href="./references#CD013474-bbs2-0033" title="Lampson BL , Kim HT , Davids MS , Abramson JS , Freedman AS , Jacobson CA , et al. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Advances2019;3(7):1167-74. ">Lampson 2019</a>; <a href="./references#CD013474-bbs2-0034" title="Lin TS , Donohue KA , Byrd JC , Lucas MS , Hoke EE , Bengtson EM , et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. Journal of Clinical Oncology2010;28(29):4500-6. ">Lin 2010</a>; <a href="./references#CD013474-bbs2-0035" title="Mato AR , Foon KA , FeldmanT , Schuster SJ , SvobodaJ , Chow KF , et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. American Journal of Hematology2015;90(6):487-92. ">Mato 2015</a>; <a href="./references#CD013474-bbs2-0038" title="MontilloM , Cafro AM , TedeschiA , BrandoB , OresteP , VeroneseS , et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica2002;87(7):695-700. ">Montillo 2002</a>; <a href="./references#CD013474-bbs2-0039" title="MontilloM , TedeschiA , MiqueleizS , VeroneseS , CairoliR , IntropidoL , et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology2006;24(15):2337-42. ">Montillo 2006</a>; <a href="./references#CD013474-bbs2-0058" title="NoyA , VermaR , GlennM , MaslakP , Rahman ZU , Keenan JR , et al. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood2001;97(7):1929-36. ">Noy 2001</a>; <a href="./references#CD013474-bbs2-0060" title="O'Brien SM , Kantarjian HM , Thomas DA , CortesJ , Giles FJ , Wierda WG , et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer2003;98(12):2657-63. ">O'Brien 2003</a>; <a href="./references#CD013474-bbs2-0062" title="OsterborgA , Wierda WG , MayerJ , HessG , HillmenP , ScheteligJ , et al. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. British Journal of Haematology2015;170(1):40-9. ">Osterborg 2015</a>; <a href="./references#CD013474-bbs2-0064" title="PleyerC , TianX , RampertaapS , MuR , SotoS , SuperataJ , et al. A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. American Journal of Hematology2020;95(11):E310-3. ">Pleyer 2020</a>; <a href="./references#CD013474-bbs2-0065" title="Rai KR , Freter CE , Mercier RJ , Cooper MR , Mitchell BS , Stadtmauer EA , et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Journal of Clinical Oncology2002;20(18):3891-7. ">Rai 2002</a>; <a href="./references#CD013474-bbs2-0066" title="RosenthalA , Dueck AC , AnsellS , GanoK , ConleyC , Nowakowski GS , et al. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. American Journal of Hematology2017;92(5):467-72. ">Rosenthal 2017</a>; <a href="./references#CD013474-bbs2-0069" title="ScheyS , AhsanG , JonesR . Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study. Bone Marrow Transplantation1999;24(9):989-93. ">Schey 1999</a>; <a href="./references#CD013474-bbs2-0070" title="Sehn LH , Assouline SE , Stewart DA , MangelJ , Gascoyne RD , FineG , et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood2012;119(22):5118-25. ">Sehn 2012</a>; <a href="./references#CD013474-bbs2-0071" title="ShadmanM , Gopal AK , KammererB , Becker PS , Maloney DG , PenderB , et al. Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. Leukemia &amp; Lymphoma2016;57(3):572-6. ">Shadman 2016</a>; <a href="./references#CD013474-bbs2-0076" title="SrockS , SchrieverF , NeubauerA , HeroldM , HuhnD . Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leukemia &amp; Lymphoma2007;48(5):905-11. ">Srock 2007</a>; <a href="./references#CD013474-bbs2-0078" title="StratiP , Keating MJ , Burger JA , O'Brien SM , Wierda WG , EstrovZ , et al. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica2017;102(12):e494-6. ">Strati 2017</a>; <a href="./references#CD013474-bbs2-0080" title="Von TresckowJ , CramerP , BahloJ , RobrechtS , LangerbeinsP , Fink A-M, et al. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia2019;33(5):1161-72. ">von Tresckow 2019</a>; <a href="./references#CD013474-bbs2-0082" title="Weiss MA , GlennM , MaslakP , RahmanZ , NoyA , ZelenetzA , et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia2000;14(9):1577-82. ">Weiss 2000</a>); no eligible intervention regimen (<a href="./references#CD013474-bbs2-0031" title="Khouri MR , Jabbour EJ , Gulbis AM , TurturroF , LedesmaC , KorblingM , et al. Feasibility of lenalidomide therapy for persistent chronic lymphocytic leukemia after allogeneic transplantation. Journal of the American Society for Blood and Marrow Transplantation2017;23(8):1405-10. ">Khouri 2017</a>;<a href="./references#CD013474-bbs2-0036" title="Mauro FR , ZinzaniP , ZajaF , GentileM , Vegna ML , StefoniV , et al. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study. Haematologica2003;88(12):1348-57. ">Mauro 2003</a>; <a href="./references#CD013474-bbs2-0059" title="O'BrienS , KantarjianH , BeranM , Robertson LE , KollerC , LernerS , et al. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood1995;86(4):1298-300. ">O'Brien 1995</a>; <a href="./references#CD013474-bbs2-0063" title="PanD , QinJ , FarberC , O'BrienJ , FilippaD , Portlock CS . CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leukemia &amp; Lymphoma2003;44(6):967-71. ">Pan 2003</a>;<a href="./references#CD013474-bbs2-0081" title="WalewskiJ , Paszkiewicz-KozikE , MichalskiW , RymkiewiczG , SzpilaT , ButrymA , et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. British Journal of Haematology2020;188(6):898-906. ">Walewski 2020</a>; <a href="./references#CD013474-bbs2-0083" title="Zinzani PL , Levrero MG , LauriaF , RondelliD , ZajaF , RussoD , et al. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Haematologica1994;79(1):55-60. ">Zinzani 1994</a>; <a href="./references#CD013474-bbs2-0084" title="Zinzani PL , BendandiM , MagagnoliM , RondelliD , deVivoA , BenniM , et al. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. European Journal of Haematology1997;59(2):82-8. ">Zinzani 1997</a>); no eligible intervention strategy (<a href="./references#CD013474-bbs2-0027" title="Kater AP , vanOers M HJ , vanNY , van derSL , DriessenJ , Posthuma W FM , et al. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica2019;104(1):147-54. ">Kater 2019</a>; <a href="./references#CD013474-bbs2-0040" title="MorenoC , GreilR , DemirkanF , TedeschiA , AnzB , LarrattL , et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology2019;20(1):43-56. ">Moreno 2019</a>; <a href="./references#CD013474-bbs2-0073" title="Shanafelt TD , Wang XV , Kay NE , Hanson CA , O'BrienS , BarrientosJ , et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. The New England Journal of Medicine2019;381(5):432-43. ">Shanafelt 2019</a>; <a href="./references#CD013474-bbs2-0074" title="Sharman JP , Coutre SE , Furman RR , Cheson BD , Pagel JM , HillmenP , et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. Journal of Clinical Oncology2019;37(16):1391-402. ">Sharman 2019</a>; <a href="./references#CD013474-bbs2-0075" title="Sharman JP , EgyedM , JurczakW , SkarbnikA , Pagel JM , Flinn LW , et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet2020;395(10232):1278-91. ">Sharman 2020</a>); non‐randomised historical comparison group (<a href="./references#CD013474-bbs2-0025" title="Huang B-T, Zeng Q-C, Zhao W-H, Li B-S, Chen R-l. How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation. Medical Oncology (Northwood, London, England)2014;31(8):104. ">Huang 2014</a>; <a href="./references#CD013474-bbs2-0072" title="Shanafelt TD , Ramsay AG , Zent CS , Leis JF , Tun HW , Call TG , et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood2013;121(20):4137-41. ">Shanafelt 2013</a>; <a href="./references#CD013474-bbs2-0077" title="StratiP , LanasaM , Call TG , Leis JF , Brander DM , LaPlant BR , et al. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. The Lancet Haematology2016;3(9):e407-14. ">Strati 2016</a>; <a href="./references#CD013474-bbs2-0079" title="ThieblemontC , BouafiaF , HornezE , DumontetC , TartasS , AntalD , et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leukemia &amp; Lymphoma2004;45(4):711-4. ">Thieblemont 2004</a>), or other types of studies (<a href="./references#CD013474-bbs2-0068" title="ScaramucciL , NiscolaP , BuffolinoS , BongarzoniV , CiminoG , MontanaroM . Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy. The Hematology Journal2004;5(2):186-7. ">Scaramucci 2004</a> with a case series study design; <a href="./references#CD013474-bbs2-0037" title="MocciaA , GhielminiM . Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy. Seminars In Hematology2008;45(2):75-84. ">Moccia 2008</a>, <a href="./references#CD013474-bbs2-0061" title="O'BrienS , Kay NE . Maintenance therapy for B-chronic lymphocytic leukemia. Clinical Advances in Hematology &amp; Oncology2011;9(1):22-31. ">O'Brien 2011</a>, and <a href="./references#CD013474-bbs2-0067" title="Ruppert AS , YinJ , DavidianM , Tsiatis AA , Byrd JC , Woyach JA , et al. Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. Annals of Oncology2019;30(4):542-50. ">Ruppert 2019</a> with a review article study design). </p> <p>We excluded registered trials for the following reasons: single‐arm trial (<a href="./references#CD013474-bbs2-0015" title="EUCTR2005-001569-33-ES. First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia [Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC) – R-FCM in CLL]. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001569-33/ES (first received 5 September 2005). ">EUCTR2005‐001569‐33‐ES</a>; <a href="./references#CD013474-bbs2-0016" title="EUCTR2008-001823-71-IT. Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) – len-cam. www.clinicaltrialsregister.eu/ctr-search/trial/2008-001823-71/IT (first received 20 May 2008). ">EUCTR2008‐001823‐71‐IT</a>; <a href="./references#CD013474-bbs2-0017" title="EUCTR2010-018519-14-IT. Rituximab-2cda + rituximab maintenance in chronic lymphocytic leukaemia and small lymphocytic lymphoma. www.clinicaltrialsregister.eu/ctr-search/trial/2010-018519-14/IT (first received 8 November 2010). ">EUCTR2010‐018519‐14‐IT</a>; <a href="./references#CD013474-bbs2-0018" title="EUCTR2014-000569-35-DE. A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol). www.clinicaltrialsregister.eu/ctr-search/trial/2014-000569-35/DE (first received 16 October 2014). ">EUCTR2014‐000569‐35‐DE</a>; <a href="./references#CD013474-bbs2-0019" title="EUCTR2014-000580-40-DE. A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax, GDC-0199) followed by ABT-199 and GA101 maintenance in CLL patients. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000580-40/DE (first received 22 January 2015). ">EUCTR2014‐000580‐40‐DE</a>; <a href="./references#CD013474-bbs2-0020" title="EUCTR2014-000582-47-DE. A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG). www.clinicaltrialsregister.eu/ctr-search/trial/2014-000582-47/DE (first received 9 February 2015). ">EUCTR2014‐000582‐47‐DE</a>; <a href="./references#CD013474-bbs2-0021" title="EUCTR2014-000590-39-DE. A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients (CLL2-BIO-trial of the GCLLSG). www.clinicaltrialsregister.eu/ctr-search/trial/2014-000590-39/DE (first received 5 November 2015). ">EUCTR2014‐000590‐39‐DE</a>; <a href="./references#CD013474-bbs2-0022" title="EUCTR2015-004985-27-NL. A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. www.clinicaltrialsregister.eu/ctr-search/trial/2015-004985-27/NL (first received 6 May 2016). ">EUCTR2015‐004985‐27‐NL</a>; <a href="./references#CD013474-bbs2-0041" title="NCT00336206. Low dose alemtuzumab for consolidation and maintenance of patients with b-cell chronic lymphocytic leukemia. clinicaltrials.gov/show/NCT00336206 (first received 12 June 2006). ">NCT00336206</a>; <a href="./references#CD013474-bbs2-0042" title="NCT00587847. Campath maintenance in chronic lymphocytic leukemia. clinicaltrials.gov/show/NCT00587847 (first received 7 January 2005). ">NCT00587847</a>; <a href="./references#CD013474-bbs2-0044" title="NCT00860457. Lenalidomide following fludarabine/rituximab (FR) in untreated chronic lymphocytic leukemia (CLL). clinicaltrials.gov/show/NCT00860457 (first received 11 March 2008). ">NCT00860457</a>; <a href="./references#CD013474-bbs2-0045" title="NCT00974233. Study of bendamustine/rituxan induction chemotherapy with revlimid maintenance for relapsed/refractory CLL and SLL. clinicaltrials.gov/show/NCT00974233 (first received 9 September 2009). ">NCT00974233</a>; <a href="./references#CD013474-bbs2-0046" title="NCT01258933. Ofatumumab for minimal residual disease (MRD) and maintenance therapy. clinicaltrials.gov/show/NCT01258933 (first received 10 December 2011). ">NCT01258933</a>; <a href="./references#CD013474-bbs2-0047" title="NCT01392079. Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fludarabine. clinicaltrials.gov/show/NCT01392079 (first received 11 July 2008). ">NCT01392079</a>; <a href="./references#CD013474-bbs2-0048" title="NCT01403246. Chlorambucil + lenalidomide and lenalidomide maintenance in untreated elderly with chronic lymphocytic leukemia (CLL). clinicaltrials.gov/show/NCT01403246 (first received 26 July 2011). ">NCT01403246</a>; <a href="./references#CD013474-bbs2-0049" title="NCT01465230. Maintenance therapy: lenalidomide following bendamustine and rituximab induction therapy for chronic lymphocytic leukemia. clinicaltrials.gov/show/NCT01465230 (first received 1 November 2011). ">NCT01465230</a>; <a href="./references#CD013474-bbs2-0050" title="NCT01496976. Ofatumumab, high dose methylprednisolone, ofatumumab and lenalidomide consolidative therapy for untreated CLL/SLL. clinicaltrials.gov/show/NCT01496976 (first received 21 December 2011). ">NCT01496976</a>; <a href="./references#CD013474-bbs2-0051" title="NCT01521689. Tolerance and efficacy of subcutanous low doses rituximab for CLL consolidation treatment. clinicaltrials.gov/show/NCT01521689 (first received 26 January 2011). ">NCT01521689</a>; <a href="./references#CD013474-bbs2-0052" title="NCT01600053. Revlimid as consolidation treatment chronic lymphocytic leukemia. clinicaltrials.gov/show/NCT01600053 (first received 14 May 2012). ">NCT01600053</a>; <a href="./references#CD013474-bbs2-0053" title="NCT01754857. Bendamustine and rituximab induction therapy and maintenance rituximab and lenalidomide in previously untreated CLL/SLL. clinicaltrials.gov/show/NCT01754857 (first received 18 December 2012). ">NCT01754857</a>; <a href="./references#CD013474-bbs2-0054" title="NCT01754870. Phase II study of bendamustine and rituximab induction chemoimmunotherapy followed by maintenance rituximab (Rituxan®) and lenalidomide (Revlimid®) in relapsed and refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). clinicaltrials.gov/show/NCT01754870 (first received 18 December 2012). ">NCT01754870</a>; <a href="./references#CD013474-bbs2-0055" title="NCT01809847. Ofatumumab induction and maintenance in elderly patients with poor risk CLL in the context of allogeneic transplantation. clinicaltrials.gov/show/NCT01809847 (first received 11 March 2013). ">NCT01809847</a>; <a href="./references#CD013474-bbs2-0056" title="NCT02013817. CHAIROS study: a study of MabThera/Rituxan (Rituximab) maintenance therapy in patients with b-cell chronic lymphocytic leukemia (CLL) naive to chemotherapy. clinicaltrials.gov/show/NCT02013817 (first received 11 December 2013). ">NCT02013817</a>); prospective case‐control design (<a href="./references#CD013474-bbs2-0057" title="NCT03847727. Bendamustine and rituximab (BR) as induction and maintenance in relapsed and refractory chronic lymphocytic leukemia. clinicaltrials.gov/show/NCT03847727 (first received 18 Feburary 2018). ">NCT03847727</a>); no comparator group (<a href="./references#CD013474-bbs2-0043" title="NCT00771602. Alemtuzumab + rituximab consolidation in CLL. clinicaltrials.gov/show/NCT00771602 (first received 10 October 2008). ">NCT00771602</a>; only included one participant); withdrawn prior to recruitment (<a href="./references#CD013474-bbs2-0026" title="ISRCTN63375144. CLL8: a randomised, phase III study to assess alemtuzumab consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL) who have responded to previous therapy. www.isrctn.com/ISRCTN63375144 (first received 12 March 2008). ">ISRCTN63375144</a>; with alemtuzumab licence withdrawn by Genyme Sanofi on 8 August 2012). </p> </section> </section> <section id="CD013474-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias in the included studies (for details, see <a href="./references#CD013474-bbs1-0001" title="">Included studies</a>) using Cochrane's RoB 1 tool, given that all 11 studies were RCTs. Overall, risk of bias was unclear; detailed assessments for each study are described in <a href="./references#CD013474-sec-0166" title="">Characteristics of included studies</a> and summarised in <a href="#CD013474-fig-0002">Figure 2</a>; <a href="#CD013474-fig-0003">Figure 3</a>, according to the methods presented in <a href="#CD013474-sec-0046">Assessment of risk of bias in included studies</a>. </p> <div class="figure" id="CD013474-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013474-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD013474-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013474-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD013474-sec-0078"> <h4 class="title">Allocation</h4> <p>Overall, the included studies were at unclear risk of selection bias. We evaluated the random sequence generation as adequate in five trials (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), which we categorised as at low risk of bias. Six studies reported randomisation procedures without sufficient detail to permit a judgement, thus we considered their risk of bias as unclear (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> <p>Allocation concealment was appropriate for four trials (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), and unclear for eight studies (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> </section> <section id="CD013474-sec-0079"> <h4 class="title">Blinding</h4> <p>Overall, we judged the risk of performance and detection bias to be low for objective outcomes and high for subjective outcomes. </p> <section id="CD013474-sec-0080"> <h5 class="title">Performance bias</h5> <p>While exploring the effect of maintenance therapy intervention on people with CLL, we found that only two RCTs had double‐blind and identical placebo designs (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). The other nine RCTs had an open‐label design; the performance of objective outcomes may not be affected, but that of other outcomes may be affected because of lack of blinding. Consequently, we judged all studies to have a low risk of bias for objective outcomes, and the risk of bias for blinding of participants and physicians as high for subjective outcomes (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> </section> <section id="CD013474-sec-0081"> <h5 class="title">Detection bias</h5> <p>We rated nine trials at low risk of detection bias for the assessment of objective outcomes. </p> <p>Given that the judgements of unblinded outcome assessors for subjective outcomes may be influenced, we assessed the risk of bias for blinding of outcome assessment in nine trials as high (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). The other two trials had a triple‐blind design (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>), thus we judged the risk of bias as low. </p> </section> </section> <section id="CD013474-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>Overall, we judged risk of attrition bias as low. No risk of attrition bias could be detected, with all randomised participants analysed in the arms to which had been assigned; we therefore judged the risk of attrition bias to be low for nine trials (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). We assessed risk of attrition bias for the other two trials as high: one trial had lost a follow‐up ratio of up to 23.7% (<a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), and the other trial enrolled 66 participants; however, only 39 participants were included in the final analysis (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>). One trial provided insufficient detail to permit a judgement, thus we considered risk of bias as unclear (<a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> </section> <section id="CD013474-sec-0083"> <h4 class="title">Selective reporting</h4> <p>Overall, we considered there to be no obvious risk of reporting bias. For 9 of the 11 included trials, for which registered protocols existed, we judged the risk of reporting bias as low (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> <p>Two trials had a registered protocol but did not fully report the prespecified outcomes. In the GCLLSG trial (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>), results for patient quality of life were not reported. In a trial performed by <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>, results were not reported for the following outcomes: duration of response, adverse event of interest (infusion reactions, infections, mucocutaneous reactions, tumour lysis syndrome, cardiovascular events, and small bowel obstruction), mean immunoglobulin (Ig) antibodies IgA, IgG and IgM over time, and number of participants who were positive or negative for human anti‐human antibodies post‐ofatumumab therapy. </p> </section> <section id="CD013474-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>We considered the overall risk of other sources of bias as low.</p> <p>We considered two trials to be at high risk of other potential sources of bias: <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a> had a prolonged randomisation process due to slow enrolment and included fewer participants than planned, leading to premature termination. <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a> had an imbalance in the number of participants with a history of disease severity between the treatment arms (20.6% of participants in the rituximab arm had Binet stage C, compared to only 9.4% in the observation arm). </p> <p>We considered three trials to be at unclear risk of other potential sources of bias: <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a> had premature closure of recruitment due to poor accrual (enrolling only 89 of the estimated 200 planned participants). <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a> did not report detailed baseline characteristics of the ofatumumab and observation arms after the second randomisation (the first randomisation was for induction therapy). <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a> was stopped prematurely due to severe infection. </p> <p>We considered six trials to be at low risk of other potential sources of bias because no obvious sources of bias were detected (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> </section> </section> <section id="CD013474-sec-0085"> <h3 class="title" id="CD013474-sec-0085">Effects of interventions</h3> <p>See: <a href="./full#CD013474-tbl-0001"><b>Summary of findings 1</b> Anti‐CD20 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</a>; <a href="./full#CD013474-tbl-0002"><b>Summary of findings 2</b> Immunomodulatory drug maintenance therapy compared to placebo/observation for people with chronic lymphocytic leukaemia</a>; <a href="./full#CD013474-tbl-0003"><b>Summary of findings 3</b> Anti‐CD52 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</a> </p> <p>A total of 11 trials were included for the main descriptive analysis (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). We excluded one trial from the quantitative analysis because it grouped non‐Hodgkin's lymphoma together and did not report prespecified outcomes specifically for participants with CLL (<a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). Given the lack of data regarding the included RCTs, MRD outcomes were not analysed. The effect estimates of all meta‐analyses were based on the intention‐to‐treat design principle if possible and presented with a random‐effects model of forest plots. </p> <section id="CD013474-sec-0086"> <h4 class="title">Anti‐CD20 monoclonal antibodies (mAbs) maintenance therapy versus observation</h4> <p>Anti‐CD20 mAbs: rituximab, ofatumumab</p> <section id="CD013474-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD013474-sec-0088"> <h6 class="title">Overall survival (OS)</h6> <p>Three trials (N = 1152) that reported OS were analysed (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). Maintenance treatment with anti‐CD20 mAbs probably results in little to no difference in OS compared with observation alone (hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.73 to 1.20; P = 0.60; <a href="./references#CD013474-fig-0004" title="">Analysis 1.1</a>). Heterogeneity was small (I<sup>2</sup> = 0%). We assessed the certainty of the evidence as moderate because the CI includes both clinically relevant benefits and harms. We downgraded one level for serious imprecision. This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> <div class="table" id="CD013474-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Random sequence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Allocation concealment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Blinding</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HR/risk ratio/rate ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI low</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI high</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HR/risk ratio/rate ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI low</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI high</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="10" scope="col" valign="top"> <p><b>Anti‐CD20 mAbs</b> <br/><b>versus</b> <br/><b>observation</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3/4 AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CRR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="10" scope="col" valign="top"> <p><b>IMiD versus</b> <br/><b>observation</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.82, I<sup>2</sup> = 0 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3/4 AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.11, I<sup>2</sup> = 61.3 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.72, I<sup>2</sup> = 0 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.17, I<sup>2</sup> = 45.8 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CRR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="10" scope="col" valign="top"> <p><b>Anti‐CD52 mAbs</b> <br/><b>versus</b> <br/><b>observation</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3/4 AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CRR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AEs</b> : adverse events; <b>CI</b> : confidence interval; <b>CRR</b> : complete response rate; <b>HR</b> : hazard ratio; <b>HRQoL</b> : health‐related quality of life; <b>IMiD:</b> immunomodulatory drug; <b>mAb:</b> monoclonal antibody; <b>MRD</b> : minimal residual disease; <b>ORR</b> : overall response rate; <b>OS</b> : overall survival; <b>PFS</b> : progression‐free survival; <b>TD</b> : treatment discontinuation; <b>TRM</b>: treatment‐related mortality </p> </div> </div> </section> <section id="CD013474-sec-0089"> <h6 class="title">Overall survival (OS): type of drug</h6> <p>A stratified analysis by drug type (rituximab versus ofatumumab) demonstrated that rituximab maintenance therapy had an HR of 0.86 (95% CI 0.58 to 1.28; participants = 672; studies = 2) (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>), while ofatumumab maintenance therapy had an HR of 0.99 (95% CI 0.72 to 1.36; participants = 480; studies = 1) (<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>) compared with observation (<a href="./references#CD013474-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD013474-sec-0090"> <h6 class="title">Health‐related quality of life (HRQoL)</h6> <p>Only one trial reported HRQoL (<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), with 480 participants. Anti‐CD20 mAbs may not reduce HRQoL compared with observation (mean difference −1.70, 95% CI −8.59 to 5.19; P = 0.63; <a href="./references#CD013474-fig-0006" title="">Analysis 1.3</a>). We assessed the certainty of the evidence as low, downgrading one level for serious risk of bias due to lack of blinding and one level for imprecision based on the wide CIs. We did not perform sensitivity analysis due to there being only one trial. </p> </section> <section id="CD013474-sec-0091"> <h6 class="title">Grade 3 and 4 adverse events (AEs)</h6> <p>Five trials assessed grade 3/4 AEs (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), including a total of 1284 participants. We reported that maintenance therapy of anti‐CD20 mAbs may result in an increase in grade 3/4 adverse events compared with observation alone (rate ratio 1.34, 95% CI 1.06 to 1.71; P = 0.02; <a href="./references#CD013474-fig-0007" title="">Analysis 1.4</a>). Heterogeneity was considerable (I<sup>2</sup> = 56%). We assessed the certainty of the evidence as low, downgrading one level for serious risk of bias due to most trials having an open‐label design and one level for serious inconsistency based on substantial heterogeneity. This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0092"> <h6 class="title">Grade 3 and 4 adverse events (AEs): type of drug</h6> <p>There was no statistically significant increase of grade 3/4 AEs reported with rituximab maintenance (rate ratio 1.30, 95% CI 0.93 to 1.82; participants = 804; studies = 4) (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), but there was a significantly increasing risk of grade 3/4 AEs with ofatumumab maintenance (rate ratio 1.43, 95% CI 1.06 to 1.93; participants = 480; studies = 1) (<a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>) compared with observation (<a href="./references#CD013474-fig-0008" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD013474-sec-0093"> <h5 class="title">Secondary outcomes</h5> <section id="CD013474-sec-0094"> <h6 class="title">Progression‐free survival (PFS)</h6> <p>Five trials assessed PFS (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), including a total of 1255 participants. Our meta‐analysis showed that maintenance treatment with anti‐CD20 mAbs probably significantly increases PFS compared with observation alone (HR 0.61, 95% CI 0.50 to 0.73; P &lt; 0.001; <a href="./references#CD013474-fig-0009" title="">Analysis 1.6</a>). Heterogeneity was small (I<sup>2</sup> = 38%). We assessed the certainty of the evidence as moderate due to lack of blinding. We downgraded one level for serious risk of bias. This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> <p>We used GetData Graph Digitizer software to estimate the HR from the survival curve provided by <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a> (<a href="./references#CD013474-bbs2-0135" title="GetData Graph Digitizer. Version 2.26. Fedorov, 2019. Available at getdata1.software.informer.com/2.2/.">GetData Graph Digitizer</a>). </p> </section> <section id="CD013474-sec-0095"> <h6 class="title">Progression‐free survival (PFS): type of drug</h6> <p>A stratified analysis by drug type (rituximab versus ofatumumab) demonstrated that rituximab maintenance therapy had an HR of 0.50 (95% CI 0.37 to 0.68; participants = 738; studies = 3) (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), while ofatumumab maintenance therapy had an HR of 0.66 (95% CI 0.50 to 0.86; participants = 517; studies = 2) (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>) compared with observation (<a href="./references#CD013474-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD013474-sec-0096"> <h6 class="title">Treatment‐related mortality (TRM)</h6> <p>Four trials assessed TRM (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), including 1189 participants. Maintenance treatment with anti‐CD20 mAbs may result in little to no difference in TRM compared with observation alone (risk ratio 0.82, 95% CI 0.39 to 1.71; P = 0.60; <a href="./references#CD013474-fig-0011" title="">Analysis 1.8</a>). We assessed the certainty of the evidence as low, downgrading one level for serious imprecision because of the wide CIs, which crossed the line of no difference, and a further level due to substantial heterogeneity (I² = 47%; and two studies suggest benefit and two suggest harm). This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0097"> <h6 class="title">Treatment‐related mortality (TRM): type of drug</h6> <p>A stratified analysis by drug type (rituximab versus ofatumumab) demonstrated that rituximab maintenance therapy had a risk ratio of 1.12 (95% CI 0.44 to 2.88; participants = 672; studies = 2) (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>), while ofatumumab maintenance therapy had a risk ratio of 0.52 (95% CI 0.25 to 1.08; participants = 517; studies = 2) (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>) compared with observation (<a href="./references#CD013474-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD013474-sec-0098"> <h6 class="title">Treatment discontinuation (TD)</h6> <p>Six trials (N = 1321) reporting TD were analysed (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). The evidence suggested that anti‐CD20 mAbs maintenance may result in a slight reduction in treatment discontinuation compared with observation (risk ratio 0.93, 95% CI 0.72 to 1.20; P = 0.57; <a href="./references#CD013474-fig-0013" title="">Analysis 1.10</a>). We assessed the certainty of the evidence as low, downgrading one level for serious imprecision because of the wide CI, which crossed the line of no difference, and a further level due to substantial heterogeneity (I² = 64%). This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0099"> <h6 class="title">Treatment discontinuation (TD): type of drug</h6> <p>A stratified analysis by drug type (rituximab versus ofatumumab) demonstrated that rituximab maintenance therapy had a risk ratio of 0.87 (95% CI 0.58 to 1.31; participants = 804; studies = 4) (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), while ofatumumab maintenance therapy had a risk ratio of 0.93 (95% CI 0.77 to 1.12; participants = 517; studies = 2) (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>) compared with observation (<a href="./references#CD013474-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD013474-sec-0100"> <h6 class="title">All adverse events (AEs)</h6> <p>Six trials assessed grade 3/4 AEs (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>), including a total of 1321 participants. Anti‐CD20 mAbs maintenance therapy may result in a slight increase in all AEs compared with observation alone (rate ratio 1.23, 95% CI 1.03 to 1.47; P = 0.02; <a href="./references#CD013474-fig-0015" title="">Analysis 1.12</a>). Heterogeneity was considerable (I<sup>2</sup> = 56%). We assessed the certainty of the evidence as low, downgrading by one level for serious risk of bias, primarily due to most trials having an open‐label design, and by another level for serious inconsistency based on substantial heterogeneity (I² = 56%) and inconsistencies in the reporting criteria for AEs. This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0101"> <h6 class="title">All adverse events (AEs): type of drug</h6> <p>A stratified analysis by drug type (rituximab versus ofatumumab) demonstrated that rituximab maintenance therapy had a rate ratio of 1.26 (95% CI 0.97 to 1.64; participants = 804; studies = 4) (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), while ofatumumab maintenance therapy had a rate ratio of 1.16 (95% CI 0.96 to 1.40; participants = 517; studies = 2) (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>) compared with observation (<a href="./references#CD013474-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD013474-sec-0102"> <h6 class="title">Complete response rate (CRR)</h6> <p>Two trials (N = 132) that reported CRR were analysed (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>). Both trials suggested that rituximab maintenance therapy may increase CRR slightly (risk ratio 1.42, 95% CI 0.81 to 2.48; P = 0.22; <a href="./references#CD013474-fig-0017" title="">Analysis 1.14</a>). Heterogeneity was small (I<sup>2</sup> = 0%). We assessed the certainty of the evidence as low because of the wide CIs, which crossed the line of no difference; the small number of participants; and high risk of bias for <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a> owing to incomplete outcome data and prolonged enrolment/low recruitment rate. We downgraded one level for serious imprecision and one level for serious risk of bias. This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0103"> <h6 class="title">Overall response rate (ORR)</h6> <p>Only two trials reported ORR (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), including 132 participants. The evidence suggested that maintenance therapy with rituximab may result in an increase in ORR compared with observation alone (risk ratio 1.53, 95% CI 1.05 to 2.24; P = 0.03; <a href="./references#CD013474-fig-0018" title="">Analysis 1.15</a>). Heterogeneity was small (I<sup>2</sup> = 0%). We assessed the certainty of the evidence as low because of the wide CIs, which crossed the line of no difference; the small number of participants; and high risk of bias for <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a> owing to incomplete outcome data and prolonged enrolment/low recruitment rate. We downgraded one level for serious imprecision and one level for serious risk of bias. This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0104"> <h6 class="title">Minimal residual disease (MRD)</h6> <p>No study reporting this outcome was identified.</p> </section> </section> </section> <section id="CD013474-sec-0105"> <h4 class="title">Immunomodulatory drug (IMiD) maintenance therapy versus placebo/observation</h4> <p>IMiD: lenalidomide</p> <p>Two trials compared an IMiD with placebo (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>), while another trial compared an IMiD with observation (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>). </p> <section id="CD013474-sec-0106"> <h5 class="title">Primary outcomes</h5> <section id="CD013474-sec-0107"> <h6 class="title">Overall survival (OS)</h6> <p>Three trials (N = 461) that reported OS were analysed (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). We found evidence suggesting that maintenance treatment with lenalidomide probably results in little to no difference in overall survival compared with observation alone (HR 0.91, 95% CI 0.61 to 1.35; P = 0.63; <a href="./references#CD013474-fig-0019" title="">Analysis 2.1</a>). Heterogeneity was small (I<sup>2</sup> = 0%). We assessed the certainty of the evidence as moderate because of the wide CIs, which crossed the line of relative risk reduction threshold, and the small number of participants. We downgraded one level for serious imprecision. The consistency of this result was maintained in sensitivity analyses using both fixed‐effect and random‐effects models, as well as when assessing the impact of high versus low risk of bias for blinding (<a href="#CD013474-tbl-0004">Table 1</a>). </p> <p>We used GetData Graph Digitizer software to estimate the HR from the survival curve provided by <a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a> (<a href="./references#CD013474-bbs2-0135" title="GetData Graph Digitizer. Version 2.26. Fedorov, 2019. Available at getdata1.software.informer.com/2.2/.">GetData Graph Digitizer</a>). </p> </section> <section id="CD013474-sec-0108"> <h6 class="title">Health‐related quality of life (HRQoL)</h6> <p>No study reporting this outcome was identified.</p> </section> <section id="CD013474-sec-0109"> <h6 class="title">Grade 3 and 4 adverse events (AEs)</h6> <p>Two trials reported grade 3 and 4 AEs (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). A total of 400 participants were included in the meta‐analysis. The evidence suggested that maintenance therapy of lenalidomide may result in an increase in grade 3/4 AEs compared to placebo (rate ratio 1.82, 95% CI 1.38 to 2.38; P &lt; 0.001; <a href="./references#CD013474-fig-0020" title="">Analysis 2.2</a>). Heterogeneity was small (I<sup>2</sup> = 0%). We assessed the certainty of the evidence as low because of wide CIs and the small number of participants. We downgraded two levels for very serious imprecision. This result remained consistent in sensitivity analyses using both fixed‐effect and random‐effects models (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> </section> <section id="CD013474-sec-0110"> <h5 class="title">Secondary outcomes</h5> <section id="CD013474-sec-0111"> <h6 class="title">Progression‐free survival (PFS)</h6> <p>Three trials assessed PFS (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>), including a total of 461 participants. Meta‐analysis showed that maintenance treatment with lenalidomide probably results in a large increase in PFS compared to observation alone (HR 0.37, 95% CI 0.19 to 0.73; P = 0.004; <a href="./references#CD013474-fig-0021" title="">Analysis 2.3</a>). Heterogeneity was substantial (I<sup>2</sup> = 68%). We assessed the certainty of the evidence as moderate because of the substantial heterogeneity with visualised dissimilarity of point estimates. We downgraded one level for serious inconsistency. The consistency of this result was maintained in sensitivity analyses using both fixed‐effect and random‐effects models, as well as when assessing the impact of high versus low risk of bias for blinding (<a href="#CD013474-tbl-0004">Table 1</a>). </p> <p>We used GetData Graph Digitizer software to estimate the HR from the survival curve provided by <a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a> (<a href="./references#CD013474-bbs2-0135" title="GetData Graph Digitizer. Version 2.26. Fedorov, 2019. Available at getdata1.software.informer.com/2.2/.">GetData Graph Digitizer</a>). </p> </section> <section id="CD013474-sec-0112"> <h6 class="title">Treatment‐related mortality (TRM)</h6> <p>Three trials assessed TRM (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>), including a total of 458 participants. Meta‐analysis suggested that maintenance treatment with lenalidomide may result in a slight increase in TRM compared to observation alone (risk ratio 1.22, 95% CI 0.35 to 4.29; P = 0.76; <a href="./references#CD013474-fig-0022" title="">Analysis 2.4</a>). Heterogeneity was small (I<sup>2</sup> = 0%). We assessed the certainty of the evidence as low because of the very wide CIs, which crossed the line of relative risk reduction threshold, and low event rates. We downgraded two levels for very serious imprecision. The consistency of this result was maintained in sensitivity analyses using both fixed‐effect and random‐effects models, as well as when assessing the impact of high versus low risk of bias for blinding (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0113"> <h6 class="title">Treatment discontinuation (TD)</h6> <p>Two trials (N = 400) that reported our secondary outcome TD were analysed (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). The evidence is very uncertain about the effect of IMiD maintenance therapy on TD (risk ratio 0.71, 95% CI 0.47 to 1.05; P = 0.09; <a href="./references#CD013474-fig-0023" title="">Analysis 2.5</a>). Heterogeneity was substantial (I<sup>2</sup> = 75%). We assessed the certainty of the evidence as very low. We downgraded two levels for very serious imprecision due to wide CIs, which crossed the line of relative risk reduction threshold, and the small number of participants. We downgraded one level for serious inconsistency due to substantial heterogeneity. This result was found not to be robust in sensitivity analysis. However, when a fixed‐effect model was applied, meta‐analysis indicated that the proportion of TD may be reduced with IMiD maintenance (risk ratio 0.78, 95% CI 0.68 to 0.89; <a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0114"> <h6 class="title">All adverse events (AEs)</h6> <p>Three trials reported all AEs (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). A total of 458 participants were included in the meta‐analysis. IMiD maintenance therapy probably increases all AEs slightly compared to placebo (rate ratio 1.41, 95% CI 1.28 to 1.54; P &lt; 0.001; <a href="./references#CD013474-fig-0024" title="">Analysis 2.6</a>). Heterogeneity was small (I<sup>2</sup> = 0%). We assessed the certainty of the evidence as moderate. We downgraded the study by one level for serious inconsistency, specifically due to inconsistencies in the reporting criteria for AEs. The consistency of this result was maintained in sensitivity analyses using both fixed‐effect and random‐effects models, as well as when assessing the impact of high versus low risk of bias for blinding (<a href="#CD013474-tbl-0004">Table 1</a>). </p> </section> <section id="CD013474-sec-0115"> <h6 class="title">Complete response rate (CRR)</h6> <p>No study reporting this outcome was identified.</p> </section> <section id="CD013474-sec-0116"> <h6 class="title">Overall response rate (ORR)</h6> <p>No study reporting this outcome was identified.</p> </section> <section id="CD013474-sec-0117"> <h6 class="title">Minimal residual disease (MRD)</h6> <p>No study reporting this outcome was identified.</p> </section> </section> </section> <section id="CD013474-sec-0118"> <h4 class="title">Anti‐CD52 mAbs maintenance therapy versus observation</h4> <p>Anti‐CD52 mAb: alemtuzumab</p> <section id="CD013474-sec-0119"> <h5 class="title">Primary outcomes</h5> <section id="CD013474-sec-0120"> <h6 class="title">Overall survival (OS)</h6> <p>No study reporting this outcome was identified.</p> </section> <section id="CD013474-sec-0121"> <h6 class="title">Health‐related quality of life (HRQoL)</h6> <p>No study reporting this outcome was identified.</p> </section> <section id="CD013474-sec-0122"> <h6 class="title">Grade 3 and 4 adverse events (AEs)</h6> <p>No study reporting this outcome was identified.</p> </section> </section> <section id="CD013474-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD013474-sec-0124"> <h6 class="title">Progression‐free survival (PFS)</h6> <p>Only one trial reported PFS (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>), with 21 participants. We reported the trial result, finding that maintenance with alemtuzumab may lead to an increase in PFS, but the evidence is very uncertain (HR 0.55, 95% CI 0.32 to 0.95; P = 0.003; <a href="./references#CD013474-fig-0025" title="">Analysis 3.1</a>). Heterogeneity was not applicable. We evaluated the certainty of the evidence as very low due to the trial's lack of reporting on random sequence generation and allocation methods, lack of blinding, potential for selective reporting, and the inclusion of 21 participants with early termination, suggesting the study may be underpowered to demonstrate an effect. We downgraded two levels for very serious imprecision and one level for serious risk of bias. We did not perform sensitivity analysis due to there being only one trial. </p> <p>We used GetData Graph Digitizer software to estimate the HR from the survival curve provided by <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a> (<a href="./references#CD013474-bbs2-0135" title="GetData Graph Digitizer. Version 2.26. Fedorov, 2019. Available at getdata1.software.informer.com/2.2/.">GetData Graph Digitizer</a>). </p> </section> <section id="CD013474-sec-0125"> <h6 class="title">Treatment‐related mortality (TRM)</h6> <p>No study reporting this outcome was identified.</p> </section> <section id="CD013474-sec-0126"> <h6 class="title">Treatment discontinuation (TD)</h6> <p>No study reporting this outcome was identified.</p> </section> <section id="CD013474-sec-0127"> <h6 class="title">All adverse events (AEs)</h6> <p><a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a> (reporting on a total of 21 participants) reported 51 AEs in the alemtuzumab arm, but did not report any events in the control arm. </p> </section> <section id="CD013474-sec-0128"> <h6 class="title">Complete response rate (CRR)</h6> <p>Only one trial reported CRR (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>), with 21 participants. We reported the trial result, finding that the effect of maintenance with alemtuzumab on CRR is very uncertain (risk ratio 1.36, 95% CI 0.28 to 6.56; P = 0.70; <a href="./references#CD013474-fig-0026" title="">Analysis 3.2</a>). Heterogeneity was not applicable. We evaluated the certainty of the evidence as very low due to the trial's lack of reporting on random sequence generation and allocation methods, lack of blinding, potential for selective reporting, and the inclusion of 21 participants with early termination, suggesting the study may be underpowered to demonstrate an effect. We downgraded two levels for very serious imprecision and one level for serious risk of bias. We did not perform sensitivity analysis due to there being only one trial. </p> </section> <section id="CD013474-sec-0129"> <h6 class="title">Overall response rate (ORR)</h6> <p>Only one trial reported ORR (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>), with 21 participants. We reported the trial result, finding that the effect of maintenance of alemtuzumab on ORR is very uncertain (risk ratio 1.41, 95% CI 0.92 to 2.14; P = 0.11; <a href="./references#CD013474-fig-0027" title="">Analysis 3.3</a>). Heterogeneity was not applicable. We evaluated the certainty of the evidence as very low due to the trial's lack of reporting on random sequence generation and allocation methods, lack of blinding, potential for selective reporting, and the inclusion of 21 participants with early termination, suggesting the study may be underpowered to demonstrate an effect. We downgraded two levels for very serious imprecision and one level for serious risk of bias. We did not perform sensitivity analysis due to there being only one trial. </p> </section> <section id="CD013474-sec-0130"> <h6 class="title">Minimal residual disease (MRD)</h6> <p>No study reporting this outcome was identified.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013474-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013474-sec-0131"></div> <p>The main objective of this review was to examine the evidence for the clinical effectiveness and safety of maintenance therapy for the treatment of CLL. A total of 11 trials were eligible for inclusion (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). For the purposes of quantitative analysis, seven trials compared anti‐CD20 mAbs versus observation: five trials used rituximab (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>), and two trials used ofatumumab (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>) as maintenance therapy. Three trials compared IMiD (lenalidomide) maintenance therapy versus placebo/observation (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>), and another trial compared anti‐CD52 mAb (alemtuzumab) maintenance therapy versus observation (<a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). One trial lumped non‐Hodgkin's lymphoma together and did not report prespecified outcomes for this review specifically for participants with CLL (<a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>); no results can be ascertained from this study. </p> <section id="CD013474-sec-0132"> <h3 class="title" id="CD013474-sec-0132">Summary of main results</h3> <p>The available evidence from these trials showed the following.</p> <section id="CD013474-sec-0133"> <h4 class="title">Overall survival (OS) (time to event)</h4> <p>We included three trials (1152 participants) comparing anti‐CD20 mAbs with observation and three trials (461 participants) comparing IMiD with placebo/observation. Both types of maintenance therapy probably result in little to no difference in OS (moderate‐certainty evidence). </p> <p>No trial comparing anti‐CD52 mAb reported OS.</p> </section> <section id="CD013474-sec-0134"> <h4 class="title">Health‐related quality of life (HRQoL)</h4> <p>Only one study (480 participants), comparing anti‐CD20 mAbs versus observation, reported this outcome. Anti‐CD20 mAbs may not reduce HRQoL (low‐certainty evidence). </p> <p>No studies evaluating IMiD or anti‐CD52 mAbs reported HRQoL.</p> </section> <section id="CD013474-sec-0135"> <h4 class="title">Grade 3 and 4 adverse events (AEs)</h4> <p>Five trials (1284 participants) evaluating anti‐CD20 mAbs maintenance therapy assessed this outcome. Anti‐CD20 mAbs maintenance therapy may result in an increase in grade 3/4 AEs (low‐certainty evidence). </p> <p>Two trials (400 participants) evaluating IMiD maintenance therapy assessed this outcome. IMiD maintenance therapy may result in an increase in grade 3/4 AEs (low‐certainty evidence). </p> <p>No trial comparing anti‐CD52 mAb reported grade 3 and 4 AEs.</p> </section> <section id="CD013474-sec-0136"> <h4 class="title">Progression‐free survival (PFS) (time to event)</h4> <p>We included five trials (1255 participants) comparing anti‐CD20 mAbs with observation; three trials (461 participants) comparing IMiD with placebo/observation; and one trial (21 participants) comparing anti‐CD52 mAbs with observation. </p> <p>Anti‐CD20 mAbs maintenance therapy probably increases PFS, and IMiD maintenance therapy probably results in a large increase in PFS (moderate‐certainty evidence). We are very uncertain whether anti‐CD52 mAb has any effect on PFS (very low‐certainty evidence). </p> </section> <section id="CD013474-sec-0137"> <h4 class="title">Treatment‐related mortality (TRM)</h4> <p>We included four trials (1189 participants) evaluating anti‐CD20 mAbs and three trials (458 participants) evaluating IMiD. Treatment with anti‐CD20 mAbs maintenance therapy may result in little to no difference in TRM (low‐certainty evidence). Treatment with IMiD maintenance therapy may result in a slight increase in TRM (low‐certainty evidence). </p> <p>No trial evaluating anti‐CD52 mAb reported TRM.</p> </section> <section id="CD013474-sec-0138"> <h4 class="title">Treatment discontinuation (TD)</h4> <p>Six trials (1321 participants) evaluating anti‐CD20 mAbs and two trials (400 participants) evaluating IMiD assessed this outcome. </p> <p>Anti‐CD20 mAbs maintenance therapy may result in a slight reduction in TD (low‐certainty evidence). The evidence for the effect of IMiD maintenance therapy on TD is very uncertain (very low‐certainty evidence). </p> <p>No trial evaluating anti‐CD52 mAb reported TD.</p> </section> <section id="CD013474-sec-0139"> <h4 class="title">All adverse events (AEs)</h4> <p>Of the 11 trials included in this review, 9 reported safety outcomes; one trial only reported safety outcomes during induction therapy, and one trial only reported safety outcomes in the experimental arm, with no information on the control arm. The reporting criteria for AEs varied across the included studies: one trial reported any AE; two trials reported AEs with an incidence of ≥ 2% of total adverse events in all cycles; four trials reported any incidence of AEs in ≥ 10%; and two trials only reported grade 3, 4, and 5 AEs. Furthermore, the duration of follow‐up for surveillance of AEs also varied across studies. </p> <p>A total of nine trials were included to assess this quantitative outcome: six trials (1321 participants) evaluating anti‐CD20 mAbs and three trials (458 participants) evaluating IMiD. </p> <p>Anti‐CD20 mAbs maintenance therapy may result in a slight increase in all AEs (low‐certainty evidence). IMiD maintenance therapy probably slightly increases all AEs (moderate‐certainty evidence). </p> <p>No trial evaluating anti‐CD52 mAb reported all AEs.</p> </section> <section id="CD013474-sec-0140"> <h4 class="title">Response rate (complete response rate (CRR) and overall response rate (ORR))</h4> <p>Two trials (132 participants) evaluating anti‐CD20 mAbs and one trial (21 participants) evaluating anti‐CD52 mAb assessed CRR and ORR. </p> <p>The evidence suggests that anti‐CD20 mAbs maintenance therapy may result in a slight increase in both CRR and ORR (low‐certainty evidence). We are very uncertain whether there is a difference in CRR or ORR between anti‐CD52 mAbs and observation (very low‐certainty evidence). </p> <p>No trial comparing IMiD maintenance therapy reported CRR or ORR.</p> </section> <section id="CD013474-sec-0141"> <h4 class="title">Minimal residual disease</h4> <p>None of the included studies reported this outcome.</p> </section> </section> <section id="CD013474-sec-0142"> <h3 class="title" id="CD013474-sec-0142">Overall completeness and applicability of evidence</h3> <p>This review provides the most up‐to‐date evidence on the role of maintenance therapy in individuals diagnosed with CLL. To facilitate the development of comprehensive inclusion criteria, we included studies that examined either consolidation or maintenance therapy. </p> <p>Eleven randomised trials met the inclusion criteria for this review: seven trials compared anti‐CD20 mAbs with observation (N = 1679, with five trials including 856 participants evaluating rituximab and two trials with 517 participants evaluating ofatumumab); three trials compared lenalidomide with placebo/observation (N = 693); and one trial compared alemtuzumab with observation (N = 21). Nine trials were phase 3, and two were phase 2 trials. </p> <p>One trial enrolled participants with non‐Hodgkin's lymphoma, while the remaining 10 trials enrolled those with CLL; the corresponding author of <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a> was unable to provide us with more detailed information on the CLL subgroup due to the inability to obtain permissions from other centres' principal investigators. We attempted to contact the original author of one study for further information required to determine eligibility for inclusion in the review, but did not receive a response (<a href="./references#CD013474-bbs2-0085" title="JaksicB , BrugiatelliM . High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL--IGCI CLL-01 trial. Nouvelle Revue Francaise d'Hematologie1988;30(5-6):437-42. ">Jaksic 1988</a>). Two ongoing trials are still active (<a href="./references#CD013474-bbs2-0086" title="NCT03280160. Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab. clinicaltrials.gov/show/NCT03280160 (first received 9 September 2017). ">NCT03280160</a>; <a href="./references#CD013474-bbs2-0087" title="Oughton JB , CollettL , Howard DR , HockadayA , MunirT , McMahonK , et al. GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials2017;18(1):353. ">Oughton 2017</a>), one of which is evaluating ibrutinib in combination with ofatumumab as a maintenance agent, and the other which is evaluating obinutuzumab as a maintenance agent. </p> <p>There are several limitations that may affect the strength and applicability of our review. These include moderate clinical heterogeneity among participants, different regimens of active interventions, uneven follow‐up durations, and previous interventions across trials. Additionally, the landscape of CLL is evolving, with novel tyrosine kinase inhibitors (TKI) treating CLL with a treatment‐until‐progression strategy that includes induction and maintenance phases. However, we did not report this comparison due to a lack of available data. </p> <p>In nine trials participants received previous treatment with rituximab‐based chemo‐immunotherapy, while those in one trial received ofatumumab‐based therapy, and in the remaining trial received chemotherapy. </p> <p>Eight trials reported baseline Binet/Rai disease stage status, with five trials predominantly involving early‐stage CLL patients but with symptoms or high cytogenetic aberrations, while the other three trials predominantly involved patients in later stages. Eleven trials reported cytogenic abnormality, with six trials having a higher frequency of cytogenic abnormality ranging from 69.7% to 80.1%. Unmutated IGHV status was reported in eight trials, ranging between 41.4% and 91%. </p> <p>The intravenous rituximab dosage was 375 mg/m<sup>2</sup> every 12 weeks in four trials and 500 mg/m<sup>2</sup> every 8 weeks in one trial. The intravenous ofatumumab maintenance dosage was 1000 mg in one trial and 2000 mg in the second trial. The lenalidomide maintenance dosage was administered with a targeted daily dosage of 5 mg or 15 mg until progression in three trials. Approximately 30 mg of alemtuzumab was administered intravenously three times per week. </p> <p>The median duration of follow‐up in seven trials that administered anti‐CD20 mAbs (rituximab and ofatumumab) ranged from 14.4 months to 73 months. In three trials of IMiD (lenalidomide) maintenance, the mean duration of follow‐up ranged from 17.9 months to 31.5 months. For anti‐CD52 mAb (alemtuzumab) maintenance therapy, the median duration of follow‐up was 12.4 months. </p> <p>There was a moderate degree of clinical heterogeneity among participant characteristics and previous interventions across trials. In particular, differences in the underlying disease severity (baseline Rai/Binet status, cytogenetic aberration, and IGHV status), as well as the previous treatment regimen, post‐therapy response, timing of maintenance therapy, and the regimens of maintenance therapy administered, may all have contributed to the expected clinical heterogeneity across these studies. Notably, for many outcomes, the values of I<sup>2</sup> were 0%, but I<sup>2</sup> values may be underestimated when there are few events or a limited number of studies included in a meta‐analysis (<a href="./references#CD013474-bbs2-0153" title="Huedo-Medina TB , Sánchez-MecaJ , Marín-MartínezF , BotellaJ . Assessing heterogeneity in meta-analysis: Q statistic or I2 index?Sychological Methods2006;11(2):193-206.">Huedo‐Medina 2006</a>; <a href="./references#CD013474-bbs2-0154" title="John P AL . Why most published research findings are false: author's reply to Goodman and Greenland. PLOS Medicine2007;4(6):e215.">Ioannidis 2007</a>). </p> <p>Two trials compared ofatumumab to observation, and only one trial reported the comparison of efficacy between alemtuzumab and observation. Therefore, the evidence is limited in regards to the efficacy of ofatumumab in people with CLL and the role of alemtuzumab in CLL maintenance. </p> <p>Across all outcomes, maintenance therapy showed efficacy in prolonging PFS, but there were insufficient data to determine if maintenance therapy has a beneficial effect on OS. Nonetheless, maintenance therapy was associated with an increased incidence of grade 3/4 AEs and all AEs. </p> <p>No trial reported minimal residual disease as an outcome.</p> </section> <section id="CD013474-sec-0143"> <h3 class="title" id="CD013474-sec-0143">Quality of the evidence</h3> <p>All 11 included studies were parallel‐group RCTs. Four trials reported random sequence generation and allocation concealment (<a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>). Adequate blinding was implemented in only two trials, utilising a placebo arm (<a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>). Nine studies were open‐label trials, with high risk of both performance bias and detection bias for subjective outcomes (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). Eleven trials received financial support from pharmaceutical companies, including Roche, GlaxoSmithKline, and Novartis AG (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0002" title="Chanan-Khan AA , ZaritskeyA , EgyedM , VokurkaS , SemochkinS , SchuhA , et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology2017;4(11):e534-43. ">Chanan‐Khan 2017</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0004" title="Fink AM , BahloJ , RobrechtS , Al-SawafO , AldaoudA , HebartH , et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology2017;4(10):e475-86. ">Fink 2017</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0043" title="NCT00771602. Alemtuzumab + rituximab consolidation in CLL. clinicaltrials.gov/show/NCT00771602 (first received 10 October 2008). ">NCT00771602</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> <p>We did not address publication bias through funnel plots because fewer than 10 studies were included in all comparisons. </p> <p>Our risk of bias judgements for the included studies are presented in the risk of bias tables in <a href="./references#CD013474-sec-0166" title="">Characteristics of included studies</a>, and risk of bias summaries are shown in <a href="#CD013474-fig-0002">Figure 2</a> and <a href="#CD013474-fig-0003">Figure 3</a>. </p> <p> <ul id="CD013474-list-0021"> <li> <p>Two trials were at high risk of bias in four out of seven domains (<a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>). </p> </li> <li> <p>Two trials were at high risk of bias in three out of seven domains (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>). </p> </li> <li> <p>Five trials were at high risk of bias in two out of seven domains (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0003" title="DartigeasC , Van Den NesteE , LegerJ , MaisonneuveH , BerthouC , Dilhuydy MS , et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology2018;5(2):e82-94. ">Dartigeas 2018</a>; <a href="./references#CD013474-bbs2-0006" title="EgleA , MelchardtT , ObrtlikovaP , SmolejL , KozakT , SteurerM , et al. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine2019;8(4):1401-5. GreilR , ObrtlikovaP , SmolejL , KozakT , SteurerM , AndelJ , et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematology2016;3(7):e317-29. ">Greil 2016</a>; <a href="./references#CD013474-bbs2-0010" title="NCT01039376. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). ClinicalTrials.gov/show/NCT01039376 (first received 23 December 2009). Van OersM , SmolejL , PetriniM , OffnerF , GrosickiS , LevinMD , et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal2019;9(12):98. vanOersM , KuliczkowskiK , SmolejL , PetriniM , OffnerF , GrosickiS , et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology2015;16(13):1370-9. ">Van Oers 2019</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> </li> </ul> </p> <p>Our GRADE assessment for most outcomes was moderate or low. The certainty of evidence for the main comparisons of each maintenance therapy versus observation or placebo is summarised in <a href="./full#CD013474-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013474-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013474-tbl-0003">summary of findings Table 3</a>. </p> <p>We evaluated the certainty of evidence as moderate for the following major outcomes.</p> <p> <ul id="CD013474-list-0022"> <li> <p>Anti‐CD20 mAbs maintenance therapy: OS and PFS. We downgraded one level due to serious risk of bias (open‐label design) or serious imprecision (wide CIs). </p> </li> <li> <p>IMiD maintenance therapy: OS, PFS, and all AEs. We downgraded one level due to serious imprecision (wide CIs) or serious inconsistency (significant heterogeneity or inconsistencies in the reporting criteria for AEs). </p> </li> <li> <p>Anti‐CD52 mAbs maintenance therapy: nil</p> </li> </ul> </p> <p>We assessed the certainty of evidence as low for the following major outcomes.</p> <p> <ul id="CD013474-list-0023"> <li> <p>Anti‐CD20 mAbs maintenance therapy: HRQoL, grade 3 and 4 AEs, TRM, TD, and all AEs. We downgraded the certainty of the evidence due to serious risk of bias (lack of blinding), serious imprecision (wide CIs), and inconsistency (substantial heterogeneity or inconsistencies in the reporting criteria for AEs). </p> </li> <li> <p>IMiD maintenance therapy: grade 3 and 4 AEs and TRM. We downgraded the certainty of the evidence based on very serious imprecision (very wide CIs, or wide CIs with small number of participants). </p> </li> <li> <p>Anti‐CD52 mAbs maintenance therapy: nil</p> </li> </ul> </p> <p>We assessed the certainty of evidence as very low for the following major outcomes.</p> <p> <ul id="CD013474-list-0024"> <li> <p>Anti‐CD20 mAbs maintenance therapy: nil</p> </li> <li> <p>IMiD maintenance therapy: TD. We downgraded two levels for very serious imprecision (wide CIs with small number of participants) and one level for serious inconsistency (substantial heterogeneity). </p> </li> <li> <p>Anti‐CD52 mAbs maintenance therapy: PFS. We downgraded one level for serious risk of bias (open‐label design) and two levels for very serious bias (single study terminated early, likely underpowered to demonstrate an effect). </p> </li> </ul> </p> <p>There was notable clinical heterogeneity in the types and stages of the malignant disease being treated, previous induction chemotherapy regimens, maintenance therapy dosage and frequency, definitions of outcomes, and differences in study quality. Unfortunately, we could not perform subgroup analyses due to the lack of suitable studies. However, these will be addressed in future review updates as further RCTs are published. </p> </section> <section id="CD013474-sec-0144"> <h3 class="title" id="CD013474-sec-0144">Potential biases in the review process</h3> <p>We are not aware of any apparent biases in the review process. We used a sensitive search strategy that included ongoing trial databases and handsearching of conference proceedings. We also contacted researchers in the field to identify any further as yet unpublished trials. We placed no restrictions on the language in which the paper was originally published or publication status. We tried to avoid bias by having all relevant processes duplicated by two review authors and resolving any discrepancies through discussion. However, as the included studies are limited to performing tests for publication bias, we cannot confidently claim that we obtained all relevant studies. </p> <p>None of the review authors was involved in the included or excluded studies.</p> </section> <section id="CD013474-sec-0145"> <h3 class="title" id="CD013474-sec-0145">Agreements and disagreements with other studies or reviews</h3> <p>We found moderate‐ to low‐certainty evidence on the effectiveness and safety of maintenance therapy for people with CLL. To our knowledge, there are few systematic reviews and meta‐analyses that fully evaluate the benefits and harms associated with the use of maintenance therapy in adults with CLL using anti‐CD20 mAbs (rituximab and ofatumumab), IMiDs (lenalidomide), anti‐CD52 mAb (aletuzumab), or other regimens. </p> <p><a href="./references#CD013474-bbs2-0163" title="LeeCH , ChenPH , LinC , WangCY , HoCL . A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia. PLOS ONE2020;3:123. [DOI: 10.1371/journal.pone.0226879]">Lee 2020</a> regularly evaluate the outcomes of people with maintenance therapy compared to standard care. Their last update was on 6 March 2019, and it reported on six included RCTs. Lee and colleagues compared the interventions for each maintenance drug, finding that lenalidomide, rituximab, and ofatumumab resulted in the longest PFS compared to no intervention (HR 0.37, 95% CI 0.27 to 0.50; HR 0.50, 95% CI 0.38 to 0.66; HR 0.52, 95% CI 0.41 to 0.66, respectively), with lenalidomide showing the greatest efficacy in preventing disease progression (HR 0.37, 95% CI 0.27 to 0.50). The study also assessed serious adverse events and provided relative risk estimates. Our assessments of clinical benefits for OS and PFS were similar, but the study did not report on HRQoL, TRM, TD, and all AEs. Additionally, the study did not include six RCTs included in our review (<a href="./references#CD013474-bbs2-0001" title="Byrd JC , Ruppert AS , Heerema NA , Halvorson AE , HokeE , Smith MR , et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advance2018;2(14):1705-18. ">Byrd 2018</a>; <a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0008" title="NCT00718549. A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL). ClinicalTrials.gov/show/NCT00718549 (first received 16 July 2008). RobakT , BlonskiJ , Skotnicki AB , PiotrowskaM , WrobelT , RybkaJ , et al. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology2018;100(5):465-74. ">Robak 2018</a>; <a href="./references#CD013474-bbs2-0009" title="Schweighofer CD , RitgenM , Eichhorst BF , BuschR , AbenhardtW , KnebaM , et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology2009;144(1):95-8. Wendtner CM , RitgenM , Schweighofer CD , Fingerle-RowsonG , CampeH , JagerG , et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia2004;18(6):1093-101. ">Schweighofer 2009</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> <p><a href="./references#CD013474-bbs2-0170" title="MkhwanaziZA , NyambuyaTM , MfusiSA , NkambuleBB . Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors. BMC Cancer2022;22:1218. [DOI: 10.1186/s12885-022-10223-0]">Mkhwanazi 2022</a> included a total of four studies that reported improved PFS following maintenance therapy with anti‐CD20 therapy compared to an observation group. The results showed a pooled effect estimate with a non‐significant improvement in PFS (HR 0.51, 95% CI 0.42 to 0.60; P = 0.93). There were no differences in OS between participants receiving maintenance therapy and those who were not on treatment. <a href="./references#CD013474-bbs2-0170" title="MkhwanaziZA , NyambuyaTM , MfusiSA , NkambuleBB . Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors. BMC Cancer2022;22:1218. [DOI: 10.1186/s12885-022-10223-0]">Mkhwanazi 2022</a> only reported on survival outcomes and did not include outcomes for clinical harms. Additionally, the interpretation of the effects on PFS was incorrect. The CI of the pooled effect estimate was 0.42 to 0.60, which is statistically significant. The study also did not include three RCTs included in our review (<a href="./references#CD013474-bbs2-0005" title="FoaR , Del GiudiceI , CuneoA , Del PoetaG , CiolliS , Di RaimondoF , et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology2014;89(5):480-6. ">Foa 2014</a>; <a href="./references#CD013474-bbs2-0007" title="OsterborgA , UdvardyM , ZaritskeyA , Andersson P-O, GrosickiS , MazurG , et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia &amp; Lymphoma2016;57(9):2037-46. ">Osterborg 2016</a>; <a href="./references#CD013474-bbs2-0011" title="Williams ME , HongF , Gascoyne RD , Wagner LI , Krauss JC , Habermann TM , et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology2016;173(6):867-75. ">Williams 2016</a>). </p> <p>The concept of maintenance therapy is not new in haematological malignancy. For instance, a review published on maintenance therapy for B‐chronic lymphocytic leukaemia announced that maintenance therapy of rituximab and lenalidomide had a potential role in deep treatment response (<a href="./references#CD013474-bbs2-0177" title="O’BrienS , Kay NE . Maintenance therapy for B-chronic lymphocytic leukemia. Clinical Advances in Hematology &amp; Oncology2011 ;9(1):22-31. [PMID: 21326143]">O’Brien 2011</a>). </p> <p><a href="./references#CD013474-bbs2-0188" title="RobakT . Maintenance in CLL. Blood2013;122(24):3854-5.">Robak 2013</a> commented on the role of maintenance in CLL, concluding that maintenance therapy had PFS benefit and deepened the treatment response, but at the expense of severe haematological and immunologic AEs, and that maintenance or consolidation therapy with rituximab, alemtuzumab, or lenalidomide should not be used outside of clinical trials. <a href="./references#CD013474-bbs2-0204" title="Tam CS . Maintenance therapy in CLL: resolving the controversy. The Lancet Hematology2016;3(7):E304-5.">Tam 2016</a> also commented that anti‐CD20 maintenance after chemo‐immunotherapy for CLL should depend on the risk of the individual, emphasising that the clinician must balance the costs and risks of two years of antibody maintenance, as there is no evident advantage in terms of the time to the next treatment and overall survival. </p> <p>After the PROLONG trial was published, ofatumumab was approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or progressive CLL who are in complete or partial remission following two or more lines of prior therapy since 2016. </p> <p>Before 2021, in the chemo‐immunotherapy era, the National Comprehensive Cancer Network (NCCN) guidelines in the US recommended lenalidomide maintenance therapy following first‐line chemo‐immunotherapy for high‐risk patients, and lenalidomide or ofatumumab maintenance therapy following second‐line chemo‐immunotherapy for people with CLL who had a complete or partial response, based on lower‐level evidence with NCCN consensus that the intervention was appropriate. However, the CLL treatment landscape is changing rapidly, and TKI have become the mainstream induction therapy in CLL. Chemotherapy‐immunotherapy has become a choice rather than a preferred regimen for induction. Therefore, because there is no evidence supporting maintenance therapy followed by TKI induction, maintenance therapies with lenalidomide and ofatumumab have been removed from later versions of the NCCN guidelines (<a href="./references#CD013474-bbs2-0174" title="National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas 2021 v5.0. www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1480 (accessed 10 February 2019).">NCCN 2021</a>). </p> <p>Even in the TKI era of CLL, maintenance therapy remains an important intervention to prolong and deepen the treatment response, in addition to the higher response rate of TKI induction. Mark‐David Levin and colleagues launched a phase 2 randomised trial (HOVON 139/GIVE trial) in which people with CLL received a fixed‐duration regimen of venetoclax plus obinutuzumab followed by consolidation with venetoclax, which resulted in high rates of undetectable measurable residual disease. This pilot trial demonstrated the potential benefit of a measurable residual disease‐guided treatment strategy and the role of maintenance therapy. We will continue to monitor available randomised trials and update this review accordingly. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013474-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD013474-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013474-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013474-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 1: Overall survival (time to event)" data-id="CD013474-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 1: Overall survival (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 2: Overall survival (time to event): type of drug" data-id="CD013474-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 2: Overall survival (time to event): type of drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 3: Health‐related quality of life" data-id="CD013474-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 3: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 4: Grade 3 and 4 adverse events" data-id="CD013474-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 4: Grade 3 and 4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 5: Grade 3 and 4 adverse events: type of drug" data-id="CD013474-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 5: Grade 3 and 4 adverse events: type of drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 6: Progression‐free survival (time to event)" data-id="CD013474-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 6: Progression‐free survival (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 7: Progression‐free survival (time to event): type of drug" data-id="CD013474-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 7: Progression‐free survival (time to event): type of drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 8: Treatment‐related mortality" data-id="CD013474-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 8: Treatment‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 9: Treatment‐related mortality: type of drug" data-id="CD013474-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 9: Treatment‐related mortality: type of drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 10: Treatment discontinuation" data-id="CD013474-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 10: Treatment discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 11: Treatment discontinuation: type of drug" data-id="CD013474-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 11: Treatment discontinuation: type of drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 12: All adverse events" data-id="CD013474-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 12: All adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 13: All adverse events: type of drug" data-id="CD013474-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 13: All adverse events: type of drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 14: Complete response rate" data-id="CD013474-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 14: Complete response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 15: Overall response rate" data-id="CD013474-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Anti‐CD20 monoclonal antibody maintenance therapy versus observation, Outcome 15: Overall response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 1: Overall survival (time to event)" data-id="CD013474-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 1: Overall survival (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 2: Grade 3 and 4 adverse events" data-id="CD013474-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 2: Grade 3 and 4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 3: Progression‐free survival (time to event)" data-id="CD013474-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 3: Progression‐free survival (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 4: Treatment‐related mortality" data-id="CD013474-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 4: Treatment‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 5: Treatment discontinuation" data-id="CD013474-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 5: Treatment discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 6: All adverse events" data-id="CD013474-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Immunomodulatory drug maintenance therapy versus placebo, Outcome 6: All adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐CD52 monoclonal antibody maintenance therapy versus observation, Outcome 1: Progression‐free survival (time to event)" data-id="CD013474-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Anti‐CD52 monoclonal antibody maintenance therapy versus observation, Outcome 1: Progression‐free survival (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐CD52 monoclonal antibody maintenance therapy versus observation, Outcome 2: Complete response rate" data-id="CD013474-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Anti‐CD52 monoclonal antibody maintenance therapy versus observation, Outcome 2: Complete response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013474-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/urn:x-wiley:14651858:media:CD013474:CD013474-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐CD52 monoclonal antibody maintenance therapy versus observation, Outcome 3: Overall response rate" data-id="CD013474-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_t/tCD013474-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Anti‐CD52 monoclonal antibody maintenance therapy versus observation, Outcome 3: Overall response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/media/CDSR/CD013474/image_n/nCD013474-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013474-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐CD20 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐CD20 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic lymphocytic leukaemia<br/><b>Setting:</b> inpatient and outpatient care<br/><b>Intervention:</b> anti‐CD20 mAb maintenance therapy<br/><b>Comparison:</b> observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with anti‐CD20 mAb maintenance therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>Follow‐up: range 33.7 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.73 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1152<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy probably results in little to no difference in overall survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000<br/>(180 to 353) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life<br/>Follow‐up: median 40.9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 1.9.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.7 lower<br/>(8.59 lower to 5.19 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may not reduce health‐related quality of life. <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 3/4 adverse events<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.34<br/>(1.06 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1284<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in an increase in grade 3/4 adverse events. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1000<br/>(466 to 752) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.61<br/>(0.50 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1255<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy probably increases progression‐free survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>639 per 1000<br/>(585 to 693) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment‐related mortality<br/>Follow‐up: range 33.7 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 0.82<br/>(0.39 to 1.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1189<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in little to no difference in treatment‐related mortality. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/>(26 to 116) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment discontinuation<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 0.93<br/>(0.72 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1321<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in a slight reduction in treatment discontinuation. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>409 per 1000<br/>(320 to 533) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All adverse events<br/>Follow‐up: range 14.4 months to 47.7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.23<br/>(1.03 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1321<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>4 9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD20 mAb maintenance therapy may result in a slight increase in all adverse events. <sup>3 6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>984 per 1000<br/>(824 to 1176) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to serious imprecision (wide confidence intervals, which cross the line of no difference).<br/><sup>2</sup>Assumed risk was calculated based on large cohort study (Mato et al 2020, DOI: 10.1182/bloodadvances.2019001145).<br/><sup>3</sup>We could not address publication bias through funnel plots, as fewer than 10 studies were included in comparison. Given our comprehensive search for unpublished studies, including contacting the experts and researchers in the field, we believe suspicion about publication bias is reduced.<br/><sup>4</sup>Downgraded one level due to serious risk of bias (high risk of bias due to lack of blinding).<br/><sup>5</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 56%).<br/><sup>6</sup>Assumed risk was calculated based on control group.<br/><sup>7</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 47%, two studies suggest benefit and two suggest harm).<br/><sup>8</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 64%).<br/><sup>9</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 56%; inconsistency in the reporting criteria for adverse events (AEs): two studies reported all AEs occurring in more than 2% of participants, while another two studies reported all AEs occurring in more than 10% of participants. Additionally, one study reported all AEs, while another study reported AEs of grade 3, 4, and 5 occurring in more than 5% of participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐CD20 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013474-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Immunomodulatory drug maintenance therapy compared to placebo/observation for people with chronic lymphocytic leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Immunomodulatory drug maintenance therapy compared to placebo/observation for people with chronic lymphocytic leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic lymphocytic leukaemia<br/><b>Setting:</b> inpatient and outpatient care<br/><b>Intervention:</b> immunomodulatory drug maintenance therapy<br/><b>Comparison:</b> placebo/observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with immunomodulatory drug maintenance therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/>(0.61 to 1.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>461<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy probably results in little to no difference in overall survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000<br/>(179 to 460) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting the outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 3/4 adverse events<br/>Follow‐up: range 17.9 months to 31.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.82<br/>(1.38 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>400<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy may result in an increase in grade 3/4 adverse events. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>748 per 1000<br/>(571 to 983) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.37<br/>(0.19 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>461<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy probably results in a large increase in progression‐free survival. <sup>2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000<br/>(585 to 870) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment‐related mortality<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 1.22<br/>(0.35 to 4.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>458<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy may result in a slight increase in treatment‐related mortality. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/>(7 to 82) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment discontinuation<br/>Follow‐up: range 17.9 months to 31.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk ratio 0.71<br/>(0.47 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>400<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>8 9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of immunomodulatory drug maintenance therapy on treatment discontinuation. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>776 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>551 per 1000<br/>(365 to 815) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All adverse events<br/>Follow‐up: range 17.9 months to 73 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.41<br/>(1.28 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>458<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Immunomodulatory drug maintenance therapy probably increases all adverse events slightly. <sup>3 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1242 per 1000<br/>(1134 to 1368) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to serious imprecision (wide confidence intervals, which cross the line of relative risk reduction threshold).<br/><sup>2</sup>Assumed risk was calculated based on large cohort study (Mato et al 2020, DOI: 10.1182/bloodadvances.2019001145).<br/><sup>3</sup>We could not address publication bias through funnel plots, as fewer than 10 studies were included in comparison. Given our comprehensive search for unpublished studies, including contacting the experts and researchers in the field, we believe suspicion about publication bias is reduced.<br/><br/><sup>4</sup>Downgraded two levels due to very serious imprecision (wide confidence intervals, small number of participants)<br/><sup>5</sup>Assumed risk was calculated based on control group.<br/><sup>6</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 68%).<br/><sup>7</sup>Downgraded two levels due to very serious imprecision (very wide confidence intervals, which cross the line of relative risk reduction threshold, and low event rates).<br/><sup>8</sup>Downgraded one level due to serious inconsistency (substantial heterogeneity, I² = 75%).<br/><sup>9</sup>Downgraded two levels due to very serious imprecision (wide confidence intervals, which cross the line of relative risk reduction threshold, and small number of participants).<br/><sup>10</sup>Downgraded one level for serious inconsistency (inconsistencies in the reporting criteria for adverse events (AEs): one study reported all AEs occurring in more than 10% of participants, while another study reported AEs of grade 1 and 2 occurring in &gt; 10% of participants, but only reported treatment‐related AEs of grade 3, 4, and 5. Additionally, one study only reported grade 3, 4, and 5 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Immunomodulatory drug maintenance therapy compared to placebo/observation for people with chronic lymphocytic leukaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013474-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐CD52 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐CD52 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic lymphocytic leukaemia<br/><b>Setting:</b> inpatient and outpatient care<br/><b>Intervention:</b> anti‐CD52 mAb maintenance therapy<br/><b>Comparison:</b> observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Anti‐CD52 mAb maintenance therapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade 3/4 adverse events – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival<br/>Follow‐up: median 12.4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.55<br/>(0.32 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anti‐CD52 mAb maintenance therapy may lead to an increase in progression‐free survival, but the evidence is very uncertain. <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>604 per 1000<br/>(419 to 746) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment‐related mortality – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment discontinuation – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All adverse events – not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reporting this outcome was identified.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious risk of bias (single study that does not report methods of random sequence generation or allocation, high risk of bias due to lack of blinding).<br/><sup>2</sup>Downgraded two levels for very serious imprecision (single study, 21 participants, terminated early, likely underpowered to demonstrate an effect).<br/><sup>3</sup>Assumed risk was calculated based on large cohort study (Mato et al 2020, DOI: 10.1182/bloodadvances.2019001145). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐CD52 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013474-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Random sequence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Allocation concealment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Blinding</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HR/risk ratio/rate ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI low</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI high</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HR/risk ratio/rate ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI low</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>95% CI high</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="10" scope="col" valign="top"> <p><b>Anti‐CD20 mAbs</b> <br/><b>versus</b> <br/><b>observation</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3/4 AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CRR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No low risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="10" scope="col" valign="top"> <p><b>IMiD versus</b> <br/><b>observation</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.82, I<sup>2</sup> = 0 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3/4 AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.11, I<sup>2</sup> = 61.3 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.72, I<sup>2</sup> = 0 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No high risk of bias trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.17, I<sup>2</sup> = 45.8 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CRR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="10" scope="col" valign="top"> <p><b>Anti‐CD52 mAbs</b> <br/><b>versus</b> <br/><b>observation</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3/4 AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ORR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CRR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>Only one trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p><b>AEs</b> : adverse events; <b>CI</b> : confidence interval; <b>CRR</b> : complete response rate; <b>HR</b> : hazard ratio; <b>HRQoL</b> : health‐related quality of life; <b>IMiD:</b> immunomodulatory drug; <b>mAb:</b> monoclonal antibody; <b>MRD</b> : minimal residual disease; <b>ORR</b> : overall response rate; <b>OS</b> : overall survival; <b>PFS</b> : progression‐free survival; <b>TD</b> : treatment discontinuation; <b>TRM</b>: treatment‐related mortality </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/full#CD013474-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013474-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐CD20 monoclonal antibody maintenance therapy versus observation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.73, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Overall survival (time to event): type of drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.58, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.72, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐8.59, 5.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Grade 3 and 4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.06, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Grade 3 and 4 adverse events: type of drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.93, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.06, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Progression‐free survival (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.50, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Progression‐free survival (time to event): type of drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.37, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.50, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Treatment‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.39, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Treatment‐related mortality: type of drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.44, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.25, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Treatment discontinuation: type of drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 All adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.03, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 All adverse events: type of drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Rituximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.97, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Ofatumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.96, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Complete response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.81, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.05, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐CD20 monoclonal antibody maintenance therapy versus observation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013474-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Immunomodulatory drug maintenance therapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Overall survival (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Grade 3 and 4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.38, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Progression‐free survival (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.19, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Treatment‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.35, 4.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.47, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 All adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.28, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Immunomodulatory drug maintenance therapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013474-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐CD52 monoclonal antibody maintenance therapy versus observation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Progression‐free survival (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.32, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Complete response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.28, 6.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.92, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐CD52 monoclonal antibody maintenance therapy versus observation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013474.pub2/references#CD013474-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013474.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013474-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013474-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013474-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013474-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD013474-note-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD013474-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013474-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013474-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013474-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013474-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013474\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013474\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013474\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013474\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013474\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013474.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013474.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013474.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013474.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013474.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717232842"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013474.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717232846"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013474.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db2e4eb439365',t:'MTc0MDcxNzIzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 